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CHEMICAL NOMENCLATURE AND ABBREVIATIONS
Most abbreviations used in this thesis are those set out in the 
Biochemical Journal Instructions to Authors (Biochem.J. (1972)
126, 1).
The abbreviation sp.act. denotes the Specific Activity (d.p.m./ 
unit mass) of a radioactive compound.
The names of certain enzymes involved in steroid metabolism are 
abbreviated as follows:
3p-Hydroxysteroid dehydrogenase At ; isomerase A  -3|5-HSD.
3p-Hydroxysteroid dehydrogenase 3^-HSD.
3tf-Hydroxysteroid dehydrogenase Ttf-HSD.
1 ' p-Hydroxysteroid dehydrogenase 17p-HSD.
Steroid nomenclature is according to the IUPAC-IUB (1967)
Revised Tentative Rules for Steroid Nomenclature5as reproduced 
in Steroids (1969) J_3> 277. Many steroids dealt with have been 
given trivial names. Common names such as testosterone, andro- 
sterone, pregnenolone do not need to be defined further. Other 
trivial names are defined as follows:
TRIVIAL
3ot-androstar ediol
3p-an drostanediol
androstenediol
dihydrotestosterone
epiandrosterone
dehydroepiandrosterone 
DHA
etiocholanolone 
androstenedione 
5(X-androstanedione 
Derivatives of the above trivial names are coined by adding the
IUPAC-IUB
5oc-andrpstane-3d, 17^-diol 
5ot-androstane-3p, 17p-diol 
5-androstene-3p, 17P-diol 
1 7p -hydroxy-3ot-androstan-3-one 
3p-hydroxy-30C-androstan-1 7-one 
3p-hyaroxy-3-s^drosten-17-one
v>oc-hydroxy-5p-androstan- 1 7-one 
A-ardrostene-3, 17-dione 
5oc-androstane-3 > 17-dione
name of the substituent as a prefix or suffix :
3p-sulphoxy-5-androsten-17-one DHAsulphate
5-androstene-3p,17p-diol-3, 17-
diacetate androstenediol diacetate
Sulphate ester of androstenediol 
where number (1 or 2) and position
(3 or 17 ) are not defined androstenediol sulphate
Steroid -D-glucosiduronides are termed glucuronides.
When a group of compounds is referred to_,a centre of unsaturation
in the steroid nucleus is denoted by the symbol / \
eg: /\^-3-oxosteroids = CA-5 unsaturated 3-oxosteroids.
Similarly the A-ring saturated steroids with 5d.-corfiguration 
are referred to as 3ot-steroids, those with 5/^-conf iguration as 
3p-steroids.
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Part. I.
INTRODUCTION
1. EFFECTS OF STEROID HORMONES ON SKIN.
^he skin is a complex organ derived from the embryonic 
ectoderm (epidermis and its appendages) and mesoderm (fibrous 
dermis). The epidermis and its appendages (hairs, sebaceous 
glands, sweat glands) require the presence of dermis for normal 
development (see Montagna, 1962). Androgens and oestrogens have 
effects on skin of man and animals. In man, androgen appears 
to cause an increased dermal collagen content (Black et al.,
1970) and in both human and rat, skin collagen and skin thickness 
are greater in males than females (Shuster and Bottoms, 1963; 
Dickerson and John, 196 4). However the most striking and well 
studied effects of steroid hormones on skin are those on hair 
growth and sebaceous gland function.
The relationship between sexual development, hair growth 
and sebaceous gland growth (causing oily skin and acne) is 
common knowledge. The fact that individuals castrated as children 
do not develop body hair, baldness, greasy skin or acne, 
emphasises this relationship.
i. Endocrine Aspects of Sebaceous Glands.
Sebaceous glands arise as outgrowths of cells from the 
developing hair follicles, early in foetal life. The growth 
of sebaceous glands in man and various other animals has been 
shown to be androgen stimulated. This includes such specialised 
sebaceous glands as rat preputial glands, mongolian gerbil 
ventral sebaceous patch, and hamster costovertebral glands 
among others (for a recent review see Ebling, 1970). Avian 
preen glands which are homologues of mammalian sebaceous glands 
are androgen controlled (Kar, 1947). Androgens of gonadal and 
adrenal origins stimulate sebum secretion in rats, and the 
growth response of the rat sebaceous glands has been used to 
bioassay androgens (Archibald and Shuster, 1969; Nikkari and 
Valavaara, 1970).
The growth of human sebaceous glands is stimulated by 
androgens, particularly testosterone. This is a direct effect
on the glands (Strauss and Pochi, 1963)* However, the sebaceous 
glands of different body areas develop to different degrees 
under androgenic stimulation. The glands of the scalp, face, 
chest, upper back and perianal region become large multilobed 
structures. Those found on the abdomen and limbs are much 
smaller, usually unilobed structures. With the sebaceous glands 
of the forehead and nose, the usual size relationship of hair 
follicle and sebaceous gland is reversed, the hair follicle 
remaining an almost vestigial structure beside the huge sebaceous 
gland (Strauss and Pochi, 1963; Montagna, 1963). Most studies 
of human sebaceous glands have used those of the forehead area.
Many experiments have established that testes, ovaries and 
adrenals are all involved in maintaining sebaceous gland growth 
in man (Strauss and Pochi, 1963; Pochi et al., 1963; Pochi and 
Strauss, 1967). Although sebaceous glands are androgen target 
organs they are actively growing in both sexes. The demonstration 
in recent years that testes, ovaries and adrenal cortex all 
synthesize and secrete androgens (Slaunwhite and Samuels, 1936;
Gandy and Peterson, 1968; Kase et al., 1961; Horton, Romanoff.and Walker? 
1966; Ichii et al., 1962; Wieland et al., 1965) supports the 
theory of their common role in controlling sebaceous gland growth.
From soon after the time they first differentiate, the 
sebaceous glands are active throughout foetal life and their 
lipid secretion goes to form the vernix caseosa (Serri and 
Huber, 1963)• After birth, the sebaceous glands regress to 
small buds of undifferentiated cells on the side of the hair 
follicles. They start to grow once again around the time of 
puberty (from 9-10 years of age) in response to the increased 
circulating androgens. In adult men, the sebaceous glands are 
maximally stimulated by testicular androgens and sebaceous 
secretion cannot be increased by testosterone administration 
(Strauss and Pochi, 1963)• According to Strauss and Pochi 
(1963), sebaceous secretion does not fall appreciably with age 
in men and castration of aged men caused a great fall in sebum 
secretion, suggesting that testicular secretion of androger is 
sufficient to maintain sebaceous secretion even in the aged male.
In male castrates, the low rate of sebum secretion, which is
still significantly greater than in children, is maintained by 
adrenal androgens (Pochi and Strauss, 1967). In women, both 
ovarian and adrenal cortical secretions are important for main­
taining sebaceous gland function. After about 30 years of age 
the sebum secretion in women decreases and drops abruptly around 
the time of the menopause (Strauss and Pochi, 1963; Krant et al.,
1968). Sebum secretion in healthy premenopausal women can be 
reduced by adrenal suppression but not to the same extent as 
in castrated men (Pochi and Strauss, 1967). Progesterone and 
glucocorticoids in physiological doses do not appear to stimulate 
human sebaceous secretion; oestrogens suppress sebum secretion 
(Strauss and Pochi, 1963) so it has been concluded that adrenal 
and ovarian androgens are the main sebaceous gland stimulators 
in women.
ii. Effects of Sex Hormones on Hair Growth in Man
This subject has been critically reviewed (Hamilton, 1958;
Rook, 1965; Hamilton et al., 1969). In man, the growth of hair 
in certain regions of the body is obviously associated with 
sexual development. In both sexes at puberty, changes occur 
in the hair follicles of pubic and axillary regions which result 
in formation of coarse terminal hairs. Similar changes in the 
beard, trunk and limbs are normally, much greater in the male 
than in the female. As with sebaceous gland growth androgens 
of gonadal and adrenal origins are involved in development and 
maintenance of adult body hair pattern. However, unlike 
sebaceous glands, whose development in different body areas is 
similar in both sexes, the hair follicles of different body 
regions differ in their sensitivity to the levels of androgens 
in male and female, eg: while axillary and pubic hair develop 
in both sexes, the growth of coarse sternal and beard hair is 
limited normally to the male.
iii. Endocrine Diseases and Skin. Abnormal Growth response to Androgens.
As sebaceous gland and hair growth are controlled by steroid
hormones, it is not surprising that abnormalities of sebaceous 
glands and body hair pattern are associated with diseases in 
which there are disturbances of steroid hormone production and
metabolism., e.g.: association of seborrhoea, acne and hirsutism 
with Stein Leventhal syndrome, Cushing's syndrome, congenital 
adrenal hyperplasia.
There are however, certain conditions in which abnormal 
hair growth patterns or abnormalities of sebaceous glands are 
present without any obvious underlying disturbances of plasma 
steroid concentrations, steroid secretion or urinary excretion, 
e.g.: idiopathic hirsutism in women and acne vulgaris in both 
sexes (see Strauss and Pochi, 1969). More detailed studies of 
variations in androgen and oestrogen secretion, plasma protein 
binding or day to day fluctuations in plasma concentrations may 
yet demonstrate an underlying abnormality of the endocrine 
glands in some cases of acne and hirsutism; e.g.: detailed 
analysis of testosterone concentrations in the plasma of some 
women with idiopathic hirsutism has shown that even though they 
may have normal plasma concentrations, the blood production rate 
and metabolic clearance rate of testosterone from blood are 
increased (Bardin and Lipsett, 1968). Thus more testosterone 
enters the blood while its concentration is not raised. It is 
thought that the increased testosterone production represents 
direct secretion. It was recently shown (Harkness et al.,
1968) that males with severe acne had greater day to day fluctuati 
in urinary testosterone glucuronide excretion than a non­
acne group. Previously, no abnormalities of urinary 17- 
oxosteroids or plasma testosterone could be detected in acne 
sufferers.(pochi et al., 1965).
However, it has also been considered possible that some 
cases of abnormal hair and sebaceous gland growth are due to 
an abnormal target organ response to hormones. The best example 
is the testicular feminization syndrome in which individuals 
are genetically male but appear superficially as normal females, 
except for absence of axillary and pubic hair. They have 
undescended testes which can synthesize androgens and oestrogens 
and they may have plasma testosterone concentrations within the 
normal male range (Griffiths et al., 1963; Southren et al.,
1965). However there appears to be a complete unresponsiveness 
of target tissues to androgenic stimulation. This includes
sebaceous glands and body hair (Gwinup et al., 1966; Strauss 
and Pochi, 1969). To explain idiopathic hirsutism on such a 
basis an "over response" to androgens by some hair follicles 
must be proposed. The different sensitivity of hair follicles 
in different body areas to male and female levels of androgen 
is well recognised; the influence of genetic/racial factors on 
this has been observed (Hamilton, 1958; Hamilton et al., 1969).
Thus it may be imagined that facial hair follicles of some 
women could develop a similar sensitivity to androgen as their 
axillary hairs. As will be seen later, it may be possible to 
explain such a change on the basis of the "prehormone concept" 
and changes in target organ steroid metabolism.
It is not so easy to explain acne on the above basis.
This is because there is no clear cut evidence that an increase 
or decrease of sebaceous gland activity is a direct causative 
factor in acne (Pochi and Strauss, 1964; Pochi et al., 1965; 
Cunliffe and Shuster, 1969; Powell and Beveridge, 1970). To 
quote Strauss and Pochi (1964), "While there may be a statistically 
significant difference in mean sebum secretion between groups 
with and without severe acne, it is not possible to characterize 
any individual as having or not having acne by their sebum 
secretion". Undoubtedly androgenic stimulation of sebaceous 
glands is necessary for acne to occur (eunuchs do not develop 
acne, but if treated with androgen they may do so). Possibly 
some other factor is required to cause the lesion in the androgen 
stimulated gland. It may be that this other factor is androgen 
itself, causing a change in sebum composition (Powell and 
Beveridge, 1970) or a blockage of the sebaceous gland duct by 
inducing excessive keratinization (Van Scott and MacCardle,
1956). In this case, the development of acne might be termed 
as an abnormal target organ response to androgen. In those 
individuals with acne who do have abnormally high sebum 
secretion rates while at the same time having normal secretion 
and plasma concentrations of androgens, there may be an over­
response of the sebaceous glands to normal androgenic stimulation.
2. THE POLE OF THE SKIN IN METABOLISM AND EXCRETION OF ANDROGENS.
Traditionally, the liver was considered as the main organ 
in which the secreted steroids are metabolized. The classical 
idea being that a steroid hormone was secreted by an endocrine 
gland, acted on its target organ was then catabolized in the 
liver and excreted in urine (see Figs. 1 and 2 pp. 7 and 8 
for metabolic transformations of androgens). However, 
evidence has accumulated to show that the liver is not the 
only site of androgen metabolism. It was shown that kidney 
tissue would convert testosterone to androstenedione (West and 
Samuels, 1951). Then it was shown that a number of human tissues 
metabolized testosterone (Wotiz et al., 1954). These included 
prostate, endometrium, myometrium, intestine, smooth muscle, 
mammary gland tissue and skin. The skin was found to be one 
of the most active sites of testosterone metabolism (Wotiz et 
al., 1954, 1956). Prostatic tissue from human and rat was 
shown to metabolize testosterone (Farnsworth and Brown, 1963; 
Shimazaki et al., 1965; Chamberlain et al., 19 6 6). A-ring 
reduction to 5<X-steroids and oxidation of the 17|3-hydroxyl 
group were the major reactions.
If this extrahepatic metabolism is quantitatively important 
then the pattern of excreted steroid metabolites will reflect 
this complex situation and it becomes necessary to investigate 
the steroid metabolism of different organs in order to discover 
the origin of different excreted metabolites. Indeed, recent 
studies by Mauvais-Jarvis et al., (1969a, 1970gt)have shown 
that different urinary metabolites may represent the androgen 
metabolism of different organs, e.g.: urinary 5l-androstanediols 
anpear to mainly reflect testosterone metabolism in tissues 
other than the liver or intestines while 5f-androstanediols 
and etiocholanolone are more representative of hepatic 
metabolism.
Another complication arises over the actual excretory 
routes for androgen metabolites. In man, steroids are
excreted mainly in urine as sulohates or glucuronides, in
Fig. 1.
IMPORTANT METABOLIC TRANSFORMATIONS OF ANDROGENS
HO
rt_3
HO HO--
OH
A
o o 9 ~ '
o 
, lA  l/ S.
HO-'
V''’
Reactions catalysed by:
1. 17|S-HSD 2. reductase 3» 5p-reductase A. 3oi-HSD 5* 3^-HSD.
The major metabolic transformations which testosterone andro­
stenedione and their metabolites may undergo are shown. The 
reactions have beer detected in various tissues of a number of 
species but particularly in the liver (see Dorfman, P.I and Ungar> 
F. (1965) Metabolism of Steroid Hormones.’ Academic Press, London 
and New York). Hydroxylation of the steroid nucleus at nositions 
1, 2, 6, 7, 16 also occurs. Hydroxyl groups at 3 and 17 form 
conjugates with sulphuric and glucuronic acids. Conversion of 
testosterone and androstenedione into oestrogens is not shown.
Fig. 2
FORMATION OF SOME OF THE MAJOP ANDROGEN METABOLITES IN MAN
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NaO,SO
DHA
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5-androstene-3B ,1 60C— 
-17p-triol
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epiandrosterone
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3d, 17P-diol
testosterone
glucuronide
In the left hand column are the main androgens secreted into 
the blood of man. Transformation into some of their major 
metabolites which are excreted in the urine as sulphate or 
glucuronide conjugates is shown.
other species elimination in faeces after excretion in bile is
important (Gallagher et al., 1951). This route also has some
importance in human infants (Gustafsson et al. , 1969)- Another
possible route for excretion is through the skin (sweat, sebum,
epidermal keratin, hair). The skin may be an excretory route
for some steroids and also for certain drugs, e.g.: tetracyclines
(Rashleigh et al. , 1967; Marples and Kligman, 1971).
steroids have been tentatively identified in extracts of human
sebum, sweat and hair. Earlier experiments (Carrie and Ruhrmann,
1955; Dubovyi, 1960) in which the Zimmerman reaction was carried
out on skin washings or hair extracts were unreliable as this
is not a steroid specific reaction. However further studies
showed that compounds could be extracted from human axillary
and pubic hairs which had similar chromatographic properties
to DHAsulphate and which gave a positive Zimmerman reaction.
After acid hydrolysis of these extracts, compounds having
similar chromatographic properties to DHA and androsterone
were isolated (Julesz et al., 1966; Julesz, 1968). Dubovyi
(1967) claimed to have isolated androsterone from extracts
of human hair fat. Cook and Lorincz (1963) bad used another
approach; they showed that human skin surface fat contained
compounds which could be oxidized by bacterial hydroxysteroid
dehydrogenases, NAD+ or NADP+ being required as cofactors.
They claimed that the lipids excreted on to the human scalp
in 24 hours could contain up to 4OOjug of steroids which were
oxidizable by the bacterial enzymes. Oertel and Treiber (1969),
injected j 7oL- 'H ] DHA- [  J  sulphat e into a man and were able
3 35to isolate a H and S labelled fraction from skin surface 
washings. About 1.4% of the injected radioactivity was re­
covered in this fraction obtained by washing arms and legs 
with an ether: ethanol: water solution 6, 12 and 24 hours 
after injection of the labelled DRAsulphate. This could be 
a significant proportion of the radioactivity when it is con­
sidered that only 30% of the body surface was extracted and 
this an area with only low density of active sebaceous glands 
and eccrine sweat glands. One would consider these glands
to be the most likely organs in skin to be involved in steroid
excretion. From the isolated radioactive fraction, Oertel and
Treiber extracted and identified a number of steroids. Most
of these were present as sulphate conjugates as judged by
chloroform/water partition, chromatographic behaviour and
solvolysis. DHA, androsterone, etiocholanolone, 5o(-
androstanedione, androstenediol and 5-androstene-3p> 16(X, 17p-
triol were identified by reversed isotope dilution with authentic
carriers. Constant specific activity of free steroids and
2, Z+-dinitrophenylhydrazone derivatives was demonstrated after
t.l.c. in several solvent systems. Oertel suggested that 
3 35because the H/ S ratio of the isolated metabolites was 
similar to that of the injected DHAsulphate, the latter com­
pound had been metabolized without losing its sulphate group. 
However, it is difficult to explain a direct conversion of 
DHAsulphate to androsterone sulphate without loss of the 
sulphate, through the action of known steroid metabolizing 
enzymes.
In addition to these isotope experiments, Oertel and 
Treiber (1969) extracted human thermal sv/eat and also direct 
skin surface washings in an attempt to isolate any endogenous 
steroids. Using techniques similar to those used in their 
tracer studies, they claimed to have isolated about 60**g of
steroids from an extract of 100 cm^ of skin surface from the 
thigh. Most of the steroids were present as sulphate conjugates. 
From the sweat extracts were isolated about 1?0^g of C^Q 
steroids. This time most of the steroids were unconjugated.
Oertel suggested that the metabolites of DHAsulphate isolated 
from the skin surface might reflect steroid metabolism in the 
skin. Only direct incubation or perfusion experiments could test 
this theory.
So far two problems concerning androgen metabolism and skin 
have arisen:
1) The role of skin in whole body metabolism of steroids.
2) The specific problem of the formation of steroids found
on the skin surface, notably the metabolites of DHAsulphate
The other major problem of skin steroid metabolism is 
related to 1) above. If a hormone sensitive organ such as skin, 
possesses the enzymes necessary to degrade active androgens it 
might also possess the enzymes necessary to synthesize them 
from inactive secreted precursors. This idea has come to be 
known as the "Prehormone Concept" and will be discussed in the 
next section.
3. PREHORMONES: BIOSYNTHESIS OF HORMONES BY PERIPHERAL TISSUES.
It has long been considered that testosterone is the most 
important androgen. The androgenicity of DHA and androstenedione, 
which may both act as intermediates in testosterone biosynthesis, 
could be due to conversion in the body to testosterone (Mahesh 
and Greenblatt, 1962). Similarly DHAsulphate the major Cyr- 
steroid secreted by human adrenals might act as a precursor of 
testosterone (Baulieu et al., 1965)* It has been shown that 
endocrine and non-endocrine tissues from various species can 
interconvert the above steroids (Ungar and Dorfman, 1954; Klempien 
et al., 1961; Pearlman and Pearlman, 1961; Smith and Ryan,
1961; Aakvaag et al. , 1964; Cameron et al., 1966; Kim and Herrmanp.,, 
1968; Fahmy et al., 19 6 8; Jones et al., 1970; Collins et al.,
1970). However 'in vivo' studies indicated that in men the 
major fraction of testosterone in the blood was secreted directly 
by the testes; secreted DHAsulphate, DHA and androstenedione 
appeared as unimportant contributors to the plasma testosterone 
pool (Tait and Horton, 1966; Bardin and Lipsett, 1968; Migeon 
et al., 1968). In women, because direct secretion of testo­
sterone is small compared to that of androstenedione, more than 
half of the blood production of testosterone may arise through 
perinheral metabolism of secreted androstenedione (Tait and 
Horton, 19 6 6; Bardin and Lipsett, 1968). Also in women 
peripheral DHA metabolism may account for up to 15% of blood 
testosterone production. The fraction of blood testosterone 
arising from DFAsulphate is very small in both men and women
even though the plasma concentration of the latter compound 
is more than 100 x that of testosterone (Tait and Horton, 1966)•
It appears therefore that if blood production rate of testosterone 
is taken as an index of biologically active androgen formation 
in man, then secretion and peripheral metabolism of "prehormones" 
is important only when testosterone secretion is small compared 
with that of secreted precursors such as androstenedione. Even 
then DHAsulphate would appear to have only a minor role as an 
androgen precursor although the finding that ovarian and mammary 
gland tumours will convert it to DHA and androstenedione (Fahmy 
et al., 1968; Jones et al., 1970) leaves the possibility that 
DHAsulphate secreted by the adrenals might be a source of testo­
sterone in some disease states.
The above arguments were based on the premise that the 
blood production rate of testosterone is a good indicator of 
the formation of biologically active androgen and that the plasma 
concentration of testosterone is a reliable measure of the amount 
of biologically active androgen available to the target organs.
As already noted, this appears to be true for the adult man. 
However, it has to be considered whether the conversion of 
DHAsulphate, DHA and androstenedione to blood testosterone truly 
reflects the importance of their secretion for supplying active 
androgen. There are three reasons why this may not be so:- 
1 ) These steroids may possess biological activity independent 
of any metabolism.
2) They could be converted to testosterone in peripheral tissues. 
This testosterone might not mix with the blood testosterone pool. 
For instance, it could be further metabolized.
3) Testosterone itself may be converted in the target organs 
to a metabolite which exerts the biological effect. Other 
androgens might also be converted to this metabolite either, 
via testosterone, or via a pathway not involving testosterone.
It has been demonstrated that various androgen target organs 
metabolize testosterone, one of the earliest studies was that 
of Wotiz et al. (1954)» Further studies of prostate gland, 
chicken comb, and preen gland showed that testosterone was
rapidly m e t a b o l i ze<3, particularly by reduction of the 4-5 
double bond to give 5o(.-steroids (Farnsworth and Brown, 1963; 
Shimazaki et al., 1965; Baggett,1962; Rongone et al., 1967). 
Dihydrotestosterone (1 7p-hydroxy-5ot-androstan-3-one ), one of 
the principal testosterone metabolites formed in prostatic 
tissue (Farnsworth and Brown, 1963; Shimazaki et al., 1965) 
was known to have high androgenic activity. In fact, Dorfman 
and Dorfman (1962, 1963a,b) had shown that it was as active or 
more active than testosterone for stimulating growth of chick 
comb and rat prostate. Evidence has since been accumulating 
that dihydrotestosterone may be one of the biologically active 
forms of androgen, and that conversion of testosterone to this 
compound in the target tissue may be important in mediating its 
androgenic action (Bruchovsky and Wilson,1968a,b ; Anderson 
and Liao, 1968; Mainwaring, 1969a,b; Gloyna et al., 1970).
If this is the case the importance of the other secreted 
androgens should be assessed by their conversion to 
dihydrotestosterone rather than by their conversion to blood
testosterone. In addition to the possibility of DHAsulphate, 
DHA and androstenedione being converted to dihydrotestosterone 
in target tissues it is quite likely that other naturally 
occurring androgens exert their effects through conversion to 
this compound. For instance, androsterone, epiandrosterone, 
5^-androstanedione, 3&_androstanediol may all be converted to 
dihydrotestosterone by the appropriate 3o(> 3pand 17p- 
hydroxysteroid dehydrogenases (fig. 1 p. 7). There was, 
however, very little information about the metabolism of 
androgens, other than testosterone, in target organs. Most 
studies had been concerned with conversion of DHAsulphate and 
DHA to testosterone little attention being paid to other 
steroids.
The work described in this thesis has been aimed at 
elucidating some of the aspects of androgen metabolism in skin. 
The skin is one of the most interesting androgen target organs 
(or collection of androgen target organs) and many disturbances 
of the endocrine system are reflected by changes in skin,
particularly by disturbances of sebaceous gland and hair growth.
The differing sensitivities of hair follicles to androgens, 
secreted by testes, ovaries and adrenals in the human, might 
result from differing abilities to utilize secreted DHAsulphate, 
DHA, androstenedione and testosterone as hormones. Possibly 
such differences could be due to varying abilities of the target 
organs to convert the secreted compounds to "active forms" 
(testosterone, dihydrotestosterone...?). The postulated abnormal 
target organ response in hirsutes might then arise from dis­
turbances of this androgen metabolism. Similarly, the postul­
ated abnormal response of sebaceous glands in acne might 
result from disturbances of androgen metabolism in skin.
4. REASONS FOR STUDYING STEROID METABOLISM IN HUMAN SKIN.
These can now be stated as:
1. The role of the skin as a site of androgen catabolism
(part 1, section 2).
2. Conversion in the skin of secreted steroids to biologically 
active species and its relation to sebaceous gland activity 
and hair growth (part 1, sections 1 and 3)*
5. EXISTING KNOWLEDGE OF STEROID METABOLISM IN SKIN.
Wotiz et al. (1956) reported studies of testosterone meta­
bolism in skin from back, axilla and scalp of men aged 22 - 30 
years. Unfortunately, in this study the possible testosterone 
metabolites were not identified, but an autoradiogram of a 
paper chromatogram of the skin steroid extracts showed that 
possibly 8 metabolites of testosterone were formed. They all 
gave a positive Zimmerman reaction and one was identified as 
androstenedione by further chromatography and infra-red spectra. 
Thus the presence of a testosterone 17p-HSD in the human skin was 
indicated.
Baillie et al. (1965) reported that the human sebaceous 
glands v/ere sites of NAD+ and NADP+ dependent hydroxysteroid 
dehydrogenase activity, which was demonstrated using histochemical
techniques. A wide variety of hydroxysteroids reacted as 
substrates in this system. Particular importance was attached 
to the presence of 3p-HSD (utilizing DHA as substrate) and 
17p-HSD (utilizing testosterone). These enzymes could catalyse 
the conversion of DHA and androstenedione to testosterone in 
the sebaceous cells. A further study of 3p-HSD led to the 
conclusion that the enzyme was restricted to the sebaceous 
glands of acne prone areas (face, upper back, chest), that the 
activity was highest in the 1 5 - 2 0  age group, then declined with 
increasing age (Baillie et al., 1966). It has however, been 
recently shown, using more refined techniques, that both 3p- 
HSD and 17p-HSD are present in sebaceous glands from all over 
the body (Caiman et al., 1970). In order to directly test the 
possibility that DHA could be converted to testosterone in 
sebaceous glands, Cameron et al. (1966) incubated slices of 
shoulder skin from men with (7ol-^H]DHA. were able to
demonstrate an extremely small conversion of DHA to testosterone 
(0.05% / 4 hours). At about the same time, Pongone (1966) re­
ported the metabolism of testosterone by mammary skin from a 
man v/ith Klinefelter's syndrome. Metabolites were identified 
by g.l.c. Testosterone was converted to androstenedione, 5ot- 
androstanedione, androsterone and etiocholanolone. These 'studies 
indicated that human skin contained 17p-HSD, 3&-HSD, 5ot-reductase 
and possibly 5p-Feductase enzymes. The 5tX-re duct ion of cortisol 
had previously been shown to take place in human foreskin 
(Hsia et al., 1964). Faredin et al. (1967) reported some ex­
periments on the metabolism of 14- ~^C | DHA in pubic skin from an 
agonadal male. Evidence for formation of androstenedione 
testosterone and androsterone was presented along with tentative 
evidence for identity of various highly polar metabolites.
These were later identified as 7-hydroxylated DHA metabolites 
(Faredin et al., 1969). In another study, Gallegos and Berliner 
(1967) incubated human abdominal skin with DHA for 5 days in 
Eagle's medium; radioactive androstenedione, testosterone and 
androstenediol were isolated and identified. In addition, the 
skin was shown to form the sulphate esters of DHA and androstene­
diol (Berliner et al., 1 96 8) indicating the presence of a steroid
sulphotransferase in male human skin. Faredin et al.(1968) 
confirmed that this reaction could also take place in female 
abdominal skin. Chakraborty,in this laboratory, had been 
investigating the metabolism of DHA in skin biopsies taken 
from individuals of different ages v/ith and without acne vulgaris 
(Chakraborty et al., 1970). By incubating thin (10^) frozen 
sections of skin in buffer with NADf and [7ol-'^ h] dHA, he was 
able to demonstrate the formation of androstenedione and andros- 
tenediol. Skin from the shoulder region was metabolically much 
more active than skin from the lateral thoracic wall or thigh 
(non-acne regions). The rate of conversion of DHA to andros­
tenedione appeared to decrease with increasing age after the 
third decade. This agreed with the earlier histochemical studies. 
However, in no experiment was Chakraborty able to demonstrate 
the conversion of DHA to testosterone by skin slices. He 
criticised the results of other workers as they did not appear 
to have purified the radioactive DHA before use and he had 
found that commercial [7ct-^ H] DHA contained amounts of testosterone
comparable to the quantities isolated from metabolic experiments
*| [±
with skin and DHA. Using [4- "Cjandrostenedione as substrate 
and an NADPH generating system to supply coenzyme, he was able 
to demonstrate the conversion of androstenedione to testosterone 
in skin. It was quite likely that his earlier failure to find 
a conversion of DHA to testosterone was due to a lack of NADPH 
in his incubating system. However, when experiments were carried 
out with NAD+ and an NADPH generating system, the result was an 
increased conversion of DHA to androstenediol, but still no 
testosterone was formed (Chakraborty, 1968 unpublished work).
There remained a conflict regarding the quantitative importance 
of conversion to testosterone as a metabolic pathway for DHA 
in human skin. Kim and Herrmann (1968) studied the metabolism 
of DHAsulphate in human neonatal foreskin homogenates and were 
able to isolate DHA, androstenedione and testosterone as 
metabolites. The [7ot-^ H| DHAsulphate used v/as extensively 
purified before use and the testosterone was finally identified 
by repeated crystallization with authentic carrier steroid.
These results contrasted with those of an earlier study by 
Warren and French (1965)} who had been unable to detect steroid 
sulphatase activity in adult skin. Chakraborty attempted to 
repeat the experiments of Kim and Herrmann using adult skin.
He was able to show a low conversion of DHAsulphate to DHA but 
no other metabolites could be detected (Milne, 1969)* Gomez 
and Hsia (1968), had reported further studies on metabolism of 
testosterone and androstenedione in human skin. Interconversion 
of the two steroids v/as demonstrated and both compounds were 
converted to A-ring saturated metabolites. Androsterone, 
epiandrosterone, and 5«.-androstanedione were major metabolites 
of both incubated steroids. In addition, testosterone was 
converted to dihydrotestosterone. Neonatal foreskin produced 
a higher yield of this compound than adult abdominal skin. In 
contrast to the earlier experiments of Pongone (1 966) no 
etiocholanolone or 5p-androstane-3 }17-dione were detected in 
the experiments of Gomez and Hsia.
The relatively active conversion of both androstenedione 
and testosterone to ^-metabolites in human skin suggested that 
the failure to detect a convincing conversion of DHA to 
testosterone in skin incubation experiments might be due to 
rapid further metabolism of testosterone, once formed. There 
was however, no information about metabolism of DHA to 
dihydrotestosterone or androstanediols in human skin, The 
experiments of the Hungarian workers had shown that in human 
pubic skin DHA could be converted to androsterone (Julesz,
1968) but no other information was available. We therefore 
set out to investigate the problems of in-vitro skin steroid 
metabolism outlined in Section 6. While these experiments were 
being carried out other groups were also making further studies 
of skin steroid metabolism. This recent work will be discussed 
in relation to the results presented here.
6. AIMS AND PUPPOSE OF PESEAPCH.
To study:
1. The conversion of DHA and DHAsulphate to testosterone and 
dihydrotestosterone in human skin. Any formation of these 
compounds would have to be related to the total metabolism, 
therefore identification and quantitation of all major 
metabolites would have to be achieved.
2. The possible conversion of DHAsulphate to other steroid 
sulphates in skin.
3. The metabolism of DHAsulphate and DHA compared with that 
of androstenedione and testosterone in the same type of skin 
from the same individual.
A. The metabolism of DHAsulphate, DHA, androstenedione and 
testosterone in skin from body regions characterized by 
abundance or lack of sebaceous glands and/or terminal hairs. 
This would be a first approach to characterizing the tissues 
involved in skin steroid metabolism.
Part. II.
MATERIALS AND METHODS
1. GENERAL OUTLINE OF INCUBATION AND ANALYTICAL METHODS.
i . Tissue and Incubation.
Tissue obtained at surgery was kept wrapped in 0.9% NaCl 
soaked gauze, on ice for up to one hour before use. The skin 
was dissected free of subcutaneous fat and cut into 0 . 5  -
0 . 7  mm thick slices using a specially madetmultibladed cutter 
(photo. 1 p. 20). The slices were incubated with shaking either 
in Erlenmeyer flasks or glass scintillation counting vials with 
the apnropriate radioactive steroid, dissolved with the aid of 
propane-1, 2-diol in Krebs Improved Ringer I medium (Krebs, 1950) 
at 37°C under an atmosphere of 95%0£: 5%C0^ for three hours as 
described for each experiment (Part III, Experiments and Results). 
The f7o(-^Hj labelled DHA, androstenedione and testosterone were 
purified the day before use by t.l.c. on silica gel in the system 
chloroform: acetone, 185:15 (v/v), then stored dissolved in 
methanol: benzene, if: 1 (v/v) at -20°C. [7d(-^h]DHAsulphate was
purified the day before use by t.l.c. on silica gel in the system 
ethyl acetate: 2-methyl-propan-2-ol: 5M-NH^0H, 100: 82: 40 (v/v), 
then stored dissolved in methanol at -20°C. Control incubations 
containing steroid but no tissue were run with each batch of 
incubations.
ii. Extraction of Steroids from Tissue and Medium.
Incubations were stopped with 5 volumes of acetone, and 
200-300 /<-g of each of the appropriate carrier steroids dissolved 
in ethanol were added. The carriers are listed with each 
experiment. The mixtures were kept at -20°C.
Total lipids were extracted by homogenizing the mixtures 
with 100 ml of diethyl ether: ethanol, 3:1 (v/v). The extracts 
were filtered through sintered glass then evaporated to dryness 
at 40°C in a rotary evaporator. The residues were suspended in 
15 ml of water and adjusted to about pH 8 . Neutral steroids 
were then extracted with 3 x 2  vol. of chloroform. The chloroform 
extracts were evaporated to dryness and partitioned between equal 
volumes of 70% aoueous methanol and light petroleum (b.p. 40-
Photo 1.
A TISSUE CUTTER FOR SLICING SKIN
The cutter consists of double edged stainless steel razor blades 
mounted on the frame as shown. Steel washers slipped between 
the blades on to the support rods provide the correct spacing 
between blades. The assembled cutter is screwed up tight and 
pressed down on to the tissue. Skin is placed, epidermis down, 
on a sheet of thick polythene ( 1 mm) for cutting.
gO°C) to separate steroids from less polar lipids. The 
methanolic extracts were evaporated to dryness and the residues 
were dissolved in methanol: benzene,4:1 (v/v).
The steroid conjugates, which remained in the aqueous 
phase after the chloroform extractions, were extracted with 
3 x 1 vol. of ether: ethanol, 3:1 (v/v) after adjustment of 
the aqueous solution to 50% saturation in ammonium sulphate 
and 0.5 M in ammonium chloride (Edwards et al., 1953). The 
ether: ethanol extracts were evaporated to dryness and the 
residue, containing steroid sulphates and glucuronides, dis­
solved in methanol.
iii. Isolation and Identification of Radioactive Steroids.
The steroid sulphate-glucuronide fractions were run on 
t.l.c. in system IX (table 1, p.27) to remove traces of neutral 
steroids and to separate sulphates from glucuronides (Pierrepoint 
1967). Bands corresponding to steroid sulphate and glucuronide 
standards were eluted (p<(?6 ) and counted for radioactivity*, 
glucuronide fractions contained only traces of radioactivity 
and were not analysed further. Sulphate fractions were solvolyse 
by dissolving the dried extracts in a saturated solution of 
1M-H^SO^ in ethyl acetate and leaving overnight at 37°C (Burstein 
and Lieberman, 1958; Wang et al., 1968). The solutions were 
back v/ashed to neutrality with 20% sodium carbonate solution, 
then water; carrier neutral steroids were then added to the 
solvolysates, as at the end of the tissue incubation and the 
extracts were analysed in the same way as the neutral metabolite 
fractions.
The neutral steroid extracts (neutral metabolites and 
neutral steroids obtained by solvolysing the sulphate fractions) 
were separated by thin-layer and paper chromatography using the 
solvents listed in table 1 (p.27). Fig. 5 (p«30) shows the basic 
sequence of solvents for separating the main groups of steroids 
investigated. In some experiments the androstenediol-androstane- 
diol fractions were further separated as shov/n in Fig. 6 (p. 51).
Aliquots of each isolated steroid fraction were taken for
radioactivity detfrmination (p. 32) and measurement of carrier 
recovered (p.33)« Identity and radiochemical purity of the 
isolated radiometabolites was then established by one of two 
methods:
a. The radioactive steroid was further purified by chromatography 
and preparation of derivatives (p39 ) until constant specific 
activity was obtained (p.49and p.55). V/hen the specific activity 
of the steroid and one or two derivatives agreed to within 10%, 
the steroid was considered radiochemically pure (Berliner and 
Salhanick, 1936).
b. A further aliquot (size depending on the amount of radio­
activity in the fraction) of the isolated steroid was re- 
crvstallized to constant specific activity with 10-20 mg of 
authentic carrier (d.38). When the specific activites of four 
successive crops of crystals agreed within 10% the steroid was 
considered radiochemically pure (Axelrod et al., 1965)* This 
method was used in most experiments.
iv. Calculation of the Percent Conversion to Each Radiometabolite.
di d.p.m. of tracer are incubated with the tissue. A carrier 
quantity of the metabolite X (Mx) under investigation is then 
added and this unlabelled material mixes homogeneously with the 
radioactively labelled X nroduced in the incubation. The now 
radioactively labelled carrier is isolated in pure form and its 
specific activity (Sx) measured. Assuming the mass of radio­
active X produced on incubation to be negligible compared with 
the mass (Mx) of carrier added, the percent conversion of tracer 
to X can be calculated:
% conversion to X = Sx.Mx . 100 ____ (1)
di
The above calculation is used with method iii.a for 
identifying and estimating radiometabolites. Sx is the mean 
of the agreeing specific activities obtained after chromatography 
and derivative formation.
V/hen the re-crystallization method for identification is 
used (iii,b) formula (1 ) must be modified to correct for the 
fact that the isolated compound X may not be 100% radiochemically
pure before crystallization.
Equation (1) becomes :
% conversion to X = Sx.Mx.100 . Sf - (2)
di St
Sf = Final constant specific activity of crystals.
St = Specific activity of crystals if X was 100% pure
before crystallization, i.e.: if all radioactivity 
of the aliquot used for crystallization was in X.
Nov/ Sx = d.n.m. in aliquot of final t.l.c. eluate taken
___________________________ for crystallization.
mg of carrier X in same aliquot (y)
St = a.p.m. in aliquot of final t.l.c. eluate taken
___________________________ for crystallization.
mg of carrier X in same aliquot (y) + mg excess 
carrier added for crystallization (Y).
Mx is now measured in mg.
% conversion to X = Sf.Mx.100 # Y + y - (3)
di * y
In practice, Y ^ 1 0 m g  while y ^ 0 . 2  mg
By accepting an extra error of ^ 2% equation (^ ) simplifies
% conversion to X = Sf.Mx.100  ^ Y (k)
di * y
The radioactivity of the final chromatographic eluate is
always measured even though it is not needed for the final 
calculation. This is so that appropriate aliquots can be taken 
for crystallization or further purification.
N.B. The final constant specific activity of the crystals (Sf) 
cannot be used to calculate the % conversion unless the amount 
of initially added carrier in the aliquot taken for crystall­
ization (y) is known. This contrasts v/ith the derivative method 
of purification (formula 1) where Sx (specific activity of the 
purified, labelled carrier) can be used directly to calculate
the % conversion.
See appendix 1 .
Fig. 3.
SUMMARY OF THE CHROMATOGRAPHIC METHOD FOR IDENTIFYING AND
ESTIMATING PADIOMFTABOLITES.
Skin + £ ^H 1 steroid (di) incubated in Krebs Ringer 
medium.
1
5 vol. Acetone + Carrier Steroids (0.2-0.3 mg) (Mx) 
added.
v
Fractionation of free and conjugated steroids by 
solvent partition.
Each r^H Isteroid purified by paper chromatography and 
t.l.c.
v
Specific activity of each steroid measured - carrier 
recovery by g.l.c., E2i+0. Radioactivity by liquid 
scintillation counting.
4
Form a derivative of steroid. Purify by paper
chromatography or t.l.c. Measure specific activity.
V
Repeat, until 3 constant specific activities are 
obtained. (Sx)
% conversion to metabolite X = Sx.Mx . 100
di
Fig. A.
SUMMARY CF THE CHROMATOGRAPHY - RECRYSTALLIZATION METHOD FOR
IDENTIFYING AND ESTIMATING RADIOMETABOLITES.
Skin + £ ^HD steroid (di) incubated in Krebs Ringer Medium
5 vol. Acetone + Carrier Steroids(0.2-0.3 nig each)(Mx).
V
Fractionation of free and conjugated steroids by 
solvent nartition.
M/
-3teach [ H J steroid purified by paper chromatography 
and t.l.c.
a.
aliquots for 
carrier recovery 
(g.l.c., E2A0)
(y)
aliquots for
radioactivity
measurement.
b.
aliquots
crystallized to
constant specific
activity (Sf) with
10 mg authentic carrier (Y).
^conversion to metabolite X = Sf.Mx]00- # Y
di y
2. CHROMATOGRAPHY
Thin layer Chromatography (t.l.c.) was done on 250 ^  
thick layers of silica gel Hf25A+366. The plates were act­
ivated for one hour at 110°C before use. The solvent systems 
used for t.l.c. are shown in table 1 (p. 27). The Rf values 
for various steroids are shown in tables 2 and 3 (up. 2 8 , 2 9 )•
After the chromatograms had been developed the steroids 
v/ere visualised on the plates under an ultra-violet lamp.
Steroids which absorbed light at 2if0 nm were visualized under
u.v. light of this wavelength while other steroids were vis­
ualized under light of 360 nm.
The steroids were eluted from the silica gel as follows:-
The steroid band was scraped from the plate into a small 
glass column with a filter paper disc in the bottom. The 
steroid was then eluted by pouring through 2 - ^ ml of a suitable 
solvent:- Ethyl AcetaterMethanol, 3/1 (v/v) for neutral steroids 
and their acetates. Methanol:Ammonium Hydroxide, 20/1 (v/v) for 
steroid sulphates. Recoveries of steroids from the plates were 
85 - 98%.
Descending Paper Chromatography was done on sheets of 
Whatman No.2 Chromatogranhy paper, 57cm long. The solvent 
systems used were of the volatile type described by Bush (1 96 1), 
(table 1). Glass tanks were lined with Whatman 3MM filter paper. 
Solvent (stationary and mobile phases) was poured into the bottom 
of the tank, which was then sealed and left 2i+ hours before use. 
Prepared chromatograms were then hung in the tanks and left to 
equilibrate for 2 - 3  hours. They were then developed with mobil 
phase at 22°C. After development the papers were dried in air. 
A L-3-oxosteroids were visualized by their absorption at 2^0 nm. 
Other steroids were then located by staining strips cut from the 
chromatogram in ethanolic phosphomolybdic acid solution (10%, w/v) 
The colour was then developed by heating the strips at 90°C for 
2 minutes when steroids showed up as green spots on a yellow 
background, (Bush, 1961). Bands corresponding to the steroid
table : 1.
SOLVENT s y s t e m s  f o p c h r o m a t o g f a p h y
A. Thin Layer Chromatography on Silica Gel.
I. chloroform:acetone 183:15 (v/v)
II. toluene:ethyl acetate 160:40 (v/v)
III. chloroform:ethanol 190:10 (v/v)
IV. toluene:ethyl acetate:cyclohexane 8 0 :5 0 : 20 (v/v)
V. cyclohexene:cyclohexanone 180:20 (v/v)
VI. benzene:ethyl acetate 180:20 (v/v)
VII. hexanerethyl acetate 150:50 (v/v)
VIII. diethvlether:ethyl acetate 190 :10 (v/v)
IX. ethyl acetate: 2-methyl-propan-2-ol; 
5M-NH,OH.
1 00:8 2 :40 (v/v)
X. chloroform:methanol:water 200:9:0.75 (v/v)
B. Paper Chromatography.
XI. light petroleum (b.p.100:120°C) -
methanol - K^O. 100:85:15 (v/v)
XII. light petroleum (b.p. 100:120°C) -
toluene : methanol - H^O 6 0 :40:85:15 (v/v)
System V was taken from Wright (1968)
System X was taken from Vandenheuvel (1968)
System IX was taken from Pierrepoint (1967)
The solvent sequences used in steroid separations are 
shown in Figs. 5 and 6 .(pp. 30 and 31)*
t-u.
table 2. CHROMATOGRAPHIC PPOPEPTIES OF STEROID CARRIERS. 1.
Rf in Solvent System
I II III IV
1 . androstenediol 0.15 0.07 0.35
2 . 3 ^-androstanediol 0.15 0.07 0.35
3. 3c(-androstanediol 0.15 0.07 0.35
4. 1-3 diacetates 0.71
3. testosterone 0.23 0.09
6. " acetate 0.63
7. DHA 0 . 2  9 0.17
8. " acetate 0.71
9. etiocholanolone 0.27 0.11 0.39
10. epiandrosterone 0.29 0.17 0.45
11 . dihydrotestosterone 0.32 0.17 0.52
12. androsterone 0 . 3 2 0.17
13. 9-12 acetates
14. androstenedione 0.43 0.19
15* 5<*-androstanedione 0.47 0 . 3 2
1 6 . 5p-androstane-3 y1 7-
dione
0.45 0 . 3 0
Rf in Solvent System
VI 'VII VIII +XI
1 . androstenediol 0 0 . 12 0.34
2. 3p-androstanediol 0 0 . 1 1 0.30
3. 3ot-androstanediol 0 0.13 0 . 3 8
4. 1-3 diacetates 0.52
5. testosterone 0 . 0 2 0.5
6 . " acetate 0.19
7. DHA 0.05 1.0
8 . " acetate 0.32
9. etiocholanolone 1 . 28
0 . epiandrosterone 1.28
1. dihydrotestosterone 1 . 28
2. androsterone 1.75
3. 9-12 acetates 0.3
4. androstenedione
5. 5<*-androstanedione
\
16. 5£-androstane-3-j 1 7-aione
' 3 x run 13 cm. + 16 hour run Ex relative to DHA = LO
0 - , .
\Li hour rur; Ex relative to androstenedicl = 1*0
.43
.40
XII
.0
.23
.70
table 3. CHROMATOGRAPHIC PROPERTIES OF STEROID CARPTERS. 2.
Testosterone Sulphate 
DHAsulphate 
DHAglucuronide 
Neutral steroids
Rf in Solvent System 
IX 
0.30 
0.30 
0.01
0.75 - 0.9
Fig. 5.
BASIC CHROMATOGRAPHIC SCHEME FOR SEPARATING C ^ -STEROIDS
SYSTEM I
Rf.O.OO-O . 10 Rf.0.15 Rf .0.23-0.32 R f .0.A3-V7
POLAR
FRACTION
ACETYLA^E
SYSTEM VI
Rf.0.00-0.2 
1 1AE
Rf.0.2-0.A 
1 6DA
SAPONIFY
16DA
Rf .0.32
SAPONIFY
SYSTEM III
SYSTEM II
AE
R f .0.30-0.32
3pAD 5aAD
SYSTEM XI
RD1.3 A
SYSTEM IV
AL EC EA 5 T
AE = androstenedione
1 1 AE = 1 ip-hvdroxyandrostenedione
5# AD - 3&-androstanedione
3pAD = 3p-androstane-3,17-dione
AL = androstenediol + androstanediols
A - androsterone
D - DHA
1 6DA = 1 6£X-hydroxy DHA-3, 1 6-diacetate
3 T = dihydrotestosterone
EA — epiandrosterone
EC = etiocholanolone
T testosterone
RD 1 .3 = Rf relativetoDHA = 1.3
Fig. 6.
SEPARATION OF ANDROSTENEDIOLS AND ANDROSTANEDIOLS
SYSTEM XII
16.Ocm 19 .0 cm 2 3 .Ocm 2 6.0 cm 2 9.Ocm
A 5 -A4 5oc-3p>, 1 7a. 501-301,17a 
5p-3(tf ,17k
SYSTEM VIII SYSTEM VII
5p-30i, 1 7p 5o(-3 p, 1 7p 50!-3Q{,17p 5f-3p, 1 7p
S N o . in cm refers to the distance of the centre of the carrier 
band from the origin after a typical 1A hour run in system XII
5<*-3p>, 17a  
, 1 7a 
5 p -3 a ,  1 7<x 
^6-3^, 170 
5 « -3 p ,  17/6> 
5o( - 3(X, 1 7(B 
5p-3pJ7 p
= androstenediol 
= A-androstene-3^,17£-diol 
= 5$-androstane-3p,17K-diol 
= 5<X-androstane-3<X, 1 7<X-diol 
= 3p-androctane-3(y, 1 7<X-diol
= 3p - a n d r o s t a n e - , 1 7/5-diol
= 3P~ardrostanediol
= SOi-androstanediol 
= 5p-androstane-3p,17^-diol
spots visualized by staining were cut from the rest of the 
chromatogram and the steroids eluted by soaking in 10 . 0 ml 
ethyl acetateimethanol, 3:1 (v/v) for 2 hours. This gave 
recoveries of 8 0-90%.
3. MEASUREMENT OF RADIOACTIVITY.
Radioactivity was measured in a Liquid Scintillation 
Spectrometer (NUCLEAR CHICAGO, Mark I).
Tritium was counted in one channel. At least 5000 counts 
and, in most cases, 10 , 000 counts were collected for each sample. 
Samples were dissolved in scintillator solution in glass counting 
vials:-
1. Crystals (0.5 - 2.0 mg.) were placed in the vial with the 
weighing pan.
2. Neutral steroids (and derivatives) dissolved in organic 
solvents were evaporated to dryness in the vial at 50°C, under 
a jet of filtered air.
3. Steroid conjugates or any compounds in aqueous solution were 
not evaporated.
Basic scintillator solution was toluene containing dissolved,
2 , 5 Diphenyloxazole (3*0 g/1) and
1, A-bis- 2-(A-Methyl-5-Phenyloxazolyl) -Benzene
(0 .1g/l)
Samples 2 and 1 excepting androstenediol and androstanediols 
were dissolved in 6 . 0 ml of this toluene scintillator.
For milligram quantities of androstenediol and androstanediols 
and for group 3 a toluene:ethanol scintillator was used:- 
toluene scintillator + ethanol 175:75 (v/v)
6 . 0 ml for androstenediol and androstanediols
10 . 0 ml, for steroid conjugates or steroids in aqueous 
solution
(this dissolves up to 0 . 2  ml of water)
Counting Efficiency:
For samples in toluene scintillator efficiency was A5-50%.
For samples in toluene:ethanol scintillator efficiency 
v/as 20-25%.
To correct for counting efficiency a standard solution of
scintillator was counted with each batch of samples.
Quenching.
No quenching was caused by up to 3 mg of neutral steroids 
dissolved in toluene or toluene:ethanol scintillator. There 
was no quenching of toluene:ethanol scintillator caused by 
steroid sulphates added in 0.2 ml of ethanol or methanol. 
Counting efficiency of aqueous samples was estimated by 
reference to a standard of 13h ] hexadecane in toluene:ethanol 
scintillator containing 0.2 ml of saturated NaCl solution. This 
was adequate as it was seldom necessary to count aqueous samples 
with a high degree of accuracy. When accurate counting of 
Quenched samples was needed internal standardisation with [yHj 
hexadecane was used to calculate counting efficiency.
4. ESTIMATION OF SmEP0ID CARRIER RECOVERIES.
This was done by u.v. absorption of- by g.l.c.
i . u.v. Absorption:
3oxosteroids and their acetates were measured by their 
absorption of light at 240 nmja Unicam S.P.500 spectrophotometer
v.rith matched silica cells was used.
An aliquot of the chromatographic eluate was evaporated to 
dryness and then dissolved in 4.0 ml of ethanol. Absorption of 
light at 240 nm was then measured against an ethanol blank. The 
concentration of steroid in the sample was then estimated from 
a calibration curve prepared from standards of varying concent­
ration and plotted as E240 .v. steroid concentration. This 
always gave good straight lines for testosterone, testosterone 
acetate and androstenedione (Fig. 7 p.34)« The absorption from 
blank areas of silica gel or paper eluted in the same way as the
(containing about ^0,CC0 d.p.m.) in appropriate
3k
Fig. 7
CALIBRATION CURVES FOF ANDROSTENEDIONE AND TESTOSTERONE
ZkO
0.3 TESTOSTERONE
ANDROSTENEDIONE
0.3
0.2
androstenedione ,l i t  / m lor testosterone
sample was measured with each batch of samples. These blanks 
generally gave E240 \0.02 and were subtracted from sample values. 
High blank values of E240 were found if there was contamination 
of the t.l.c. eluate by silica gel particles and care was 
taken to exclude them from eluates.
ii. Gas Liquid Chromatography (g.l.c.)
The following steroids were measured by flame ionization 
detection after g.l.c. :
1. androstenediol
2. 3[—  androstanediol
3. 3!Xr-androstanediol
4 . 1-3-diacetates
3. epiandrosterone
6. androsterone
7. etiocholanolone
8. DHA
9. DHA acetate
10. dihydrotestosterone
1 1 • 30(-androstanedione
12. 5p-androstane-3,17-dione.
A Pye series 104 gas chromatograph with hydrogen flame 
ionization detector linked to a Speedomax W. chart recorder 
was used.
Glass columns 4 ft long and 4 mm internal diameter were 
silanized and packed with 3% S.E.30 coated on acid washed sil- 
anized Gas-Chrom Q (100-120 mesh).
Column temperature was 230°C.
Carrier gas was nitrogen. Flow rate = 30 ml/min.
Under the above conditions, the free steroids all had 
retention times (relative to 3)(-cholestane = 1) of 0.38 -
0.46. However, as shown in Fig. 8 (p. 36) there was sufficient 
separation between compounds 5 - 8, 10, and 11 - 12 to make 
g.l.c. a useful check on their resolution by paper chromatography 
and t.l.c.
An aliquot (usually 1/20th) was taken from the eluate, 
containing the carrier to be measured. To this was added a
Fig. 8.
CARRIER STEROIDS WHICH SEPARATE ON G.L.C.
Conditions. 3% SE.30 on Gas Chrom Q (100-120mesh) 
Column temperature 230°C 
Carrier gas . Flow rate 50ml/min
1. = 3^-androstanedione
2. = 3^-androstane-3j17-dione
3. = dihydrotestosterone
4. = DHA, epiandrosterone, androsterone
5. = etiocholanolone
Table 4«
ACCURACY OF G.L.C. MEASUREMENTS.
DHA.Internal standard : progesterone.
knownyu g/sample Estimated f* g/saraple.
mean + S.E. (4)
2.0 2.03 1 0.07
4.0 3.90 +0.11
6.0 6.11 + 0 . 1 4
8.0 8.05 1 0.25
10.0 10.60 + 0.23
androstenediol diacetate. Internal standard: DHA acetate.
known^M g/sample Estimated yUg/sample.
mean + S.E. (5)•
2.5 2.53 + 0.10
5.0 4.94 + 0.10
7.5 7.52 + 0 . 1 8
10.0 9.66 + 0.23
15.0 14.8 + 0.30
androstenediol. Internal standard: pregnenolone acetate.
known yWg/sample EstimatedyMg/sample.
mean +_ S.E. (4)
2.5 2.56 + 0.10
5.0 5.02 + 0 . 1 4
10.0 10.5 + 0.28
12.5 12.7 + 0.50
known amount of another steroid to serve as an internal standard. 
The solution was evaporated and taken up in ethanol. 1-2^1 were 
then injected into the gas chromatograph. Aliquots generally 
contained 2-10^ /Ug of carrier. 1 Oy(ig of internal standard were added 
and the final volume of the ethanolic solution was 0.05 ml* Thus
0.0i+ - 0.2^ug were injected into the gas chromatograph. The 
peak heights of sample and internal standard shown on the chart
recorder were measured and the ratio of peak height of sample
to peak height of internal standard calculated. The mass of 
sample steroid was then determined from a calibration curve, 
constructed using varied quantities of sample steroid with a 
constant amount of internal standard and plotted as peak heights 
ratio v. mass of steroid.
The following internal standards were used:-
Carriers (p.35) Internal Standard
1 - 3  pregnenolone acetate
1 - 3 diacetates DHA acetate
5 - 8 ,  1 0 - 1 3  progesterone
9 androstenediol
diacetate.
Accuracy of g.l.c. measurement:
Linear calibration curves were obtained. The accuracy of 
the g.l.c. measurements v/as assessed by constructing standard 
curves and using them to estimate the concentrations of known 
standard solutions.Data are shown for DHA, androstenediol, and 
androstenediol diacetate (table k p.37)*
5. RECRYSTALLIZATION OF STEROIDS.
A known quantity of radioactive sample was taken in a 
test tube. To it was added 10 - 20 mg (accurately measured) 
of carrier for crystallization. If a large number of samples 
were to be crystallized the carrier was made up as a volumetric 
solution and added by pipette. Otherwise the carrier was 
weighed on the raicrobalance and transfered directly to the tube.
The sample and carrier were thoroughly mixed and then the 
solution was evaporated to dryness at 50°C under a jet of 
filtered air. The steroid was then dissolved in an appropriate 
solvent mixture and crystallized. Solvents used were acetone: 
hexane, acetone:water, benzene:hexane, chloroform:methanol: 
hexane, methanol:water. The tubes were left in a fridge at 
-20°C and then the mother liquor was removed. The crystals were 
washed and washings were combined with the mother liquor, which 
was then evaporated to dryness. Crystals and mother liquors 
were then left overnight in a vacuum dessicator to dry.
Weighing of Crystals:
Crystals and mother liquor residues were wreighed on a Cahn 
Microbalance, 0.5 - 2.0 mg of sample were weighed and then trans- 
fered directly to a scintillation counting vial with the weighing 
pan (a 1 cm square piece of aluminium foil) for radioactivity 
measurement.
Accuracy:
The 5 mg range of the balance was used. This allows 1 mg 
to be weighed to four significant figures. When a 1 mg weight 
was weighed at different times on different pans the maximum 
variation between recorded weights was 0.5%> and with a 0.5 mg 
weight the variation was 1% of the mean value.
6. PREPARATION OF DERIVATIVES.
Methods of Derivative formation were taken from Bush (1961) 
and Griffiths et al. (196.3)*
i. Acetylation of Secondary Hydroxyl Groups.
The solution containing the steroid was evaporated to 
dryness then equal volumes of anhydrous pyridine and acetic 
anhydride were added and the solutions left overnight in 
stoppered tubes at room temperature. For up to 300yug steroid,
0.1 ml pyridine and 0.1 ml acetic anhydride were used. After
reaction methanol was added and reagents were evaporated under 
a stream of filtered air.
For larger quantities of steroids (up to 5 mg) 0.5 ml 
of each reagent was used and after reaction the steroids were 
precipitated by adding water.
ii. Chromic Acid Oxidation of Secondary Hydroxyl Grours.
For up to 300 M g  of steroid the Kiliani Reagent, prepared 
according to Fieser and Fieser (1967), was used (5*3g CrO^ + 
8.0g H^SO^ + i+0 ml H^O). 0.2 ml of Kiliani Reagent was mixed
with 10 ml of acetone. The precipitate which formed was re­
moved by centrifuging then 0.5 ml of the supernatant was added 
to the dry steroid extract. The solution was left for 30 min. 
at room temperature then 2 ml of water were added and the 
steroids extracted with ethyl acetate. 1 - 5 mg of steroid 
were oxidized by dissolving in a small volume of glacial acetic 
acid then adding an equal volume of a 2% aqueous chromic oxide 
solution and leaving overnight at room temperature. Water was 
then added to precipitate the steroids. If precipitation was 
not satisfactory the steroids were extracted with ethyl acetate.
iii. Reduction of Ketonic to Hydroxyl Groups with Sodium 
Borohydride.
To the dried steroid extract kept at 0 - 4°C were added
0.3 ml of an ice-cold methanolic sodium borohydride solution 
(5 mg NaBH^ in 10 ml methanol). The solution was left at
0 - Zf°c for 20 min , 1 drop of glacial acetic acid and 1.0 ml
H2 O were then added and the steroids were extracted with ethyl 
acetate.
iv. Saponification of Acetates.
For up to 300yug steroid,0.25 ml of 2% aqueous potassium 
carbonate were added to the extract which had been dissolved
in 1.0 ml of methanol. The solution was left overnight at
room temperature, then 3«0 ml H-,0 were added and the steroids 
extracted with ethyl acetate. For larger amounts of steroid 
proportionately larger quantities of reagents v/ere used.
7. CONTROL INCUBATIONS.
A control incubation with each substrate was carried out 
along with every batch of tissue incubations. The controls 
were taken right through the analytical procedure or until 
the radioactivity associated with any carrier, except the 
incubated substrate, was less than 0,02% of the total radio­
activity. In the case of an incubation with k x 10^ d.p.ra. of 
starting substrate, this amounts to there being a total of 
less than 200 c.p.m. in any carrier after purification. In 
practice, this was routinely achieved and reported % conver­
sions to any metabolite from tissue incubations were always 
equal to or more than 1 Ox the maximum possible % conversions 
in the control.
androstenediol : After acetylation and t.l.c. in system VI 
androstanediols: there was <0 .02% conversion to this group
of compounds in controls.
testosterone : In general, after purification by either
derivative formation or recrystallization there was < 0 .02% conversion 
to testosterone in controls (except testosterone controls of 
course). However, in experiments 5D and 5AE (pp.93-109 ) there 
was about 0 .1% conversion to testosterone in the controls.
epiandrosterone, etiocholanolone ) After recrystallization there
androsterone, dihydrotestosterone ) was <0 .02% conversion to
these in all controls.
androsteredione : Controls from DHA and testosterone incubations 
contained (0.1% conversion to androstenedione and DHAsulphate 
controls contained <0.01% androstenedione. This was usually 
10x less than the % conversion in corresponding tissue incub­
ations.
5^-androstanedione : The amounts of radioactivity associated 
with the carrier could be reduced to (0.02% in DHAsulphate 
and DHA controls. In androstenedione and testosterone controls, 
there was sometimes about 0 .1% conversion to 5iX-androstanedione. 
However, this was negligible compared to the % conversions in 
tissue incubations.
DHA : (0.5% in all controls (except DHA incubations). In 
DHAsulphate experiments the % conversions to DHA in tissue 
incubations were always 10x greater than those for controls.
DHAsulphate : (0.02% in androstenedione and testosterone con­
trols. <0.1% in DHA controls - always 10x less than in tissue 
incubations.
epiandrosterone sulphate : About 0.1% conversion after re­
crystallization of epiandrosterone to constant specific activity 
from DHAsulphate controls and tissue incubations. (0.02% in all 
other controls.
Polar Neutral Fraction : <1% in all controls compared with 
10% in most tissue incubations.
Sulphates of testosterone, androstenedione, 5o(-androstanedione, 
androstenediol, androstanediols, androsterone, etiocholanolone, 
dihydrotestosterone: <0.02°^ conversion after solvolysis, 
chromatography and recrystallization of the appropriate fractions.
In practice the average recovery of the four substrates used
in control incubations was 90% (75 - 100%). However in only one
DHA control was the low recovery of 75% obtained. The recoveries 
of substrate from the other 11 controls ranged from 89 - 100%.
8 . HISTOCHEMISTRY.
Histochemical localization of hydroxysteroid dehydrogenase 
activity was done by the method of Muir et al. (1968). This 
consists of the following steps :
1. tissue was frozen on solid C0 2then 10^thick sections 
were cut in a cryostat at -20°C and attached to glass 
coverslips by momentary thawing.
2. The section on the coverslip was covered with 1.0 ml of
incubating medium and incubated for 2 hours at 37°C.
3. The sections, attached to coverslips were washed in 
water, stained with Mayer's Haematoxlin, dehydrated in
alcohol and counterstained with a saturated solution of 
tartrazine in methyl cellosolve.
4. The coverslips were mounted on glass slides and examined 
to localize the blue-black deposits of nitrobluetetrazolium 
diformazan which indicate sites of hydroxysteroid dehydro­
genase activity.
Incubating medium contained in 9.7 ml of 0.1M-sodium phos­
phate buffer pH7-4 0.3 mg steroid dissolved in 0.3 ml dimethyl
formamide, 2.0 mg NAD+ or NADP+ and 1.0 mg nitrobluetetrazolium. 
Blank incubations which contained no steroid were carried out. 
Control incubations were carried out to demonstrate the presence 
of NAD(P)H-diaphorase activity in the sections; the incubating 
medium contained in 10.0 ml of 0.1M sodium phosphate buffer 
pH7.4 : 2.0 mg NADH or NADPH and 1.0mg nitrobluetetrazolium.
9. AUTORADIOGRAPHY.
Autoradiographic demonstration of the uptake of I.'H jthymidine 
into cell nuclei was done using a modification of the method of 
Lachapelle and Gillman (1969). This consisted of the following
steps :
1. Slices of skin 0.5 - 0.7 mm. thick were cut writh the 
multibladed slicer (p.20). The slices were incubated in
20.0 ml of tissue culture medium 199 (Morgan et al., 1950) 
containing 2.0^Ci/ml £6- H]thymidine (so. act. 25Ci/mmol.) 
at 37°C for two hours under an atmosphere of 95%02 : 5%C0 2 »
2. The slices were removed from the medium, washed three
times with 10 .0 ml of tissue culture medium to remove 
x
unincorporated [ H]thymidine and frozen on to chucks for 
sectioning in a cryostat at -20°C.
3. Thin (7 - 10>u) frozen sections were cut, mounted on 
glass slides by momentary thawing and fixed in calcium- 
formol solution (8% aqueous formaldehyde containing 10%, 
w/v, calcium chloride).
4. Autoradiography was done with Kodak AR - 10 stripping
film (see Ruthmann, 1970). The exposure was for four 
weeks, during which time the film covered slides were 
kept in a light-tight box at 4°C. After developing and 
fixing (D . 1 9 Eastman-Kodak developer) the autoradiographs, 
the sections were stained through the film with haematoxlin 
and eosin.
Part III
EXPERIMENTS AND RESULTS.
1. AUTORADIOGRAPHIC AND HISTOCHEMICAL DEMONSTRATION OF 
VIABILITY OF SKIN INCUBATED IN VI^RO.
Slices of skin composed mainly of whole cells were incubated 
in a Krebs Ringer-Bicarbonate-buffered medium (Krebs Improved 
Ringer I medium (Krebs, 1950). It has been shown that human 
and animal skin slices take up oxygen and evolve carbon dioxide 
when incubated in such media (Wohlgemuth and Klopstock, 1926; 
Gilbert 1962). This avoided the addition of cofactors such as 
NAD+ , NADP+ , ATP.
Histological examination of skin slices which had been 
incubated for up to 4 hours in Krebs Improved Ringer I medium 
showed that they retained a relatively normal appearance (photo.
2 , p. 4 6 ).
An autoradiographic experiment with male forehead skin
showed that ]_ H]thymidine was incorporated into cell nuclei of
sections cut from all levels of 0 . 5  - 0 . 7  mm thick skin slices
incubated in vitro.
The 0.5 - 0.7 mm thick slices, cut with the multibladed
cutter, were incubated with pHlthymidine in medium 199 (Morgan
et al., 1950) under 95%Op : 5%C0p at 37°C. for 3 hours. The slices
3were then washed to remove excess R H^thymidine and frozen on 
solid C0o. 10yu thick transverse sections were cut parallel to 
the largest face of each slice in a cryostat at -20°C. Every 
other section from a slice was taken on to a glass slide, fixed 
in calcium formol, dehydrated and then treated to demonstrate 
incorporation of radioactivity into DNA by the autoradiographic 
technique (p. 43). The other sections from each slice were 
treated to demonstrate NADH-diaphorase, NADPH-diaphorase and 
NAD+ dependent testosterone 17B-HSD (p. 42).
Results: Uptake of R^HJthymidine into cell nuclei could be demon­
strated in sections cut from all levels of the skin slices (photo.
3, p. 47). Cells in the middle of sebaceous acini did not usually 
show any radioactive nuclei. This is not surprising as the nuclei 
of these cells are gradually being destroyed (Montagna, 1963)
and mitotic figures are rare in the central acinar cells. Most
Photo 2.
SKIN HISTOLOGY AFTER IN VITRO INCUBATION
Breast skin was cut into 0.5 mm thick slices and incubated for 
k hours in Krebs Improved Ringer I medium at 37°C under an 
atmosphere of 95% 0^ : 5% C0 2 * The skin was fixed in calcium- 
formol solution, dehydrated with alcohol and embedded in wax. 
Sections 5^ thick were cut and stained with Haematoxlin and Eosin. 
The relatively normal appearance of sebaceous gland and surrounding 
tissue is seen.
Magnification X 650.
Photo 3.
UPTAKE OF c ’K']THYMIDINE INTO SEBACEOUS GLAND CELLS.
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0 . 5  mm thick slices of forehead skin were incubated with if'H] 
thymidine in medium TC.199 as described (p. A5)» Sections were 
cut and the incorporation of ^H into cell nuclei demonstrated 
by autoradiography.
Incorporation of [_H]thymidine (arrows) into the nuclei of 
sebaceous gland cells is shown.
Magnification X 650.
cell division in sebaceous glands occurs around the edge of the 
acini. An occasional cell with radioactive nucleus was seen in 
the centre of a sebaceous acinus.
After 3 hours of incubation, NADH and NADPH diaphorase still 
showed a histochemical reaction in all cells of sections cut 
from all levels of the skin slices. This indicated that the part 
of the electron transport chain involved in transfer of electrons 
from NADH to the acceptor nitrobluetetrazolium was still functional. 
Sebaceous gland cells showed 17P»^ *HSD activity when testosterone 
was used as substrate and NAD+ as cofactor.
Conclusion : The 0.5 - 0.7 mm thick whole skin slices are satis­
factory for incubation experiments as far as viability and 
diffusion of small molecules is concerned.
2. PRELIMINARY INCUBATION EXPERIMENT WITH [70C - V )  DHA.
i. Experimental.
Full thickness skin was obtained from the midline side of 
the breast of a AO yr. old woman who underwent mastectomy for 
breast cancer.
The skin was trimmed of subcutaneous fat, sliced and 2 g 
of slices were incubated with A3 nmol of|~7o(- ^Hj DHA ( s p .  act.
= 500 mCi/mmoL)in 25.0 ml of Krebs Original Ringer Bicarbonate 
medium (Krebs, 1950) containing glucose (0.23%, w/v). Incubation 
with shaking was for 3 hours at 37°C. under 95%0p : 5%C0 2 * The 
steroid was dried down in the incubation flask from methanol: 
benzene solution containing A drops of propylene glycol. The 
Krebs medium was then added to dissolve the steroid., A control 
incubation with steroid but no skin was carried out.
The incubations were terminated by adding 50 ml of acetone. 
Then the following unlabelled carrier steroids dissolved in 
ethanol were added to each flask: DHA (500^ug), testosterone 
500^ig), androstenedione (500^g), androstenediol (500yttg) and DHA­
sulphate (500/ug). About 1 g of skin slices were added to the 
control and then all flasks were kept at -20 C overnight.
The radioactive steroids were then extracted, as described 
in Part II Sections 1.i and 1.ii. :The neutral steroid extracts 
were separated in system I. The isolated steroids were then 
purified to constant specific activity by t.l.c. and derivative 
formation (Part II section l.iii - iv) as shown in table 5 below.
CHARACTERIZATION OF RADIOACTIVE STEROIDS BY CHROMATOGRAPHY
AND DERIVATIVE FORMATION WITH AUTHENTIC CARRIERS -
Compound isolated Solvent Rf.same Specific activity
and chemical system. as (d.p.m./nmol)
reaction
DHA I DHA 2 7 ,6 0 0
acetylated VI DHA acetate 2 6 ,5 0 0
DHAsulphate IX
solvolysed I DHA 742
acetylated VI DHA acetate 743
saponified I DHA 790
an drostenediol I
acetylated VI androstenediol
diacetate 95 . 1
table 5 .
saponified I androstenediol 92.5
androstenedione I androstenedione 34.5
reduced I testosterone 30.3
acetylated VI testosterone acetate 2 9 . 8
testosterone I
acetylated VI testosterone acetate 12.6
saponified I testosterone 7.0
oxidized I androstenedione 1 .2
(ii) Pesults :-
There was very little metabolism of DHA in this experiment. 
Fvidence was obtained for formation of [_^HJandrostenediol, 
androstenedione and L5h ]  DHAsulphate (table 5 ) .  Percent convers­
ions are shown in table 6 (p. 5 0 ) .  Radioactivity associated with 
testosterone carrier fell to 0.005%  of the total radioactivity 
after purification by t.l.c., acetylatior and chromic acid
oxidation. mhe DHA fraction was chromatographed on paper in 
system XI. Scanning of this chromatogram showed only one peak 
which had the mobility of DHA. The recovered [^H]DHA accounted 
for 92% of the total starting radioactivity. Some radioactive 
material remained at the origin after t.l.c. in system I. This 
was about 9% of the total radioactivity and in the control 
about 1%.
table 6 .
METABOLISM OF [7ltf-5H]DHA IN BFEAST SKIN FROM A WOMAN AGED Z*0 YEARS.
Radioactive Steroid % conversion/3 hours/2.0 g tissue
1DHA S92
DHAsulphate 1 .9
androstenediol 0 . 3
androstenedione 0 . I
testosterone ^ 0 .0 0 5
polar neutral fraction 4
2.0 g of skin slices were incubated for 3 hours at 37°C. in
23.0 ml of Krebs Ringer Bicarbonate Glucose medium with
A3.0 nmol L7k,-^HJDHA under an atmosphere of 95% 0-, : 5% CO-,.
§ This figure represents initial substrate remaining after 
3 hours, ie:% not converted.
(iii) Discussion
The conversion of DHA to DHAsulphate confirmed the presence 
of a steroid sulphotransferase enzyme in human female skin. In 
the same skin specimen, the activity of A^-3B-HSD and 17p-HSD 
must have been low. This was shown by the meagre formation of 
androstenediol (0 .3%) and androstenedione (0 .1 >%) and the 
absence of testosterone formation.
3. METABOLISM OF DHA IN HUMAN FEMALE BPEAST SKIN.
EXPERIMENTS ID AND 2D.
After the preliminary experiment it seemed that the rate 
of DHA metabolism in breast skin was very slow. As Chakraborty 
et al. (1970) had found previously that they could increase the 
percent conversion of DHA by lowering the DHA concentration from 
3 -^O^ aM to 17.0yUM, it was decided to try some further experiments 
with breast skin using lower DHA concentrations. In addition, 
if the 17|S-HSD of skin could act on both DHA and androstenedione 
then the presence of a large excess of DHA over a much smaller 
concentration of its metabolite androstenedione could effect­
ively inhibit the conversion of the latter steroid to testo­
sterone, if the concentration of the 17/3-HSD was small enough 
to be saturated by the DHA. In such a case, it might be possible 
to increase formation of testosterone by using a lower initial 
DHA concentration,
i) Experimental :
Skin samples from the midline side of the breast were 
obtained from two women who underwent mastectomy as treatment 
of breast cancer. They were aged 52 years (specimen 1, exper­
iments 1a and 1b) and 2+8 years (specimen 2, exreriments 2a and 
2b). The skin appeared grossly normal. The piece from the 
woman aged 48 showed two coarse hairs but the piece from the 
woman aged 52, showed no sign of any hairs. Histological exam­
ination (Dr. F.M. Vint) showed each specimen to have a normal 
appearance.
From each skin specimen were cut two pieces weighing about 
1 g. The rest was frozen at -20°C and kept for histology. Each 
piece was trimmed free of subcutaneous fat, weighed and cut into 
slices 0.5 - 0.7 mm thick. The slices were then incubated in 
Krebs Improved Ringer I medium (10.0 ml/g tissue) containing 
[7x-^HjDHA (sp.act. 500 mCi/mmol). For one lot of slices from 
each specimen (experiments la and 2a) the DHA concentration was 
3«5^M (17 jlACi) and for the other lot (experiment 1b and 2b) it
was 0. 35^*M (1 . T7yUCi). The steroid was dried down from methanol 
solution containing 50^.1 of propylene glycol and then dissolved 
in Krebs medium. Incubation with shaking was for 3 hours at 
37°C under 95%02 : 5%C02 -
The incubations were stopped by adding 40 ml acetone. The 
following carrier steroids dissolved in ethanol were then added 
to each flask:
DHA (300yfcg) (600 jxg DHA in control 1c)
DHAsulphate "
androstenediol "
testosterone "
dihydrotestosterone "
androsterone "
epiandrosterone "
etiocholanolone "
androstenedione "
5K-androstanedione M
All flasks were kept at -20°C overnight. The radioactive 
metabolites were extracted,purified and estimated and their 
identity and radiochemical purity was established after repeated 
t.l.c., derivative formation and recrystallization to constant
specific activity with authentic carriers (Part II sections 1.
ii - 1.iv, 2 . Fig.5)•
ii) Results :
A radiochromatogram scan after t.l.c. of the neutral
fractions in system I showed that there had been much more
metabolism of [7oC_ ^Hj DHA than in the first experiment. The
- 3  “ ievidence for identification of those V H J metabolites purified 
by derivative formation is given in table 7 (p. 55) ar!^  of those
purified by recrystallization in tables 8a - h (pp. 5 6 -6 0 ).
Percent conversions to the different metabolites are shown in 
table 9 (p. 65)* Identification methods for certain DHA 
metabolites deserve further mention :
(a) The androstenediol fraction isolated after t.l.c. of the 
diacetate and free steroid could have contained various isomers 
of androstanediols. The fact that the radioactivity remaining
with androstenediol after recrystallization accounted for 85% 
or more of the radioactivity in the androstenediol carrier 
fraction (table 8d) eliminated the possibility of a significant 
formation of most androstanediols (506 and 5f*)« However, in 
view of the evidence for some dihydrotestosterone formation 
the androstenediol fraction was also checked for the presence 
of 3(X-androstanediol and 3^-androstanediol. Aliquots of the 
androstenediol fractions from experiments 1a and 2a were cry­
stallized with 3D(-androstanediol. After two crystallizations 
less than 2% of the radioactivity remained with the crystals. 
Therefore it was concluded that neither androstenediol fraction 
contained 30(-androstanediol in measurable quantity (/0.01% 
conversion). Further aliquots from the same experiments were 
crystallized with 3p-androstanediol. After five crystallizations, 
the specific activities had fallen to 51% and 62% of the 
theoretical values (for 100% purity) without having become 
constant. It is probable that androstenediol and 3^-androstane- 
diol cocrystallize like DHA and epiandrosterone (see below).
There was insufficient material for any further investigations. 
However, as crystallization with androstenediol gave constant 
specific activity of 85% or more of the theoretical value, it 
was concluded that this compound was the major component of 
this fraction.
(b) epiandrosterone :
Evidence for conversion of {70(-3hJ DHA to T/H^) epiandrosterone 
appears in table 8f. It was noticed that the epiandrosterone 
fraction from the control incubation, v/hich contained radio­
activity after chromatography, could not be cleared of this 
radioactivity after crystallizations with authentic epiandrosterone. 
Similarly, the specific activity of the epiandrosterone fraction 
from experiment 1a, fell gradually over 4 crystallizations 
without becoming constant. Chromatographic separation of epiand­
rosterone and DHA is difficult and possibly the epiandrosterone 
fractions from the control and experiment 1a were contaminated 
by [3H 3 DHA which might cocrystallize with epiandrosterone 
carrier. Possible cocrystallization of DHA and epiandrosterone
* 1 •
was therefore checked in the following way :
26,000 c.p.m. of DHA (purified chromatographically in systems 
I and XI) were added to 12.0 mg of unlabelled epiandrosterone, 
which was then recrystallized from acetone-hexane:-
Specific Activity No. of Crystallizations % Theoretical sp.act
of the Crystals 
(c.p.m./mg.)
1690 1 79.2
1 ^ 5  2 67.7
1380 3 6*f. 8
1165 6 54.6
1000 + 8 46 .8  
carrier acetylated before 7th crystallization.
Obviously, recrystallization of neither free steroids nor 
acetates was satisfactory for distinguishing epiandrosterone 
from DHA.
When a A~3p-bydroxysteroid is oxidised with chromic acid, 
it forms a ZV-3>6 diketone, however an A-ring saturated 3p- 
hydroxysteroid simply forms the corresponding 3-monoketone. If 
[7<X-^h] DHA is oxidized to 4-androstene-3 , 6 , 1 7-trione tritium is 
lost from the steroid molecule, possibly due to enolization of 
the 6-ketone (Pierrepoint et al., 1967). Such a reaction should 
be useful for distinguishing [7o6-^hJdHA from [7(X.-^ Hj epiandrosterone. 
43jOOO c.p.m. of [7&- H] DHA were mixed with 5*16 mg of unlabelled 
epiandrosterone. The mixture was oxidized with chromic acid 
(p. 40), and the recovered 5oL-androstanedione precipitated from 
water then recrystallized once from aqueous acetone. The 
specific activity of the crystals was 67 c.p.m/mg (0.8 % 
theoretical value), showing that this was a good method of 
distinguishing [7<X-^Hl epiandrosterone and ^ 7oL-^ClDHA. The epiand­
rosterone fractions from experiments 1, 2 and control were there­
fore oxidized with chromic acid after 4 crystallizations. In 
experiments 1b, 2a, 2b, the specific activity of the crystals 
(which was constant before oxidation) remained unchanged. This
Table 7.
METABOLISM OF DHA IN HUMAN FEMALE BREAST SKIN
INCUBATIONS 1 a 1b 2a 2b CONTROL 1c.
CHARACTERIZATION OF RADIOACTIVE STFROIDS BY CHROMATOGRAPHY 
AND DERIVATIVE FORMATION WITH AUTHENTIC CARRIER STEROIDS.
Steroid investigated 
and chemical reaction
Rf. same 
as that of
Solvent
system
1 a
like DHA 
acetylation
DHA
DHA acetate
XI
VI
25800
22600
like androstenedione
reduction
acetylation
androstenedione 
testosterone 
testosterone acetate
II 
I
III
655
678
606
like testosterone 
acetylation 
saponification 
oxidation 
reduction
testosterone 
testosterone acetate 
testosterone 
androstenedione 
testosterone
XI
VI
I
I- 1 
I
32.6 
21.8 
21.3 
20.2
like androstenediol
acetylation
saponification
androstenediol
" diacetate 
androstenediol
I
VI
III
kk&
398
like 5<X.-androstanedione
i t
i t
5(X-androstanedione
i i
I I  T
II
III
V
1740
1700
like DHAsulphate 
solvolysis
DHAsulphate
DHA
DHA
IX
I
XI
1210
983
7b
Table 8a—8h.
METABOLISM OF DHA IN HUMAN BREAST SKIN.
EXPERIMENTS 1a, 1b, 2a, 2b AMD CONTROL 1c.
IDENTIFICATION OF RADIOACTIVE STEROIDS BY RECRYSTALLIZATION TO 
CONSTANT SPECIFIC ACTIVITY.
Breast skin was incubated with [Vtf-^HjDHA at a concentration 
of 3» 5/VM (17.0|kCi) in incubations 1a, 2a and 1c or 0*35JiM 
(1.7^Ci) in incubations 1b and 2b.
Radioactive steroids isolated by chromatography were mixed 
with authentic carrier and recrystallized to constant specific 
activity.
Specific activities (1, 2, 3) were measured after successive 
crystallizations.
^c = sp.act. of crystals, m = sp.act. of mother liquors.
Table 8a
steroid : [^HjDHA derivative crystallized: acetate,
solvents : acetone-water.
Specific Activity (d.p.m./mg) % calculated
sp.act.
1 2 3
c m c m c m
1 a 8220 8020 8020 8150 7500 7750 98
1b 2165 2180 2170 2170 21 85 2060 103
2a 12Z+00 12700 12500 12800 12500 - 100
2b 1 900 2360 1920 1990 1930 - 97
1 c 17900 17300 16800 17A00 1 7100 - 102
Table 8b.
steroid : [^H]DHAsulphate. derivative crystallized: DHA.
solvent : acetone-hexane.
Specific Activity (d.p. m./mg) % calcuL 
sp. ac
1 2 5
c m • c m c m
1a 6130 5920 6020 - 6030 5350 99
1b 693 718 685 - 705 625 92
2a 3510 3390 3510 - 3480 3430 97
2b 495 506 487 - 482 484 85
Table 8c.
steroid : L5h ] dihydrotestosterone carrier : 2 0 .0mg
derivative crystallized : parent steroid and acetate.
solvents : acetone-hexane, acetone-water, methanol -water.
Specific Activity (d.p. m./mg) % calculate^ 
sp.act.
1 2 3 4 5 +
c m c c c c
1a 2^7 1480 46 52 41 33 22
2a 502 1300 399 377 393 353 42
2b 184 21 9 162 172 161 _ 54
Because of poor recoveries of crystals from
the first and second recrystallizations, there
was not enough material left to recrystallize
for a fifth time. Therefore the mother liquor
residues obtained after crystallizations 1 - 4 
were combined scrystallized 4 times, acetylated and
the acetates crystallized a further 3 times before 
specific activity measurement.
Table 8d.
steroid :
derivative :
£ H 2 androstenediol
solvent : acetone-hexane.
1
Specific -Activity (d.
2
p.m./mg)
3
%
4
calculated 
sp.act.
c m - c m c m
1a 1470 1465 1605 1590 1380 1505 90
1b 161 210 133 188 - 92
2a 1060 1090 1080 1315 932 1083 87
2b 221 251 205 161 173 21 1 85
Table 8e. 
steroid :
3
LH] androsterone carrier : 2 0 . 0 mg
derivative : -
solvent acetone-hexan e.
Specific Activity (d.p.m./mg) 
- 2 3 
m C m c m
la 159o 1680 1420
1b 585 615 605
2a 14800 15200 14900
2b 4070 3910 ^420
148 0 
642 588 
14900 14300
4270 4380
% calculated 
sp.act.
I55O
600
15100
4500
92
86
91
103
Table 8f.
steroid : [; H j  epiandrosterone carrier : 20.0 mg
derivative : parent steroid; 5^-&ndrostanedione
solvents : acetone-hexane, acetone-water.
Specific Activity (d.p.m./mg) % calculated
sp.act.
1 •2 3 4 5 6+ 7
c m c ' m c m c c c c
1 a 3110 6080 3100 4475 2740 2540 2490 343 - 8
1 b 161 380 124 202 161 166 121 161 159 - 89
2a 2 820 4620 2920 3000 3020 3000 3050 3050 2900 2950 73
2b 309 648 305 245 259 - 284 326 290 285 70
+
crystals oxidized to 50(-ar drostanedione before the 6th 
recrystallization.
Table 8g.
x _
steroid : j_ HJ androstenedione. derivative crystallized:
testosterone acetate.
solvents : acetone-water, acetone-hexane.
Specific Activity (d.p.m./mg) % calculated
1 2 3
sp
c m c m c m
1 a 868 1051 881 880 888 - 90
1b 64 • 8 87.3 62.9 78.4 59.7 - 65
2a 607 656 610 648 598 - 92
2b 122 157 115 134 119 76
Table 8h.
steroid
solvents
L5h] 50C~androstanedione. 
acetone-water
Specific Activity (d.p.m./mg)
m
% calculated 
sp.act.
la 3260 2800 3240 - 2730 3040 98
1b not crystallized
2a 5350 4850 5070 - 3020 4780 100
2b 1930 1390 1910 1900 1925 1770 102
was taken as good evidence that the radioactivity in these 
fractions was ["’Hiepiandrosterone. Radioactivity was lost 
from control crystals after oxidation. The specific activity 
of theepiardrosterone crystals from la fell to 8% of the 
value immediately before crystallization. This residual radio­
activity possibly represented [^Hjepiandrosterone.
(c) etiocholanolone :
Radioactivity was present in this fraction isolated from 
tissue and control incubations. However, after recrystallization 
twice with authentic etiocholanolone only 5% of this remained 
with the crystals (<^0.001 % conversion).
(d) -androstane-3,17-dione :
1OOyKg of this carrier was added to the 5K-androstanedione 
fractions before t.l.c. in system V, which separates these two 
isomers. After t.l.c., some radioactivity remained with 5p- 
androstane-3,17-dione carrier. This carrier was seen on g.l.c. 
to be contaminated with about 10% of 5K.-androstanedione• After 
another t.l.c. in system V all measurable radioactivity was lost 
from 5p-androstane-3 ,17-dione carrier.
(e) Sulphate Fraction :
The neutral steroid fraction obtained after solvolysis of 
the sulphate fractions was separated according to Fig. 3 (p.30). 
Only the DHA carrier was associated with a significant amount of 
radioactivity. This provided evidence for conversion of DHA 
to DHAsulphate (tables 7, p. 55 and 8b p. 37 ).
(f) Polar Fraction :
This fraction remained at the origin after t.l.c. of the 
neutral steroid fraction in system I. It accounted for 10 -23% 
of the total radioactivity in tissue incubations, no correction 
being made for extraction losses. In the control incubation, 
it accounted for 0.8% of the total radioactivity. The polar 
fractions from 1a and 2a were combined. An aliquot was partit­
ioned L[ times countercurrently between toluene and 0.1 M NaOH 
(Fig. 9 p ■62 ).
90% of the radioactive material was extracted into the 
toluene fractions. As seen in Fig. 9, there v/as some residual
FOUR TRANSFER COUNTERCURRENT DISTRIBUTION OF POLAR 
FRACTIONS POOLED FROM INCUBATIONS 1 a AND 2 a 
BETWEEN TOLUENE AND O.IM-NaOH.
3 RADIOACTIVITY TOLUENE
0.2
NaOH
2 3 5
TUBE NO.
27,000 c.p.m.of polar fraction (non-conjugated material remaining 
on the origin after t.l.c. in system I) were partitioned four 
times countercurrently between 2.0 ml volumes of toluene and O.IM- 
NaOH. Aliquots of the toluene and NaOH phases from each tube 
were removed for counting. Radioactivity in each phase is expresse 
as a fraction of the total c.p.m. partitioned •
Fig. 10
REACTION OF COMBINED POLAF FRACTION FROM EXPERIMENTS 1 a 
AND 2 a  WITH GIRARD'S REAGENT-T
MOI OHYDFAZONE
NON-KETONIC
DIHYDRAZONE
20,000 c.p.m. of polar fraction were applied to a silica gel 
t.l.c. plate and reacted in situ with Girard's reagent-t 
overnight, by the method of Lisboa (1966). Marker steroids 
were treated similarly on the same plate. The plate was then 
run in a solvent system consisting of the upper phase obtained 
after shaking together equal volumes of butan-1-ol, 2-methyl- 
pronan-2-ol and water. Scanning of the chromatogram for radio­
activity revealed two peaks, a major one having the mobility of 
a steroid monohydrazone and a minor one having the mobility of 
a free steroid. Marker steroids were visualized by spraying the 
plate with a solution of conc.H^SO^ in ethanol (50%, v/v) and 
heating at 110°C.
1. = 3^-androstanediol standard + unreacted DHA and androsteneaione.
2. = DHA and androstenedione monohydrazones.
3. = androstenedione dihvdrazone.
radioactivity which partitioned in favour of NaOH solution.
This alkali soluble material could not be any more readily 
extracted into toluene or diethyl ether after acidification of 
the aqueous solution, showing that it was not necessarily 
phenolic.
Another aliquot of the polar fraction ( 20,000 c.p.m.)
was run on t.l.c. in system X (chloroform : methanol : water,
200 : 9 : 0.75, v/v). The plate was scanned and one radioactive 
peak was seen, which appeared to run just behind a 5-androstene 
-3p , 1 6o(, 1 7p-triol standard (Rf.0.16). Another aliquot of the 
polar material was acetylated. This changed the mobility in 
System X to Rf. 0.78, suggesting the presence of esterifiable 
hydroxyl groups. t.l.c. in system VI (benzene : ethyl acetate,
180 : 20 v/v) showed an Rf. 0.12; this is less than that of 5- 
androstene-3p , 1 6 oc, 1 7p-triol triacetate (Rf. 0.26), 1 6(X.-hydroxy- 
DHA-diacetate (Rf. 0.29) or testosterone acetate (Rf. 0.13), 
suggesting that the material had ketone or unesterifiable 
hydroxyl groups. An aliquot of the original polar fraction was 
reacted with Girard's reagent-t (trimethylacetohydrazide) by the 
method of Lisboa (1966) and the resulting products run on t.l.c. 
as described in Fig. 10 (p.63). Two similarly sized peaks were 
seen on scanning, one of Rf. 0.21 indicating a monohydrazone 
and another of R.f. 0.70 indicating an unreacted steroid. When 
another aliquot of polar fraction was reacted with a greater 
excess of Girard's reagent the monohydrazone peak accounted for 
about 8C% of the radioactivity on the t.l.c. plate and the 
unreacted material about 15% (Fig. 10). It was concluded that 
the polar material had one ketone and at least two hydroxyl 
groups.
(g) 1 6iX,-hydroxy DHA (3p , 1 6c(-dihydroxy-5-ar drostene-1 7-one ).
200^*g. of this steroid were added to the androstenediol 
fraction from experiment 2a after t.l.c. in system I. Acety- 
lation and t.l.c. in system VI separated the two carriers.
There was radioactivity in the 16oL-hydroxy DHA diacetate fraction. 
The fraction was saponified and chromatographed on silica gel 
in cyclohexane:ethyl acetate (1:1, v/v). The carrier was still
Table 9.
METABOLISM OF DHA IN HUMAN FEMALE BPEAST SKIN.
PEPCENT CONVERSION/3 HOURS.
Female 52 years Female A8 year
1 a 1b 2 a 2b
DHA 58.5 A8.3 72.3 AO.O
DHAsulphate 2. A 3.1 1 • 6 2.9
androstenediol 1 .0 0.7 0.8 1 .0
androstenediol sulphate - - -
androsterone 0.5 3.1 5.5 1A • 6
epiandrosterone 0.1 0.6 0.8 1.1
testosterone 0.05 0 .0 8 0.03 0.20
•dihydrotesterone 0.05 - 0.2 0.7
androstenedione 1.5 1.8 1 .2 A. 1
5<X-androstanedione A.2 6.A A.5 9.8
polar neutral steroids 20 18 10 23
Initial DHA concentration: a = 3*5 pM b = 0.35>*M
§
= % steroid substrate recovered.
Breast skin was incubated in Krebs Improved
Ringer I medium with [7ol- Hj DHA for 3 hours
at 37°C under an atmosphere of 95%0P : 5%CO„
C- C— •
The radioactive products were isolated and 
estimated as described in the text.
radioactive and remained so after further t.l.c. in cyclohexane: 
ethyl acetate:ethanol (8:8:2, v/v). The radioactivity in the 
16tf.-rhydroxy DHA fraction was now about 0.1% of the total starting 
d.p.m. (uncorrected for losses). However, when this fraction was 
recrystallized with 6.0 mg of authentic 16ot-hydroxy DHA constant 
specific activity could not be obtained (specific activities of 
crystals (d.p.m./rag) = 3 1 2 , 261, 2 4 5 ? theoretical value = 426).
iii) Discussion.
Experiments 1a/b and 2a/b showed that there are four 
reactions of DHA in human female breast skin:
1. Oxidation of the 3^-hydroxyl and isomerization of the
C 3-6 double bond to form androstenedione.
2. Peduction of the 17-ketone to form androstenediol.
3. Hydroxylation probably on at least two different carbon
atoms.
4. Conjugation with sulphate to form DHAsulphate.
The percent conversions to androstenedione were 1.2 - 4-1%.
On their own, these results would give a considerable under- 
c;
estimate of 2a -3^-HSD activity. The percent conversions to 5&- 
androstanedione, androsterone and epiandrosterone add up to 
3.7 - 28%. These three steroids are most likely formed from 
androstenedione by the action of 5^-reductase, 3D^-HSD and 3^- 
HSD, (Fig.1, p. 7). Therefore, the rate of conversion of DHA 
to androstenedione measured from the total of all 4 metabolites 
ranges from 7% - 32% conversion/3 hours. It is worth noting 
that the percent conversion to androsterone always exceeded that 
to epiandrosterone (ratio 3/1 - 14/1). This shows that in 
breast skin, the 3<X-reduction of 50(-androstanedione predominates 
over 3p-red.uction. In theory, epiandrosterone could be formed 
by direct reduction of the C3-6 double bond of DHA. This reaction 
has never been demonstrated in other tissues while the 3p- 
reduction of 30C~androstanedione is well known . (Ungar, 1 960 ;
Rubin and Strecker, 1961). However the occurrence of direct 
conversion of DHA to epiandrosterone would represent a potential 
route to dihydrotestosterone involving neither androstenedione 
nor testosterone. It might be noted that evidence has been
obtained for direct conversion of cholesterol (3p>-0H - A ^ )  to 
73-cholestan- f?-ol (Rosenfeld et al. , 1954).
. ■ ■ -z
[ ;Hj testosterone and (j Hj dihydrotestosterone were isolated 
from experiments 1 and 2 (tables 7 & 8c.pp.55&57)• This is 
proof that these steroids can be formed from DHA in skin.
The higher % conversion to dihydrotestosterone than to test­
osterone could indicate a rapid further conversion of testosterone 
by 5DC“reductase or a conversion of 5(X.-androstanedione to dihy- 
drutestosterone. There is no direct evidence that 50(- 
androstanedione can be a substrate for 17^-HSD in skin, however 
the reverse reaction (i.e. oxidation of dihydrotestosterone) 
has been demonstrated histochemically in sebaceous glands 
(ealman, 1970a). The other possible route to testosterone and
dihydrotestosterone is via androstenediol. The existence of
5
this pathway depends on whether the /\"3{S-HSD can use androstene­
diol as a substrate. Whatever the pathway of testosterone and 
dihydrotestosterone formation, it is obvious that in experiments 
1 and 2, these compounds were only minor metabolites compared 
to the formation of 17-oxosteroids.
It is difficult to assess the importance of androstenediol 
formation relative to that of androstenedione without knowing 
whether androstenediol is further metabolized. If the percent 
conversions to testosterone and dihydrotestosterone are added 
on to the conversions to androstenediol this only brings the 
total to a maximum of 1.9% in experiment 2b. However, the 
possibility that androstenediol is a precursor of polar fraction 
cannot be dismissed on the evidence available.
On the basis of the chromatographic experiments, it is 
suggested that the polar fraction contains one or more steroids 
with one ketone and 2 or 3 hydroxyl groups. There are three 
important possible metabolites which car be excluded as com­
ponents of the polar fraction:
706-hydroxy DHA. Formation of this compound from 67/-^}
DHA would have resulted in a loss of [^H].
7-keto DHA. Formation of this compound would also result
in loss of [^Hj.
Faredin et al. (1969) reported the conversion of 
DHA to the above steroids in human skin. Experiments 1 and 2 
provide evidence for formation in skin of other hydroxylated 
DHA metabolites.
5-androstene-3|>, 1 , 1 7j$-triol. The fact that the polar
material is ketonic rules out this possibility. Oertel &
Treiber (1969) isolated the sulphate of this compound from skin 
after injection of [7^-;H] DHA-F ^ sJ sulphate into a man. Our 
results show that it is not a major metabolite of DHA in-vitro.
4. [^HjDHAsulphate was the only I"Hj compound which could be 
isolated from the sulphate fraction. This indicates that it 
was not further metabolized. In addition, the fact that there 
was no evidence for [^Hj androsterone or\^HJ polar fraction in 
the sulphate fraction, indicated that these steroids are not 
acted on by sulphotransferase in human skin.
The results from experiments using 3«5A*M DHA (experiments 
1a and 2a) and 0.35^M DHA (1b and 2b) show some interesting 
di f ferences.
If the activity of A-3p-HSD is measured from the total 
conversion to androstenedione and 5(X-steroids then a 10-fold 
reduction of DHA concentration (i.e. from 3»5/M to 0.35^M) 
resulted in a 3-fold reduction in the rate of oxidation of 
DHA (i.e. a 2-fold increase in % conversion/3 hours) as shown by 
the % conversion ratios for experiments 1a and 1b and 2a and 2b 
(1a/1b = 0.53, 2a/2b = 0.41)• If if is assumed that the A~3^-HSD 
reaction followed Michaelis-Menton type kinetics, then if both 
DHA concentrations were sufficient to saturate the enzyme 
(i.e. reaction zero order with respect to substrate concentration) 
a 10-fold change in substrate concentration should not alter 
the true reaction rate, i.e. for a 10-fold reduction the % 
conversion should increase 10 times. If neither DHA concen­
tration was sufficient to saturate the enzyme (i.e. reaction 
first order v/ith respect to substrate concentration for 3»5^M 
and 0.35^M) then a 10-fold decrease in substrate concentration 
should result in a 10-fold decrease in reaction rate, i.e. the
% conversion should not be altered. The observed results fall 
between these two extremes. This suggests that the 3« 5AM DHA 
concentration was sufficient to saturate the enzyme while the
0.35yMM DHA concentration was not.
The % conversions to testosterone and dihydrotestosterone 
were higher in experiment 2b than 2a, but the increase was 
not strikingly greater than that for the other steroids.
The % conversions to androstenediol were similar (0.7 - 
1.0%) in all experiments. Without a knowledge of whether 
androstenediol is further metabolized, it is not possible to 
interpret this finding.
All the above arguments are based on highly simplified 
assumptions. However, one practical point emerged from 
the experiments with the two DHA concentrations. This was 
that there was no great advantage to be gained by using DHA 
concentrations less than 3»5MM as the increased % conversions 
obtained did not compensate for the smaller amount of radio­
activity which could be used (the specific activity of the 
t7a-5HjDHA available being 500 mCi/mmol). This point was 
particularly relevant later when experiments had to be carried 
out with much smaller skin samples.
Experiments 1 and 2 confirmed the conversion of DHA to 
testosterone in human skin and further showed that DHA was 
converted to dihydrotestosterone. However, these two compounds 
were only minor metabolites compared to formation of polar 
fraction, androstenedione and other 17-oxosteroids. It is 
therefore fair to say that under the experimental conditions 
used, DHA was converted mainly to compounds of low androgenic 
activity by human female breast skin. In addition, it has 
been shown that in an incubation system such as was used in 
experiments 1 and 2, the measurement of conversion of DHA to 
androstenedione and testosterone alone gives a considerable 
underestimate of the rate of DHA metabolism because of the 
high activity of 5d(.-reductase in skin.
4. METABOLISM OF DHASULPHATE IN HUMAN FEMALE BPEAST SKIN.
EXPERIMENT 1 DS
i. Experimental.
A piece of breast skin was obtained from a woman aged 
56 years who underwent mastectomy for breast cancer. Histolog­
ical examination (Dr. F.M. Vint) showed a normal appearance 
with rather small sebaceous glands. There were no visible 
coarse terminal hairs. The specimen was used for a preliminary 
investigation of DHAsulphate metabolism. The specimen was 
trimmed of fat, weighed and sliced as before. 1.0 g of slices 
were incubated in 10.0 ml of Krebs Improved Pinger I medium
7 _ C
containing J>, 5^M - \7oL- h] DHAsulphate (8.96 x 10 d.p.m.).
Incubation with shaking was for 3 hours at 37°C under 95% 0^ :
5% CO^* A control containing steroid but no tissue was carried 
out. The DHAsulphate was dried down from methanol solution 
containing 100^1 of propylene glycol and then dissolved in 22.0 ml 
of Krebs Improved Pinger I medium. 10.0 ml of this solution were 
used for the tissue incubation and 10.0 ml for the control.
The reactions were stopped by adding 40 ml of acetone.
Carrier steroids were then added as in experiments 1 and 2. The 
radioactive steroids were then extracted purified by t.l.c. and 
paper chromatography (Part II sections l.ii, 2, Fig.5) and their 
identity and radiochemical purity established by recrystallization 
to constant specific activity (Part II sections 1.iv, 5, Fig.4).
ii. Results.
Evidence for identity of metabolites purified by recrystall­
ization to constant specific activity is shown in table 10 (p.71). 
n^able 11 (p.72) shows % conversions of DHAsulphate to the various
metabolites.
The idertification of [ HJandrostenediol sulphate was based 
on the recovery of [JHJandrostenediol from the sulphate fraction 
after solvolysis. This gave no indication of whether the sulphate 
group was at C3 or C17•
[_H]epiandrosterone sulphate was identified in control and 
tissue incubations. Radioactive material which co-crystallized
Table 10.
METABOLISM OF DHASULPHATE IN HUMAN FEMALE BPEAST SKIN. 
IDENTIFICATION OF RADIOACTIVE STEROIDS AFTER RECRYSTALLIZATION 
TO CONSTANT SPECIFIC ACTIVITY WITH AUTHENTIC CARPIERS.
Experiment 1DS. Breast skin from a 56 yr. old woman was incubated
■7 C
with [7iX- H] DHAsulphate at a concentration of 3»5^M (8.96 x 10 
d.p.m.) for 3 hours as described in the text.
Specific activities were measured after successive recrystalliz­
ations and were all determined on the crystals.
Steroid Specific Activity (d.p.m./mg)
1 2 3 4
DHA 7170 8050 7380 -
DHAsulphate 0 79600 76700 77800 -
androstenediol 79 95 78 73+
androstenediol sulphate 0 103 103 'sO Oo
+
-
androsterone 281 276 259 278+
androstenedione 1 86 178 1 80 184
504-androstanedione 451 475 470 -
o crystallized as the free steroid after solvolvsis with
ethyl acetate/H2S0^ (p.21).
+ crystals acetylated before 3rd or 4 h recrystalli^ation 
and sp.act. measurement (p.39).
carrier for crystallization : lO.Omg
Table 11.
METABOLISM OF DHASULPHATE IN HUMAN FEMALE BPEAST SKIN. 
PERCENT CONVERSION/3 HOURS.
DHA 2.3
?DHAsulphate 91.0
androstenediol 0.05
androstenediol sulphate 0.1
androsterone 0.2
epiandrosterone 
testosterone 
dihydrotestosterone
androstenedione 0.06
50(.-androstanedione 0.2
polar neutral steroids.
6
= % steroid substrate recovered.
Breast skin was incubated in Krebs Improved Ringer 
I medium with [7(X- ?H]DHAsulphate for 3 hours at 
37°C under ar atmosphere of 95% 0^ : 3% C02* The 
radioactive products were isolated and estimated 
as described in the text.
with epiandrosterone was isolated after solvolysis of the 
sulphate fraction. The radioactivity remained with the epiand­
rosterone carrier after oxidation to 50(-androstanedione. It 
was concluded that [^H^epiandrosterone sulphate (about 0.02%) 
was either present as an impurity in the \7(Xr H] DHAsulphate or 
was formed by decomposition during incubation. DHAsulphate, 
androstenediol sulphate and epiandrosterone sulphate were the 
only radioactive steroids detected after solvolysis of the sul­
phate fraction, even though the solvolysates were subjected to 
a complete chromatographic and recrystallization analysis,
iii. Discussion.
A conversion of DHAsulphate to neutral steroids in human 
female skin was demonstrated (2.8%/3hours). This indicates the 
presence of steroid sulphatase in skin.
It appeared to be the rate of hydrolysis of DHAsulphate
which limited its metabolism. The isolation of [\lIandrosterone, 
r3 ~ -3 ~ 3!_ Hj 5(X-ar drostanedione , [_Hj androstenedione and [" E] androstenediol 
as well as [^HlDHA shows that DHA liberated from DHAsulphate 
underwent a similar metabolism to that of exogenously administered 
DHA. Even though the % conversions to the different metabolites 
were small, the overall pattern of metabolites which accumulated 
after 3 hours was similar to that in experiments 1 and 2 (using 
j7<5(-"H^ DHA). The most obvious feature of the results (table 11) 
is the greater % conversion to androsterone and 50t-androstanedione 
than to androstenedione, once again indicating that there was 
an active 50(-reductase in the skin which metabolized the androst­
enedione as it was formed.
Fo formation of p'H]testosterone or [^H]dihydrotestosterone 
could be detected in experiment 1 DS. However, when the low % 
conversion of DHA (experiments 1 and 2) to these compounds is 
considered along with the low % conversion Of DHAsulphate to 
neutral steroids in 1 DS it is not surprising that any formation 
of testosterone or dihydrotestosterone was below the sensitivity 
limit of experiment 1 DS (<(0.01%); e.g.: in experiment 2a, (table 
9, p.65) the ratio of % conversions of DHA to:
testosterone + dihydrotestosterone
   =  0.02
androstenedione + 5Dtandrostanedione + androsterone
= 0.02. An equivalent ratio in experiment 1 DS would mean a 
total % conversion to testosterone + dihydrotestosterone of only 
0 .008%.
Another interesting result was the absence of any polar 
neutral steroid formation (tissue incubation = 0.1%, control =
0.2%). This contrasts with the ^HA experiments where polar 
neutral steroids were major metabolites.
Analysis of the j^Hjsteroids obtained after solvolysis of 
the sulphate fraction showed that JL^Hjandrostenediol sulphate 
had been formed from [ H(DHAsulphate but there was no evidence 
for formation of sulphoconjugated androstenedione, testosterone, 
A-ring saturated steroids or polyhydroxylated steroids. This 
experiment therefore, provided no support for the hypothesis 
that DHAsulphate is extensively metabolized in human skin v/ithout 
loss of the 3$-sulphate. Certel and Treiber (1969)> put forward
z z c;
this idea when they isolated H/ S labelled C 1r,-steroid
r  3  3 3  "1sulphates from human skin after injecting f7<X- 'H"| DHA [ ^Sj sulphate 
into a man.
5. METABOLISM OF DHASULPHATE, DHA, ANDROSTENEDIONE AND TESTOSTERONE
IN HUMAN MALE FOREHEAD SKIN.
EXPERIMENTS 3 AND k (DS, D, AE, T).
Pieces of forehead skin were obtained from two men aged 
38 (specimen 3? expts. 3DS, 3D, 3AE, 3T) and 83 years (specimen 
k , expts. h-DS, 4D, ^AE, 4T). This was normal skin obtained 
during plastic surgery. The forehead skin is characterized by 
its numerous, large sebaceous glands with only tiny vellus 
hairs (Montagna, 1963). Strauss and Pochi (1963) have shown 
that in men, there is no great decrease in sebaceous secretion 
up to around 80 years of age and that this secretion is still 
androgen stimulated as shown by the considerable drop in 
sebum secretion observed when old men were castrated. The two
skin specimens therefore provided an opportunity to study 
steroid metabolism in skin dominated by its sebaceous glands.
This was the nearest possible approach to studying human seb­
aceous gland metabolism without actually dissecting the pure 
glands.
i) Experimental :
It was decided to study the metabolism of DHAsulphate, DHA, 
androstenedione and testosterone in each skin specimen. The 
incubation system was scaled down because of the small amounts of 
tissue available. The steroid concentration, tissue/steroid 
ratio and tissue/medium ratio were kept the same as in previous 
experiments.
A small piece from each specimen was taken for histology 
and histochemistry. The rest of each specimen was trimmed of 
fat and cut into k pieces which were weighed and cut into 0.5 -
0.7 mm thick slices as before. Slices were incubated in 2.0 ml,
1.0 ml,or 0.5 ml of Krebs Improved Ringer I medium with |_7<X-^ H]
DHA (sp.act., 0.5 Ci/mmol) |_7fl(-3H]DHAsulphate (sp.act., 20Ci/mmol) 
or Q?(X- ~)H]androstenedione (sp.act., 5.0 Ci/mmol) or |_7(X- H] 
testosterone (sp.act., 1.5 Ci/mmol). Table 12 (p.76) shows 
the tissue weights, volume of medium, quantity of steroid, etc.,
r*3for each incubation. The j H ] steroids were dissolved as 
before in. Krebs Improved Ringer I medium with propylene 
glycol (5Ml/ml medium). Controls containing
Table 12
EXPERIMENT 3. INCUBATION CONDITIONS.
Wt.Skin(mg) Steroid
Incubated
nmol
steroid
1 0~x d.p.
H
63 DHAsulphate 3.5 12.5
1 80 DHA 6.2 6.9
88 androstenedione 3*5 16.9
1 90 testosterone 6.8 16.7
EXPERIMENT 4- INCUBATION CONDITIONS
Wt.Skin(mg) Steroid
Incubated
nmol
steroid
10~^xd.p
H
89 DHAsulphate 3.5 12.3
96 DHA 3.5 2.45
48 androstenedione 1.75 4.76
44 testosterone 1.75 4.76
ml medium
1 .0
2.0 
1 .0
2.0
ml medium
1 . 0  
1 . 0
0.5
0.5
pHj steroids but no skin were incubated at the same time as the
experiments.(CDS,CD,CAE,CT.)
Reactions were stopped with 5 m l . of acetone then the follow­
ing carriers dissolved in ethanol (total volume 6 - 8 ml) were 
added:-
3o(-androstanediol "
3^-androstanediol "
androstenediol "
testosterone M
dihydrotestosterone M
androsterone "
epiandrosterone M
etiocholanolone M
androstenedione "
50(-androstanedione "
58-androstane-3, 17-dione M 
The mixtures were kept at-20 C then the radioactive steroids were 
isolated, purified by t.l.c. and paper chromatography (Part II 
sections l.ii and 2, Fig.5) and their identity and radiochemical 
purity established by recrystallization to constant specific activ 
ity (Part II, sections 1 . iv, 3, Fig. if),
ii) Results.
The evidence for identity and radiochemical purity of those 
metabolites which were crystallized to constant specific activity 
with authentic carriers is given in tables 13a-m (pp. 8 0 - 8 6  )•
% conversions to the different metabolites are shown in tables 
1'5> 16 (pp. 89 & 90 )• As the tissue/steroid ratios, tissue/ 
medium ratios and steroid concentrations were kept constant in 
the different incubations the results expressed as % conversions 
car be compared directly between incubations. An exception to 
this is experiment 3DS in which the mass of tissue used was 
less than that used in other incubations with 1.0 ml of medium.
The details of the identification of certain metabolites
DHAsulphate
DHA
)
) added to DHA and DHAsulphat 
 ^ incubations only
need to be further explained.
a) The androstanediol and androstenediol carriers were isolated 
as a group and estimated together by g.l.c. using an SE.30 column.
The three compounds all had the same retention time so only one 
peak was observed when the mixture was run on g.l.c. As all three 
comnounds showed similar molar responses on the flame ionization 
detector measurement was made with reference to an androstenediol 
standard and the recovery of each carrier was taken to be one 
third of the total. This assumed that the recovery of all three 
carriers was similar. Those fractions which contained sufficient 
radioactivity were divided up and aliquots were crystallized with 
androstenediol, 3p-androstanediol and 30t-androstanediol (tables
13©, f5 g. pp. 82 and 83 )» Evidence was obtained for the conver­
sion of DHAsulphate and DHA to androstenediol and for conversion 
of DHAsulphate to androstenediol sulphate. Testosterone and
androstenedione were both converted to 3<X.-androstanediol and 30-
"2
androstanediol. The radiochemical purity of jL^ H _.j 3p-androstanediol 
from experiments 3AE and 3T was further checked by oxidizing the 
3p-androstanediol carrier with chromic acid after it had been 
crystallized to constant specific activity. The resulting 5(X- 
androstanedione was nurified by t.l.c. in system T, recrystall­
ized and its specific activity measured. This was not signif­
icantly different from the specific activity of the 3p-androstanediol 
crystals before oxidation and therefore eliminated the presence 
of [^Hjk-a^drostene-3p , 1 7p-diol or f*H] androstenediol which might 
cocrystallize with 3|B-androstanediol carrier.
b) In experiments with testosterone (3T, AT) and androstenedione 
(3AE, 4AE) there was evidence for formation of fp’HJ etiocholanolone. 
Radioactivity was associated with etiocholanolone carrier after 
chromatography and constant specific activity was obtained after 
recrystallization (table 131, p. 86). However, the final 
constant specific activity of the crystals accounted for only 
about 30% of the radioactivity in the etiocholanolone fraction. 
Another possible metabolite which would be found in the etio­
cholanolone fraction is 17p-hydroxy-5p-androstan-3-one.
There was no evidence for formation of 50-androstane-3,
17-dione in any of the experiments. Any radioactivity in this 
fraction was always lost after recrystallization.
c) Polar Neutral Fraction.
In experiment 3 with the skin specimen from a 58 yr. old 
man a major fraction of the radioactivity was associated with 
material which was extracted from water into chloroform but which 
remained on the origin when chromatographed in system I. These 
were called the polar neutral steroid fractions as before. 
Aliquots of these fractions from experiments 3D, 3AE, and 3T 
were run on t.l.c. in system X. The t.l.c. plates were scanned; 
3D showed a major peak (Rf. 0.15) and a minor peak (Rf. 0.36).
3AE showed two equal sized peaks (Rf. 0.15 and Rf. 0.41). 3T 
showed a major peak (Rf. 0.16 ) and a smaller peak (Rf. 0.42). 
These neaks were eluted and subjected to acetylation, borohydride 
reduction and chromic acid oxidation reactions together with 
further t.l.c. The results are shown in table 14 (p. 8$.
d) Sulphate Fractions.
After solvolysis all sulnhate fractions were analysed by 
chromatography and recrystallization as were the neutral metabol­
ite fractions. Evidence was obtained for conversion of DHA to 
DHAsulphate and androstenediol sulphate and of DHAsulphate to 
androstenediol sulphate. No evidence for formation of testo­
sterone sulphate, polyhydroxy steroid sulnhates, or A-ring 
saturated sulnhates was obtained. Even though sulphate fractions 
from incubations with testosterone and androstenedione contained 
radioactivity, the only radioactive compounds isolated after 
solvolysis and chromatography were epiandrosterone and traces 
of material remaining on the origin after t.l.c. in system I.
Histochemical Investigation of Forehead Skin.
Samples of the forehead skin were investigated histochem- 
ically for the presence of hvdroxvsteroid dehydrogenase activity. 
3|B-HSD and 17B-HSD activities were demonstrated in the sebaceous 
glands. The results are considered later in more detail together 
with similar studies of axillary skin (p .109 )•
Table 13&-13m*
METABOLISM OF DHASULPHATE, DHA, ANDROSTENEDIONE AND TESTOSTERONE 
IN HUMAN MALE FOREHEAD SKIN.
EXPERIMENTS 3DS, 4DS, 3D, 4D, 3AE, 4AE, 3T, 4T. CONTROLS CDS, CD, CAE, CT. 
IDENTIFICATION OF RADIOACTIVE STEROIDS BY RE CPY ST ALLIZ AT ION TO 
CONSTANT SPECIFIC ACTIVITY.
Forehead skin from a man of 58 yrs. (expt. 3 ) and a man of 83 yrs.
(expt. 4 ) was incubated with DHAsulphate (3DS, kDS)
DHA (3D, AD) [VoC-^H] androstenedione (3AE, 4AE) and [?$- '^ H] testo­
sterone (3T > 4T ) as described in the text.
Radioactive steroids isolated by chromatography were mixed with 
authentic carriers and recrystallized to constant specific 
activity.
Specific activities (1.2.3..) were measured after successive 
crystallizations.
c = sp.act. of crystals, m = sp.act. of mother liquors.
Table 13a.
steroid : [VlDHA
solvent : acetone-hexane
carrier : 10 .0 mg
Specific Activity (d.p.m./mg) % calculated
sp.act.
1 2 3 4
c c c c
3D 79000 77000 81500 81800 107
4D 73300 74000 73800 78500 96
CD 362000 358000 - 369000 92
3DS 19800 19100 19200 20900 90
4DS 6210 6350 6450 - 85
CDS 371 378 388 - 89
Table 13b.
steroid : L H-] androsterone
solvents : acetone-hexane, CHC1^-hexane
carrier : 10 .0 mg
Specific Activity (d.p.m./mg) % calculated
sp.act.
1 2 3 4
c c c c
3D 21800 20800 20800 19600 93
4D 4520 4470 4320 4420 1 04
3DS 1310 1310 1 312 1250 75
4DS 540 512 500 515 92
3AE 61300 59300 56000 60200 90
4AE 12500 1 1700 1 1 800 1 1600 91
3T 64000 64000 62300 61700 105
4T 20300 18700 19600 18500 96
Table 13c.
steroid : f^HJepiandrosterone
derivatives crystallized : epiandrosterone, 5^-androstanedione. 
solvents : acetone-hexane. acetone-water.
carrier ; 1 0 .0 mg
Specific- Activity
1 2 - 3
c c v c
3D 5070 4950 *3970
3DS 510 467 460
3AE 1 1 300 1 1000 1 1700
4T 1850 1835 1705
d.p.m./mg) % calculated
sp.act.
4 5
c c
+ 3770 *3790 30
+343 *347 57
1 1200 + 11500 68
+ 1495 *1490 53
+ crystals were oxidized to 50t-androstanedione which was 
precipitated from water, purified by t.l.c. in system I then 
recrystallized before further sp.act. measurement.
Od •
Table 13d.
steroid :
derivatives ) 
solvents )
E EQepiandrosterone sulphate
as for epiandrosterone
carrier )Specific Activity
3
(d.p.m ./mg)
5 % calculated1 2 4
c c c c c sp.act.
3D 484 465 492 355+ 325+ 67
3AE 795 870 Co O o
+
73
3T 1 120 1140 1 165 952+ VO o
+
80
crystals oxidized to 50(-androstanedione which 
was precipitated from water and recrystallized 
before further sp.act. measurement.
Table 13©.
steroid
derivative
solvent
carrier
3DS
3D
4D
L'HJandrostenediol
acetone-hexane; chloroform-hexaner metharol-water
10.97 mg 3DS, 10.12 mg 3D, 12.62 mg 4D. 
Specific Activity (d.p.m./mg)
1
c
119
271
220
2 - 
c - m 
105 100
257 306
202 214
c
113
276
m
123
304
4
c
272
% calculated 
sp.act.
not measured
Table 1£f.
steroid
derivative
solvent
carrier
LHJ3f-androstanediol
" + 50(-an drostanedione
CBC1^-Methanol (2/1)-Hexane;Methanol-Water
11.02 mg 3D, 10.34 mg 3AE, 10.02 mg 3T, 11.02 mg 4T.
Specific Activity (d.p.m./mg) % calculated
sr>. act.
1 2 -3 4 5
c c • c c m c
3D 286 231 258 95+
3AE 106 79.5 73.2 73.5 70.5+
3T 398 283 297 273 300 268+
4T 63.6 46.0 54.5 54.it
carrier was oxidized to 50(-androstanedione
which was then purified by t.l.c. (solvent
rot measured
and recrystallized before further sp.act. 
measurement.
Table 13g.
steroid
derivative
solvent
carrier
-3|_ TfJ 30(.-androstanediol
CHC1,-Methanol (2/1)-hexane
3
: 10.04 mg 3T, 10.93 mg 4T ^AE, 10.08 rag 3AE.
Specific Activity (d.p.m./mg) % calculated
sp.act.
2 - 3 4
not measured
c c .m c m c
3T 442 423 390 416 465 398
4T 1 34 132 - 122 - -
3AE 247 204 - 188 - -
4AE 68.3 65.7 - 72.3 - -
Table 13h.
■Z
steroid : [. HJtestosterone
solvents : acetone-hexane
carrier 10.0 mg
Specific Activity (d.p.m. /mg
1 2 3 - 4 5
c c c * c c
3b 148 126 150 136 136
4D 324 322 303 333 305
3DS 88 . 1 100 100 -
4DS 407 293 307 307
3AE 559 590 533 557 581
4AE 713 647 662 679
3T 81500 79000 80700 84700
4T 56200 57300 54700 58500
CT 918000 937000 893000 -
% calculated 
std. act.
23
87
78
48
51
68
81
89
8/f
Table 13i*
steroid -androstanedione
solvent : acetone-water
carrier : 10.0rag
Snecific-Activity (d.p.m./mg) % calculated
1 2 - 3 4
sp.
c c - c c
3D 95700 100000 97800 98600 95
4D 28800 29000 29000 - 92
3DS 9880 10800 10500 11000 99
4DS 2140 2210 2195 2175 85
3AE 443000 462000 459000 457000 90
4AE 77500 80900 78100 79300 91
3T 443000 459000 462000 467000 98
4T 71300 73800 71100 73800 87
Table 1 3j.
steroid : [^Hjandrostenedione
solvents : acetone-hexane
carrier : 10.0 mg
Specific Activity (d.p.m./mg) % calculated
1 2 3 A 5
sp.act
c c c c c
3D 5750 5620 5380 5A50 81
AD 7980 7950 8180 7950 91
3DS 2810 2A20 2A65 2A35 76
ADS 1 322 1260 12A5 1220 1 320 63
3AE 102000 9A300 9A000 ;93000 90
AAE 126000 122000 128000 122000 96
CAE 1010000 10A0000 1010000 985000 9A
3T 83500 77200 79700 77600 92
AT 63100 58600 56AOO 56500 89
Table 13k.
steroid : C^Hjdihydrotestosterone
solvents : acetone-hexane,CHCl_-hexare.
5
carrier : 10.0 mg
Specific Activity (d.p.m./mg) % calculated
si), act.
1 ‘ 2 3 A 5
c » c c c c
3D 990 913 808 802 832 18
AD 383 308 300 276 272 9
ADS 8 0 . 9 73.7 71 .3 90.3 - 19
3AE 1620 1A00 1395 1A00 1A 15 68
AAE 369 307 331 333 319 55
3T 657 607 595 585 597 63
AT 7A50 8070 7280 7 A 50 7800 81
Ob
Table 131. 
steroid 
solvents 
carrier
[^Hjetiocholanolone
acetone-s-hexane, CHCl^-hexane
10 .0  mg
Specific Activity (d.p.m./mg)
1 2 * 3 4
c c * c c m
3AE 278 293 290 288 -
4AE 262 231 283 250 255
3T 252 257 278 24 8 -
4T 616 569 566 619 614
Table 13m
steroid : C^ H J DHAsulphate
derivative crystallized : DHA
solvent : acetone-hexane.
carrier : 10 .0 mg
Specific Activity (d.p.m./mg)
1 2 3 4
c c c c
3D 5950 6020 5570 5880
4D 7 80 840 771 730
CD 119 125 - -
3DS 236,000 235,000 2 3 2 ,0 0 0 -
4DS 2 92 ,0 0 0 302 ,000 307 ,00 0 2 8 8 ,0 0 0
CDS
000
154,000 156 ,000 147,000
% calculated 
sp.act.
28 
16
30
32
% calculated 
sp.act.
100
105
96
90
99
Table 14.
INVESTIGATION OF POLAR NEUTRAL FRACTIONS FPOM EXPERIMENT 3. 
Treatment Pf. of Radioactive Peak.
T 1 T2 AE] a e 2 D1 D2
1 . 0.16 0.42 0.145 0.41 0 .1 5 0 .3 6
2. 0.77 0.76 0.76 0.74 0.74 0.73
3 . 0.10 0.04 0.12 0.05 0 . 1 3 0.04
4 . 0.60 - 0.62 - 0 .6 0 -
5. 0.21 - 0.1 9 - 0.23 -
6. 0.09 0.04 0.1 1 0.03 - 0.02
7. 0.74 0.72 0.72 — — 0.70
1. Polar neutral steroid fractions were run on t.l.c. in system 
X. Scanning of the plate showed each fraction to be resolved into 
two radioactive peaks (3D ^ , 3D2 , 3AE^ , 3AE2 , 3T^ , 3T2 ) with the 
recorded Rf. values. The Pf. of androstenediol run on the same 
plate was 0.30. Each peak was eluted from the plate.
2. An aliquot of each radioactive peak isolated from step 1. was 
acetylated (p. 39)'.- A portion of the acetylated material was run 
in system X.
3. The rest of the acetylated material was run in system VI.
4. Aliquots of peaks 3D., 3AE.J and 3T^ were acetylated, reduced
with sodium borohydride (p.4 0 ) and then run in system X.
5. Aliquots of peaks 3D^ , SAE^ and 3T^ were acetylated, reduced
with sodium borohydride, re-acetylated and run in system VI.
6 . Aliquots of fractions 3D2 , 3AE^, 3AE2 , 3T^ and 3T2 were 
acetylated then oxidized with Kiliani’s reagent (p. 40F. A portion 
of the material was then run in system VI.
7. The rest of the acetvlated-oxidized material was run in system X.
In each case the fractions from incubations with DHA (3D) androst-
enedione (3AE) and testosterone (3T)were run on the same plate.
In the case of acetylated, reduced and oxidized derivatives, samples 
of the parent compounds or a previous derivative v/ith which direct 
comparison of Pf. was to be made, were also run on the same plate.
Radioactive material was located on the plates with a Panax 
radiochromatogram scanner.
system X : chloroformrraethanol:water ,200:9:0.75 (v/v) 
system VI : benzene:ethyl acetate,?0O:20 (v/v)
Table 1 4.
INTERPRETATION OF THE PESULTS. OF 171 ABLE 14
Incubation of forehead skin with DHA, androstenedione and 
testosterone results in formation of at least two metabolites 
more polar than androstenediol, 1606-hydroxy DHA or 11^-hydroxy 
androstenedione (Rf.'s 0.50, 0.50, 0.60 in system X). Fractions 
3T] , 3AE.J and 3D^ are probably compounds with at least two 
acetylable hydroxyl groups and one ketone group. The presence of 
a ketone group in fractions 3D^, 3T^ and 3AE^ was inferred from 
the change in Rf. after borohydride reduction of the starting 
material and borohydride reduction of the acetylated material 
followed by further acetylation. Absence of any reaction with 
chromic acid after acetylation indicated that there were no 
hydroxyl groups which resisted acetylation (e.g.: 11p-0H (Bush, 
1961 ).
Fractions T2 , AE0 and Dn are compounds with at least one 
acetylable hydroxyl group and possibly have a ketone group where 
compounds T^, AE^ and D. have a hydroxyl. This conclusion is 
based on the reversal of the relative Rf.s of comrounds 1 and 2 
after acetylation.
It is pointless to speculate on the possible identities of 
the different fractions. It cannot even be deduced for certain 
whether and retain the/\-3p-0H structure or whether T ^ , T2 
and AE.j , AE2 retain the/\-3-oxo structure.
The possibility that compounds AE^ and T^ are 17jS-hydroxy- 
steroids while AE2 and T2 are 17-oxosteroids must be considered. 
If this were the case, it would mean considerably more conversion 
of androstenedione to 17p-hydroxysteroids than is apparent from 
analysis of the identified 02 metabolites. If 3AE^ had a
17[3-hydroxyl group this would mean about 4% 17(3-reduction of 
androstenedione in experiment 3AE. This is still, however, small 
compared with 17-oxidation of testosterone (which incidentally 
would be increased if formation of 3T2 was taken into account).
Table 15*
METABOLISM OF DHASULPHATE, DHA, ANDROSTENEDIONE AND TESTOSTERONE 
IN HUMAN MALE FOREHEAD SKIN.
% conversion/3 hours
3DS 3D 3AE 3T
DHA 2.70 + 19 .6 - -
DHAsulphate +83.3 3.65 - -
androstenediol 0.03 0.32 - -
androstenediol sulphate 0.36 0.09 - -
3f-androstanediol - - 0.03 0 . 1 2
30(-androstanediol - - 0.07 0 .1 1
androsterone 0 .6 0 1k.5 2k . 8 19.3
epiandrosterone 0.07 1.33 2.01 0 .2 0
epiandrosterone sulphate - 0 . 2 0 . 1 8 0 . 2 0
etiocholanolone - - 0 . 0 8 0 . 0 8
testosterone 0 . 0 2 0 .0k 0.07 +8 .97
dihydrotestosterone 0 .0 2 0.25 0 . 2 8 0.09
androstenedione 0.25 1 .03 + 7.24 7.53
5tf--androstanedione 1.66 3 0 . 8 54.8 52.9
polar neutral steroids - 2 1 .0 8 . 2 8.5
+ - % substrate recovered
Slices of forehead skin from a 38 yr. old man were inc ubated
for 3 hours in Krebs Improved Ringer I medium with one of the 
following: [7<*- H]DHAsulphate (3DS), [7(X- ’'h JDHA (3D), L7(X-5Hi 
androstenedione (3AE), [7o(-^H]testosterone (3T). Amounts of 
tissue and incubation conditions are shown in table 12 (p.76).
Table 16.
METABOLISM OF DHASULPHATE, DHA, ANDROSTENEDIONE AND TESTOSTERONE 
IN HUMAN MALE FOREHEAD SKIN.
% conversion/3 hours
4DS 4D 4AE 4T
DHA 1 .07 +50.7 - -
DHAsulphate +93.2 1 .30 - -
androstenediol - 0.32 - -
androstenediol sulphate 0 .1 8 - - -
3jS-androstanediol - - - 0 . 1 0
3 ^-androstanediol - - 0 .0 6 0 .2 8
androsterone 0 .2 8 9.81 17.9 19.5
epiandrosterone - 1.07 - 0.67
et iocholanolone - - 0 .3 6 0 .6 2
testosterone 0.05 0.19 0 • 26 +2 3 . 0
dihydrotestosterone 0 . 0 2 0.27 0 . 2 2 3.56
androstenedione 0.15 4.20 +37.3 1 6 .8
5(X.-androstanedione 0 .3 6 20.5 35.4 31.3
polar neutral steroids - 3.0 3.5 3.9
+ = % substrate recover ed
Slices of forehead skin from an 83 yr. old man were incubated
for 3 hours in Krebs Improved Ringer I medium with one of the 
following: [7o(-3H] DHAsulphate (4DS), L7<*-VjDHA, (4D)T t 7a- ’H J 
androstenedione (4AE), L 7c<-3Hltestosterone (4T). Amounts of 
tissue and incubation conditions are shown in table 12 (p,76).
iv) Discussion :
The first obvious feature of tables 15 and 16 is the extensive
metabolism of DHA, androstenedione and testosterone in human male
forehead skin. The total rates of metabolism in specimen 3 (male
58 yrs.) were greater than those in specimen 4 (male 83 yrs.).
This difference was in part due to the much greater % conversions
to polar metabolites by specimen 3» The conversion of DHA to
androstenedione and of testosterone to androstenedione showed the 
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presence of a Za -3^-HSD and a 17^-HSD in forehead skin. This 
confirmed the histochemical studies which showed a reaction in 
sebaceous glands with DHA and with testosterone.
The rate of DHAsulphate metabolism was much less than that of 
DHA, androstenedione or testosterone. It appeared to be limited 
by the hydrolysis of DnAsulphate to DHA. (Total % conversion /
3 hours of DHAsulphate to neutral steroids = 5.33% 3DS; 1.92%
4DS). The metabolism of neutral steroids formed from DHAsulphate 
was essentially similar to that of r7et-3H]DHA (3D and 4D).
Excluding the polar neutral fraction, 5(3(-androstanedione and 
androsterone were the major metabolites which accumulated in 
experiments with DHA, androstenedione and testosterone. This 
indicated the presence of 506-reductase and 3Q6-HSD in the skin.
The conversion of DHAsulphate, DHA and testosterone to androstene­
dione and the conversion of all four steroids to 50(.-androstanedione 
+ androsterone makes it likely that androstenedione is a common 
intermediate in the formation of these A-ring saturated steroids.
As testosterone itself is a substrate for 50(-reductase the assumpt­
ion that androstenedione was the major intermediate between 
testosterone and 504-androstanedione + androsterone may not be 
valid. A proportion of these two steroids could have been formed 
via dihydrotestosterone (Fig.1§» p.112) and it is not possible to 
deduce from experiments 3 and 4 whether the very low % conversions 
of testosterone to dihydrotestosterone were due to low rates of 
formation or rapid further metabolism of 50t”dihydrotestosterone.
In all experiments, the % conversions to 17^-hydroxysteroids 
were low. It appears that 17B-HSD present in the skin worked almost
exclusively to catalyse the oxidation of 17p-hydroxysteroids 
rather than reduction of 17-oxosteroids. This accounts for the 
very low % conversions to dihydrotestosterone and androstanediols 
even in experiments with testosterone.
H'H ^epiandrosterone was isolated from experiments with all 
four substrates. The conversion of testosterone and androstenedione 
to this steroid suggests the presence of a 3p-H£D in the skin 
specimens. This enzyme probably reduces the 3-oxo group of pOC- 
androstanedione to form epiandrosterone and also the 3-oxo group 
of dihydrotestosterone to form 3j$-androstanediol. As in the previous 
experiments the 3Ct~reduction of 5$-androstaredione (to form 
androsterone) predominated over 3|$-reductioh.
The isolation of ^H'Jetiocholanolone from incubations with 
androstenedione and testosterone raises the problem of how it was 
formed. [^H_j5p-androstane-3> 17-dione is the logical intermediate. 
However, no formation of this steroid could be detected in any 
experiment, although it could be an intermediate which, like 
androstenedione, did not accumulate. An alternative pathway 
could go via 17|3-hydroxy-5p-androstan-3-one and 5p-androstane- 
3(V, 17p-diol. The former compound would be found in the etio- 
cholanolone fraction after chromatography. As the final specific 
activity after recrystallization never accounted for more than 
30% of the radioactivity in the etiocholanolone fraction, it is 
possible that there was also some 17p-hydroxy-5p-androstan-17-one.
The conversion of DHA to DHAsulphate indicated the presence 
of a sulphotransferase in the skin specimens. The failure to 
detect formation of either testosterone sulphate or androsterone 
sulphate suggests that the sulphotransferase in skin acts 
preferentially on 3^-hydroxysteroids rather than on 17p-hydroxy 
or 3<X-hydroxysteroids such as testosterone and androsterone.
6. METABOLISM OF DHASULPHATE, DHA, ANDROSTENEDIONE AND TESTOSTERONE
IN HUMAN FEMALE AXILLARY SKIN.
EXPERIMENT 5 (DS, D, A E , T).
A piece of skin was obtained from the armpit of a woman aged
20 years, who underwent a skin grafting operation. She was 
suffering from hyperactivity of the eccrine sweat glands. However, 
no histological abnormalities of the excised armpit skin could be 
detected (Prof. J.A. Milne, Dr. F.M. Vint). The skin specimen 
had numerous large terminal hairs and also apocrine sweat glands.
The sebaceous glands (associated with each hair) were smaller
than those of the face skin.
The growth of the axillary hair and apocrine glands is 
stimulated by androgens, therefore this piece of skin provided 
the opportunity to study:
a) steroid metabolism of an androgen responsive organ of the 
human female;
b) to compare steroid metabolism of hairy skin with that of skin 
dominated by sebaceous glands (forehead, section 3 expts. 3 and 4).
i) Experimental :
Four pieces, each weighing about 400 rag were cut from the 
specimen. Each piece was cut into 0.3 - 0.7 mm thick slices and 
incubated in ml of Krebs Improved Ringer I medium with one
of the four steroids; 1 . 7 # DHAsulphate , [7o(- yHj DHA , J7oC-^H]
androstenedione or |70(-^ Hl testosterone (table 17 p.94)» The
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steroid concentration (3»5/l/M) and tissue/steroid ratio (10/1), 
were kept the same as in previous experiments. Incubation with 
shaking was for 3 hours at 37 C under 9^/o0^ : 3%C0^. Reactions 
wrere stopped with acetone, and carrier steroids were added as in 
experiments 3 arid 4 (p. 77). The radioactive steroids were then 
isolated, purified by t.l.c. and paper chromatography (Part II 
sections 1,ii and 2, Figs. 3, 6) and their identity and radio­
chemical purity established by recrystallization to constant 
specific activity (Part II sections 1. iv and 3, Fig. 4).
Table 17.
EXPERIMENT 5» Incubation Conditions.
Skin (mg) Steroid
Incubated
nmol
steroid
10” x d.p.m.
H
ml medium
430 DHAsulphate 14 4.83 4.0
390 DHA 14 13.82 4.0
386 androstenedione 14 15.75 -p- • o
383 testosterone 14 14.85 4.0
ii) Results :
Evidence for identity and radiochemical purity of those 
I^Hlsteroids which were recrystallized to constant specific 
activity is given in tables 18a - n (pp. 97-104 )• The percent
conversions are shown in table 20 (p. 1 06) and are not corrected 
for tissue weights as these were similar in all experiments.
The methods for establishing radiochemical purity of certain 
steroids were modified in experiment 5 and will now be described 
more fully.
a) androstenediol and androstanediols (tables l8i, j, k, 1 , pp. 101- 1 0 3)
Scanning of the first t.l.c. plate (solvent I) for radio­
activity showed large peaks in the androstanediol region. T’his 
radioactivity remained with the carrier after acetylation and 
t.l.c. in system VI. The acetylated material was saponified then 
run on paper in solvent XII, which separated various isomers 
of the androstenediols and androstanediols (p. 31). Further 
purification by t.l.c. showed that radioactivity was associated with 
androstenediol (5DS, 3D), 3^-androstanediol (3D, 3AE, 5T) and 
30C-androstanediol (5DS, 5D, 3AE, 31) • Aliquots of the radio­
active fractions were therefore crystallized to constant specific 
activity with the apurouriate carriers.
a.i.) C^H.landrostenediol was identified in the neutral steroid 
fractions and in the steroids obtained by solvolysis of the 
sulphate fractions from experiments 3D and 5DS. The chromato­
graphic purification eliminated any possibility of 3p-androstane- 
diol contaminating this fraction.
a.2.) [*Hl3&-androstanediol was identified in experiments 3D,
5DS, 5AE and 5T. The fact that the final constant specific 
activities of the crystals were around 100% of the theoretical 
value (table 18k) indicates that the improved chromatographic 
method was sufficient to purify 3tX.-androstanediol from any sign­
ificant contaminants, 
a. 3.) 3(S-androstanediol.
■ r
Paper chromatography and t.l.c. separated this compound 
from 4-androstene-3^, 17|5-diol and androstenediol which might 
cocrystallize with it. Pecrystallization then established the 
radiochemical purity of C^H]3|3-androstanediol from incubations 
3AE and 3T. In experiment 5D a highly significant amount of 
radioactivity ( 3% conversion) remained with 3(5-androstanediol
carrier after chromatography. However, the sample was re­
chromatographed in system XII to remove any ^Hlandrostenediol 
contaminant. Fig. 11 (p. 96) shows the distribution of radio­
activity on the first and second paper chromatograms run in 
solvent XII, showing that there was radioactive material associated 
with 3{3-androstanediol carrier which was not androstenediol. The 
3ji-androstanediol was recrystallized to constant specific activity 
and then oxidized to 30(-androstanedione. There was only a slight 
drop in specific activity of the crystals after oxidation (table
z
181). This provided good identification of E Hj3p-androstanediol
in experiment 5D. 
z
b) C H]testosterone from incubations 3DS, 3D, 3AE, was acetylated 
and purified by t.l.c., using solvent VI. The acetate was re­
crystallized to constant specific activity then saponified and 
the free steroid crystallized further (table 18m). However, in 
experiments 5DS and 5D, C^H]testosterone was isolated from 
control incubations (0.1 %). This was probably due to contamination 
of a test tube by E^H] testosterone. Because of this, no exact 
quantitation of testosterone formation in experiments 3D and 5DS 
could be made.
Fig. 11.
Vb.
ISOLATION OF LIU3p-ANDROSTANEDIOL AFTER INCUBATION OF F7<X-5Hj 
DHA WITH FEMALE AXILLARY SKIN
1St PAPER
DIRECTION OF 
RUN
o  cz>o
10 ^x d.p.m. 
200
-  100
3p5<* A5A^
V
2nd PAPER
-210 x d.p.rru
250
o o
s t1" Paper: The androstenediol-androstanediol fraction isolated
by t.l.c. in systems I and VI (p. 31 ) was chromatographed on
paper in system XII. Bands corresponding to the carrier steroids 
and intermediate bands were cut out, eluted and counted to deter­
mine the distribution of radioactivity on the chromatogram.
2nd Paper: The 3p-androstarediol fraction isolated from the first
paper was re-run in system XII. Three bands were eluted and 
counted, giving the distribution of radioactivity shown.
It can be seen that the 3^-sindrostanediol fraction contained 
radioactivity associated with neither androstenediol nor /+- 
androstene-3^, 1 7^-diol.
3# 5<* = 3<X-androstanediol 
3f-androstanediol 
androstenediol 
U-androstene-3|5>, 1 7p-diol= L i
Table l8 a-l8n.
METABOLISM OF DHASULPHATE, DHA, ANDROSTENEDIONE AND TESTOSTERONE 
IN HUMAN FEMALE AXILLARY SKIN.
IDENTIFICATION OF RADIOACTIVE STEROIDS BY RECRYSTALLIZATION TO 
CONSTANT SPECIFIC ACTIVITY.
EXPERIMENTS 5DS, 3D, 5AE AND 5T. CONTROLS CDS, CD, CAE, CT.
Axillary skin from a woman aged 20 yrs. was incubated with 
[ 70C- '^HjDHAsulphate (5DS) 3[7(Y-^H]DHA (5D) , [7a(-3H]androstenedione 
(5AE) and P7(X-3HJ testosterone (5T) as described in the text. 
Radioactive steroids isolated by chromatography were mixed with 
authentic carriers and recrystallized to constant specific activity. 
Specific activites were measured after successive crystallizations
(1.2.3.0
c = sp.act. of crystals m = sp.act. of mother liquor.
Table 18a. 
steroid 
solvent 
carrier
1I3H]DHA
acetone-hexane 
10.0 mg
Specific Activity (d.p.m./mg) % calculated 
sp.act.
c c c c
1 2- 3 k
3D 123000 1 21+200 125300 123500 92
CD 386000 378000 380000 372000 98
5DS 2880 2990 3110 3110 82
CDS 300 293 300 288 70
Table 18b.
steroid : r3HlDHAsulphate
derivative crystallized : DHA.
solvent : acetone-hexane
carrier : 10 .0 mg
Specific Activity (d.p.m./mg) % calculated 
sp.act.
1 2 3 k
c c c c
5D 10600 10560 10400 10550 91
CD 77 65 74 - -
5DS 201000 205000 205000 188000 85
CDS 215000 217000 225000 198000 87
Table 18c. 
steroid 
solvents 
carrier
I3H]epiandrosterone. 
acetone-hexane, acetone-water 
10.0 mg
Specific Activity (d.p.m./mg) °/r Calculate 
sp.act.
1 2 3 k 5 6
c c c c c c
5D 5350 5050 4980 4930 + 51 30 - 87
5DS 21 k 226 193 182 200 + 130 52
5AE 1270 1 340 1255 1280 + 1 350 - 92
5T 1 680 1600 1535 1510 1670 1 560 85
+ carrier oxidized to 5&-androstanedione which was precipitated 
from water, purified by t.l.c. in system I, then recrystallized 
before sp.act. measurement.
Table l8 d.
steroid : L ^ J  epiandrosterone sulphate
derivative crystallized : epiandrosterone.
solvents ; acetone-hexane, acetone-water
carrier : 10.0 rag
Specific Activity (d.p.m./mg) % calculated
sp.act.
1 2 3 4 5 6
c c c c c c
5D 6^1 623 667 667 h 8 2 +521 7 0 .5
5AE 230 246 230 244 +293 91 .5
5T 330 374 377 379 +261 +278 70.0
+ carrier oxidized to 5&-androstanedione which was precipitated
from water then recrystallized before sp.act. measurement.
Table 18e .
steroid [^Hj ardrostenedione
solvent acetone-hexane
carrier 10.0 mg
Specific Activity (d.p.m ./mg) % calculated 
sp.act.
1 2 - 3 4
c c • c c
5D 2740 2640 2740 2700 80
5DS no result
5AE 65700 68000 65600 68600 94
5T 1 1600 12100 11900 12100 92
Table l8 f.
steroid
3
!_ HJ 506-androstanedione
solvent ; acetone-water
carrier : 10.0 mg
1
Specific Activity (d.p.m. 
•2 3
/mg)
4
% calculat 
sp.act.
c c c c
5D 24000 24400 24400 24100 80.5
5DS 588 596 596 - 83.7
5AE 53300 50200 52100 51000 80.5
5T 32000 32000 31200 31400 86.0
Table 18g •
steroid [VH]androsterone
solvents acetone-hexane, CHCl-^-hexane.
carrier 10.0 mg
Spe cific Activity (d.p.m/mg)
% calculated
sp.act.
1 2 • 3 4
c c c c
5D 49700 50800 51000 50200 107
5DS 1890 1930 1835 1870 93.0
5AE 72100 73200 73600 74200 102
5T 94200 96500 95000 96200 95.0
Table l8h.
steroid
solvents
carrier
5AE
5T
Table l8i. 
solvents
steroid
carrier
5D
5DS
Jetiocholanolone 
acetone-hexane, CHC1^-hexane, benzene-hexane
10.0 rag
Specific Activity (d.p.m./mg) % calculated
sp.act.
1 2 3 4
c c- c c
630 612 570 58 2 23.0
477 414 465 30.0
acetone-hexane, CHCl^-methanol-hexane, acetone-water,
androstenediol 
10.2 mg
Specific Activity (d.p.m./mg) % calculated
sp.act.
1 2 3 
c m  c m  c m
7050 6600 6530 6500 6800 6930 98.5
216 245 190 215 186 200 94.0
Table 18 J.
steroid : C HJandrostenediol sulphate
derivative crystallized : androstenediol
carrier : 10.2 mg solvents : as for l8i.
Specific Activity (d.p.m./mg) % calculated
sp.act.
1 2 3 
c m  c m  c m
3D 4500 4300 4680 4060 4620 4450 94.0
5DS 6650 6900 6300 6400 6630 6250 94.8
Table 18k.
steroid : L^H] 3<t-androstanediol
carrier : 10.0 mg solvents : as for l8i.
Specific Activity (d.p.m./mg) % calculated
' sp.act.
2 3
c m c m c m
5D 5400 5210 5130 5210 5220 4750 103
5DS 485 585 520 483 500 503 78
5AE 8650 8150 8230 8100 8030 7200 104
5T 6520 — 6890 6800 6850 7000 100
Table 181.
steroid
carrier
E^H j ^ p-ar. dr ostanediol 
10.7 mg solvents as for l8i,
Specific Activity (d.p.m./mg) 
2 • 3
% calculated 
sp.act.
c m c m c m c m
3D 910 1680 969 915 855 1320 °785 - 62.2
5AE 320 665 503 565 550 502 532 523 8 0 .6
5T 800 1020 792 830 762 825 802 757 77.5
+ crystallized twice between each measurement of sp.act.
o crystals oxidized to 50L-androstanedione which was
precipitated from water, purified by t.l.c. in system 
I then recrystallized before 4 ^ sp.act. measurement.
Table 18m.
steroid : T^H3testosterone
derivative crystallized : acetate (except 5T , CT)
solvents
carrier
acetone-water, acetone-hexane, CHCl^-hexane
10.0 mg
Specific Activity (d.p.m./mg‘ ) % calculated 
sp.act.
1 2 3 4 5
5D 2790 2970 2890 + 2860 3010 102
5DS 265 302 31 1 + 300 344 74.0
5AE 3500 3490 3770 3670 3790
5T 64200 65100 64600 63900 - 8 0 .0
CT 563000 555000 5500^0 555000 - 83.5
+ saponified to give testosterone which was then recrystallized before 
. th , .A sp.act. measurement.
§ all corrected to mol wt. of testosterone acetate, (except , 5T, C^1)
Table l8n.
steroid
solvents
carrier
Q^HT-dihydro testosterone
acetone-hexane, CHC1-,-hexane
5
10.0 mg
Specific Activity (d.p.m./mg)
% calculate 
sn.act.
1 2 3 4 5 6
5D 20900 20700 18950 20900 +2 1050 - 93.5
5DS 990 947 942 925 987 +893 72.5
5AE 5200 3780 5180 4830 5100 + 5050 96.0
5T 10430 10350 10020 10300 + 11250 — 98.0
+ crystals oxidized to 5iX-androstanedione v/hich was precipitated 
from water and purified by t.l.c. in system I then recry­
stallized before sp.act. measurement.
c) A polar neutral steroid fraction was isolated from each 
of the incubations 5D, 5AE, 5T. It accounted for 10-25% of 
the radioactivity in each incubation. The fractions were 
analysed by t.l.c. in system X (table 19 below).
Table 19*
INVESTIGATION OF POLAR FEACTIONS FROM EXPEEIMENT 5.
Rf. of Radioactive Peak in System X.
T = testosterone 
AE = androstenedione 
D = DHA
System X = t.l.c. on Silica Gel in CHC1 -^/Methanol/H^, 
200:9:0.75 (v/v).
The eolar neutral steroid fractions isolated from incubations 
5D, 5AE and 5T were run on t.l.c. in system X. Scanning of the 
plate showed each fraction to be resolved into two peaks (5T,, 
5T2 etc.) with the recorded Rf. values. The Rf. of andro­
stenediol run on the same plate was 0 .5 5 *
Bands 5T,, 5AEf, and 59,, had Rf. values similar to those of 
compounds 3T , 3AE, and 3D isolated from incubations of male 
forehead skin (table 14 p. 87 )• However, bands 5T2 , 5AE2 and 
5D2 had Rf. values only half those of the fractions 3T2 , 3AE2 
and 3D2 from forehead skin.
5T1 5T2 5AE1
0.15 0.25 0.1 A
5AE2
0.22 0.15 0.27
Table 20.
METABOLISM OF DHASULPHATE, DHA, ANDROSTENEDIONE AND TESTOSTERONE 
IN FEMALE AXILLARY SKIN.
% conversion/3 hours
5DS 5D 5AE 5T
DHA 1 .20 +14.65 - -
DHAsulphate +74.7 1.67 - -
androstenediol 0.1 1 12.45 - -
androstenediol sulphate 11.33 2.19 - -
3jS-an dr ostanediol - 1 .21 0.27 0.48
3N-androstanediol 1.27 6.92 14.95 15.70
androsterone 1 .72 12.81 34.0 24.90
epiandrosterone 0.07 1.52 0.84 0.56
epiandrosterone sulphate -
s
'0.13 ?r0.05 ^0.06
etiocholanolone - - 0.23 0.09
testosterone 0.1 8 0.44 0.70 +7.76
dihvdrotestesterone 0.56 6 .0 8 7.75 15.85
androstenedione 0.9 0.29 +8.23 1.20
5ft-androstanedione 0.05 4.65 10.23 6.44
polar neutral steroids _ 25 1 1 18
+ - % substrate recovered 
§ = tentative identification
Slices of axillary skin from a 20 yr. old woman were incubated 
for 3 hours in Krebs Improved Ringer I medium with one of the 
following: [7<X- ”'hJ DHAsulphate (5DS) , [?(X- ’h] DHA (3D), [?<*-%]
androstenedione (5AE), [?0C- ij] testosterone (3T). Amounts of
tissue and incubation conditions are shown in table 17 P»94«
107
iii) Discussion :
DHA, androstenedione and testosterone were extensively 
metabolized by the axilla skin, (86% - 93% conversion/3 hours).
The formation of neutral steroid metabolites from DHAsulphate 
was slow (9% conversion/3 hours) as in face skin incubations. 
However, there was 11.6% conversion of DHAsulphate to androstene­
diol sulphate; this was not observed in previous experiments. 
Conversion of DHAsulphate and DHA to androstenedione and
testosterone occurred, as did interconversion of androstenedione
5
and testosterone. This indicates the presence of A'-3P-
RSD and 17p-HSD enzyme systems in the female axilla skin. However,
as in previous experiments, the A-ring saturated C, .-steroids
• y
v/ere the major neutral metabolites which accumulated in all 
incubations. In contrast to the face skin experiments, the % 
conversions to dihydrotestosterone (5T) and 5(X-androstanediols 
(AL) were similar to % conversions to 5(X-androstanedione (AD) and 
androsterone (A); (5T+AL)/(AD+A) = 1.04, 5DS; 0.75, 5D; 0.52,
5AE; 1.01, 5T. This indicated that in the axilla the 17^-HSD 
reaction proceeded equally in oxidative and reductive directions, 
in contrast to the male face skin where the reaction was almost 
exclusively oxidative. The active reduction of 17-oxosteroids 
was also seen in the conversion of DHA to androstenediol (12.5%) 
and of DHAsulphate to androstenediol sulphate (11.6%).
This high % conversion of DHA to androstenediol raises the 
possibility that the latter compound was a precursor of testo­
sterone, dihydrotestosterone and androstanediols. In the case 
of DHAsulphate, there is another possible metabolic sequence.
That is DHAsulphate -> androstenediol sulphate -> androstenediol 
testosterone. This would depend on the ability of the steroid 
sulphatase to hydrolyse androstenediol sulphate. Like the 
conversion of androstenediol to testosterone, the occurrence of 
this reaction in skin has yet to be proved. As found in previous 
experiments, the formation of the 30(-hydroxysteroids predominated
over the formation of 3^-hydroxysteroids ( ratio -.oi-androstanediol/ 
3p-androstanediol = 56, 5AE; 32, 5T; 6, 5D. ratio androsterone/ 
epiandrosterone = 41, 5AE; 43, 5T; 10, 5D). However, it can 
be seen that in experiment 5D, the % conversions to the 3^- 
hydroxysteroids were considerably greater relative to formation 
of 3d-h,yd.roxysteroids than were those in experiments 5AE and 5T 
(table 20 p. 106).
The formation of trace quantities of etiocholanolone in 
experiments 5AE and 5T confirmed the results of the forehead 
skin experiments. Once again no evidence of 5^-androstane-3,
17-dione formation could be obtained. However, the final constant 
specific activities of etiocholanolone after recrystallization 
accounted for only 23% and 30% of the radioactivity associated 
with etiocholanolone carrier after chromatographic purification 
(table 18h p. 101). 1 7fS-hydroxy-5^-androstan-3-one could have
been present in this fraction.
The female axilla skin showed steroid sulphotransferase 
activity. DHA was converted to DHAsulphate and androstenediol 
sulphate. It is not possible to deduce whether the androstenediol 
sulphate was formed by reduction of DHAsulphate or sulphation 
of androstenediol. Both reactions are possible.
There was very little radioactivity in the sulphate or 
glucuronide fractions isolated from experiments 5AE and 5T.
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Tentative evidence for formation of L 'H]epiandrosterone sulphate 
was obtained (table 18d p. 99) but no other steroid sulphates 
could be identified. This supports the earlier tentative con­
clusion that the skin enzymes will not sulphate 17j3-hydroxy- or 
3ot-hy dr oxy steroids.
DHAsulphate was shown to undergo two reactions:
(a) Hydrolysis to DHA.
(b) 17p-reduction to androstenediol sulphate.
No other steroid sulphate metabolites could be detected in 
experiment 5DS, even though the solvolysates from all the fractions 
expected to contain steroid sulphates were subjected to a full 
chromatographic and recrystallization analysis. As with face
skin incubations, there was a notable lack of conversion of 
DHAsulphate to polar neutral steroids or polar steroid sulphates 
(i.e. compounds yielding polar neutral steroids after solvolysis).
7. HISTOCHEMICAL STUDIES OF FOREHEAD ADD AXILLA SKIN.
Samples cut from the forehead and axilla skin specimens 
were examined histochemically for hvdroxysteroid dehydrogenase 
activity. The method of Muir e'tal. ( E68>) (p.k^) was used. The 
following steroid substrates were examined :
DHA (3^-OH)
eniandrosterone (3|3-OH) 
androsterone (3&-0H)
testosterone (17j3-OH)
dihydrotestosterone (17p>—OH )
NADH-diaphorase and NADPH-diaphorase activities in the skin 
specimens were checked. Each steroid was incubated with NAD+ 
ar.d NADP+ as cofactors in different experiments.
The histochemical staining method depends on the reduction 
of the dye, nitrobluetetrazolium by KADH or NADPH formed during 
oxidation of the steroid substrate. The reduced dye is deposited 
at the reaction site as insoluble blue-black granules. The 
transfer of hydrogen (electrons) from NAD(P)H to the dye requires 
the mediation of part of the electron transport chains of the cell. 
This is termed the "NAD(P)H diaphorase activity". Thus, for the 
histochemical method to give reliable localization of hydroxy- 
steroid dehydrogenase, all the cells examined must show NAD(P)H 
diaphorase activity.
All types of cell examined in the skin sections gave a 
staining reaction for NADH-diaphorase. Staining was particularly 
intense in sebaceous glands and apocrine and eccrine sweat 
gland enithelia. Staining was much less intense in the cells 
of the terminal hair follicles below the point where sebaceous 
glands were connected. The staining reaction for NADPH-
diaphorase was generally less intense than that for NADH. Hair 
follicles showed only very weak staining when sklfi was incubated 
with NADPH.
Table 21.
HISTOCHEMICAL DEMONSTRATION OF HYDROXYSTEROID DEHYDROGENASE IN
SEBACEOUS GLANDS.
Forehead Axilla
NAD+ NADP+ NAD+ NADP+
DHA + +
epiandrosterone + - ++
androsterone - -
testosterone + -
dihydrotestosterone + -
+ = reaction observed. - = no reaction.
Reactions were seen only in sebaceous glands.
The histochemical results provide some evidence that 
sebaceous glands are sites of steroid metabolism in face and 
axilla skin. However, they also show' inconsistencies with the 
findings of the radioisotope studies.
1. Incubations of [ Hj-steroids with forehead and axilla skin 
showed the presence of 17£>-HSD. However, only in the sebaceous 
glands of the forehead could a histochemical demonstration of
17/5-hydroxysteroid dehydrogenase activity be obtained.
2. Incubation of C'Hj-steroids showed that both forehead and 
axilla skin contained 3tf-HSD. The nresence of this enzyme was 
inferred from the conversion of androstenedione and testosterone 
to androsterone and 3(X-ardrostanediol. All attempts to localize 
the enzyme nistochemically in the skin failed.
3. Incubation of -steroids with breast, forehead and axillary
skin showed that % conversions to epiandrosterone (3 p> -OH) and 
3(3-androstanediol were usually at least 10 X less than total % 
conversions to 30C-hydroxysteroids. However histochemistry 
indicated that in sebaceous glands there was an intense 3p- 
HSD reaction with epiandrosterone as substrate in contrast to 
the apparent absence of any reaction with androsterone ( 3 OH).
PAPT IV. 
GENERAL DISCUSSION
Fig. 12
PROBABLE PATHWAYS OF C ^ -STEROID METABOLISM IN SKIN IN VITRO.
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Reactions catalysed by:
1. 17B-HSD 2. Sulnhatase 3* Sulnhotransferase if. ^ - 3 p - H S D
3. 3d-reductase 6. 3&-HSD 7. 3p-HSD
In addition DHA, androstenedione and testosterone are converted 
to hydroxvlated metabolites.
Androstenedione is converted to etiocholanolonet possibly via the 
intermediate 3p-androstane-3, 17-dione.
GENERAL DISCUSSION
I. PATHWAYS AND ENZYMES OF STEFOID METABOLISM IN SKIN.
i) The pathways of androgen metabolism in skin, which have 
been deduced from the results of incubation studies, are shown 
in Fig. 12 (p.112). The experiments have shown that both DHA- 
sulphate and DHA are converted in skin to A-ring saturated 
neutral steroids. Androstenedione and testosterone appear to be 
intermediates in these transformations and it can be seen that 
common metabolic pathways for all four steroids investigated 
anpear to exist in human skin.
The pathways of skin steroid metabolism found from 'in-
vitro' studies are similar to the overall 'in-vivo' metabolic
pathways for C .n-steroids, deduced from analysis of the fate of 
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injected tracers and analysis of urinary metabolites (compare 
TFigs. 2 and 12 pp. 8 and 112 ). There are some differences
however; notably the skin did not form glucuronides of DHA, 
androstenedione or testosterone or of their major metabolites. 
Sulphates of testosterone, dihydrotestosterone, 3ci-androstanediol 
and androsterone appear not to be formed in skin.
ii) Enzymes :
a. Steroid sulphatase (EC. 3.1.6.2 .)
Hydrolysis of DHAsulphate by homogenates of human neonatal 
foreskin was reported by Kim and Herrmann (1968). The work 
described here confirms the presence of a steroid sulphatase in 
adult skin. The extent of DHAsulphate hydrolysis was least in 
old male (83 yrs.) forehead and female (56 yrs.) breast skin 
(1.9% and 2.9% conversion to neutral steroids) and greatest in 
the younger male (58 yrs.) forehead and female (20 yrs.) 
axillary skin (5*3% and 5*1% conversion). The rate of DHA­
sulphate hydrolysis was much less than that of other metabolic 
transformations of androgens.
The anatomical localization of steroid sulphatase in skin 
is completely unknown; attempts to localize steroid sulphatase
in skin, histochemically, by coupling the reaction with further 
oxidation of DHA, have failed (Muir, 1971). Histochemically 
detectable aryl sulphatase (substrate: 6-Bromo-2-napthyl 
sulphate) gives an intense reaction in sebaceous glands, eccrine 
sweat glands and epidermis (Vezekenyi, 1968). However, the 
aryl sulphatases appear to be distinct from the steroid specific 
sulphatase, which has been isolated from liver (Roy, 1957).
b. 5^-Hydroxysteroid sulphotransferase (EC. 2.8.2.2.)
The experiments have extended the findings of Berliner et al. 
(1968), and Faredin et al. (1968), who showed that DHA was 
converted to DHAsulphate in human abdominal skin. The reaction 
has been shown to occur in male and female breast, forehead 
and axillary skin. The sulphotransferase, which presumably 
catalyses the reaction appears to act on DHA, androstenediol and 
epiandrosterone, but not on testosterone or androsterone. In 
forehead and axillary skin experiments the formation of sul- 
phocorjugates from testosterone and androstenedione was sought. 
While about 1% of the incubated radioactivity was found in the 
sulphate fractions isolated from incubations with these two 
steroids, after solvolysis followed by chromatograohy and re­
crystallization only epiandrosterone and material remaining on 
the origin after t.l.c. in system I were radioactive.
It is interesting that the percent conversions of DHA to 
DHAsulphate were similar in all experiments, despite considerable 
variations in formation of other metabolites. Recently, it has 
been shown in this laboratory that conversion of DHA to DHA­
sulphate could be demonstrated in rat skin but not in the 
preputial gland (Hodgins and Hay, 1971 unpublished work) and 
it is possible that, while total hydroxysteroid dehydrogenase 
and 5oc-reductase activity in a piece of skin may be related 
to the presence of pi.losebaceous units, the activity of steroid 
sulphotransferase is not.
c. UDP-Glucuronyl Transferase (EC. 2.4.1.17).
In no experiment was more than 0.05% (uncorrected for 
recovery) of the total radioactivity recovered in the glucuronide 
fraction. This suggests that "in vitro", neither DHA nor
testosterone nor any of their major metabolites are converted 
in significant amounts to glucuronides in skin,
d . 5P-Hydroxysteroid dehydrogenase- - 5 jsomerase.
(£^-3p-HSD : abbreviation).
The conversion of a C5-6 unsaturated 3^-hydroxysteroid to 
the corresponding C4-5 unsaturated 3-oxosteroid is catalysed by 
this enzyme complex. The presence of A  -3p-HSD in human skin 
was first inferred from the histochemical studies of sebaceous 
glands (Baillie et al., 1963)* Cameron et al. (1966), then 
Chakraborty et al. (1970) used biochemical techniques to 
demonstrate the enzyme system in human skin. Chakraborty showed 
that DHA was converted to androstenedione by human skin and that 
NAD+ was required as co-factor. Enzyme activity was higher in 
shoulder skin than in thigh or lateral thoracic wall skin. As
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the histochemical studies suggested that A"-3p~HSD was localized 
in sebaceous glands, Chakraborty's finding could be interpreted 
in terms of the more numerous and larger sebaceous glands in 
shoulder skin than in the other two areas, (Montagna, 1963;
Caiman et al. , 1970). Chakraborty' s experiments also showed 
that enzyme activity in shoulder skin decreased with advancing 
age as had previously been suggested by Baillie et al. (1966). 
However, the experiments described here have shown the presence 
of active A' -3^-HSD in forehead skin from an 83 year old man.
This could be related to the presence of numerous large sebaceous 
glands in this skin specimen. Further support for the theory 
that the enzyme is localized in sebaceous glands has come from 
studies of the rat preputial gland, which is composed almost 
entirely of sebaceous cells. A histochemical 3p-HSD-reaction 
with DHA as substrate and NAD+ as co-factor has been demonstrated 
in the lipid laden cells of this gland (Muir et al, 1970). The 
presence of A  -3p~HSD has been confirmed by demonstrating 
conversion of DHA to androstenedione by preputial gland preparat­
ions (Hodgins and Hay, 1971 unpublished work).
c.
A"-3p-HSD is a key enzyme in biosynthesis of steroid 
hormones. In skin, it catalyses a first step in conversion of
DHA to the highly active androgens, testosterone and dihydrotesto­
sterone. Thus the stimulation of sebaceous secretion by DHA 
(Pochi and Strauss, 1969) may be mediated through its metabolism 
by A 5-3p-HSD.
e. 1 7j3-Hydroxysteroid Dehydrogenase 
(abbreviation : 17p-HSD)
Wotiz et al. (193b), first demonstrated the conversion of 
testosterone to androstenedione by human shoulder and scalp skin 
in the presence of NAD'. Histochemical studies have localized 
17p-HSD (testosterone or oestradiol as substrate, NAD+ as cofactor) 
in sebaceous glands from all over the body (Caiman et al., 1970). 
There appears to be a localization of enzyme activity in groups 
of cells around the edges of sebaceous gland acini (Caiman, 1970b).
It has been shown that DHA is converted to androstenediol in 
skin and that NADPH will act as a cofactor (Chakraborty, 1968 
unpublished work). The experiments described here have established 
the conversion of androstenedione to testosterone in human male 
and female skin. They have also shown that DHAsulphate is 
converted to androstenediol sulphate in skin thus opening the 
possibility of conversion of DHAsulphate to testosterone by a 
pathway involving neither DHA nor androstenedione as intermediates 
( see Fig. 12 p.1 1 2 ).
However, the main point of interest arising from the breast,
forehead and axillary skin experiments is the difference in the
direction of the 17p-HSD reaction which predominated in the
various skins. In male forehead skin there was extensive oxidation
of the testosterone 17p-hydroxyl group but only minute conversions
of DHAsulphate, DHA or androstenedione to 17p-hydroxysteroids.
A similar situation may exist in female breast skin. This was
not incubated with testosterone, but incubation with DHAsulphate
and DHA showed very little conversion to 17p-hydroxysteroids.
In contrast, the female axillary skin actively reduced DHAsulphate,
DHA and androstenedione to 1 7p>-hydroxysteroids which were major
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metabolites. Because of the high activities of A  -3p-HSD and
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5l-reductase in all skin specimens, it appeared to be the 
17f>-HSD reaction which was responsible for the differences in 
accumulation of androgenically highly active compounds (dihyd­
rotestosterone, androstanediols) or relatively inactive compounds 
(androsterone, epiandrosterone) in the various experiments. It 
cannot yet be decided which factors control the interconversion 
of 17p-hydroxy and 17-oxosteroids in skin but a possibility is 
the availability of oxidized and reduced forms of NAD and NADP 
which are coenzymes in the reaction. Gurpide and Welch (1969) 
showed that interconversion of oestradiol and oestrone and of 
testosterone and androstenedione in human endometrial tissue was 
influenced by tissue slice thickness and oxygenation of the 
incubating medium. This was interpreted as an effect of tissue 
oxygenation on the generation of oxidized and reduced NAD and 
] ADP. The experiments described here were carried out with 
uniformly thick tissue slices and conditions of incubation were 
similar in all cases. It is therefore likely that the different 
results obtained with the various skins reflect basic metabolic 
differences between the skins rather than artefacts due to 
varying incubation conditions.
Studies of rat liver have shown that the ratios of the 
concentrations of unbound NAD+/NADH and NADP+/NADPH differ widely 
between the mitochondrial and cytoplasmic compartments of the cell 
(Williamson et al., 1967; Veech et al., 1969). It has been shown 
that there exist in guinea pig liver two forms of 17p-HSD which 
interconvert testosterone and androstenedione (Endahl, et al. , 
I960). One form, localized in the soluble cytoplasm requires 
KADP(H) as coenzyme, the other, localized in the mitochondrial- 
microsomal fraction requires NAD(H). In view of the above it 
would be of interest to know the subcellular localization and 
coenzyme specificity of 17p-IISD of human skin from different 
body sites.
f. 3x-Peductase (E.C. 1.3.1. )
There was extensive 50C-reduction of testosterone and
androstenedione when they were incubated with skin. In addition, 
when DHAsulphate or DHA were incubated, the low % conversions 
to testosterone and androstenedione compared with those to ol- 
steroids showed that active 5<i-reduction had occurred. Sol- 
Reductase, a key enzyme in metabolism of testosterone and andro­
stenedione, is present in many tissues - liver, gonads, accessory 
sex organs ... skin (Stylianou et al., 1961; Forchielli et al.,
1963; Gloyna and Wilson, 1969)? Most androgen target tissues so 
far investigated contain the testosterone 5(i-reductase (Gloyna and 
Wilson, 1969)5 an exception is the rat levator ani muscle. In the 
rat prostate the enzyme has been detected in the cell nuclei and 
it has been proposed that conversion of testosterone to dihydrote- 
sfcoster-one in the prostate cell nucleus is followed by binding 
of the latter steroid to the chromatin (Bruchovsky and Wilson,
1968a,b). The further effects of androgen on the cell would then 
follow from this nuclear binding of dihydrotestosterone. However 
Gloyna and Wilson, (1969) found only low 50t-reductase activity in 
the prostates of mature rabbit and bull. In addition Jeffcoate 
and Short (1970) concluded that testosterone not dihydrotestosterone 
may be the active androgen in the bull testis, after their failure 
to isolate dihydrotestosterone from this organ. Voigt et al.
(1970), could not find any Dflk-reduc tase in the nuclear fraction 
prepared from human foreskin and all conversion of testosterone 
to dihydrotestosterone took place in the microsomal fraction.
As pointed out by Voigt this does not exclude dihydrotestosterone 
from being the active form of androgen in skin, because it does 
not need to be formed in the cell nuclei to exert its effects, 
demonstrated by the androgenicity of injected or topically 
applied dihydrotestosterone (Dorfman and Dorfman, 1962, 1963a5b). 
Voigt et al. (1970) showed that conversion of testosterone to 
dihydrotestosterone by foreskin microsomal fractions had an 
absolute requirement for FADPH as coenzyme. It was also shown 
that the same enzyme catalyses 50t-reduction of progesterone and 
probably androstenedione. This finding supports the claim 
that the differences in nercent conversions of testosterone
to dihydrotestosterone between axilla and forehead skin were 
the result of the action of 17£-HSD and not due to differences 
in activity of a 5oi-reductase specific for testosterone.
As dihydrotestosterone may be the active molecular species 
of androgen it is important to consider the possible anatomical 
localization of 5oL-reductase in skin. Northcutt et al. (1969) 
have shown that plucked pubic hair follicles contain the 
enzyme. The rat preputial gland and chicken uropygial glands, 
which are composed mainly of sebaceous cells, have high 
reductase activity (Gloyna and Wilson, 1969; Rongone et al.
1967). Thus we have evidence for the presence of 6<x-reductase 
in haii- follicles and sebaceous glands, on which basis the 
presence of 5ol-reductase in breast, forehead and axillary skin 
could be explained. Wilson and Walker (1969) found that human 
neonatal foreskin had high concentrations of 5<X-reductase. They 
used the stretching technique of Van Scott (1962) to separate 
foreskin into ’'epidermis” , "dermis” and "sub dermal fibrous 
tissue” (Wilson and 'Walkers' terminology). The”sub dermal 
tissue” had highest 5o(-reductase activity with dermis and 
epidermis (probably contaminated by dermis) having lower enzyme 
activity. It is difficult to know what the exact composition of 
Wilson and Walkers’ "dermal” and "sub dermal”fractions were, 
but they claim the result shows that fibrous tissue cells may 
have high 506-reductase contents. As foreskin contains many 
sebaceous glands some of the 5o(.-reductase could have been 
localized in them. However, Wilson and Walker also detected 
6d-reductase activity in skin from palmar and plantar skin which 
have no sebaceous glands.
The presence of 5o(-reductase in fibroblasts could help 
to explain the observation that lot-reductase activity in foreskin 
decreased greatly with increasing age from birth (Wilson and 
Walker, 1969), when enzyme activity was expressed on a "per 
v/et tissue weight” basis. In the foetus and neonate the fibrous 
tissues of the dermis are much more cellular than in adults 
(Montagna, 1962). (i.e. more fibroblasts, less fibrous material).
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As the fibrous tissue constitutes most of the skin's dry weight, 
the number of enzyme containing cells per wet weight of tissue 
will decrease with increasing age and therefore lead to the 
observed decrease of 50(-reductase activity. This theory could 
be simply checked by expressing enzyme activity on a "per yug. 
of DNA" basis.
It might be considered that, if fibroblasts of skin do 
contain 5ot-reductase, they may differ in enzyme content over 
different parts of the body. Their enzyme content could perhaps 
be related to the presence of pilosebaceous units, as areas of 
skin with many of these have high enzyme activity (facial skin, 
axilla, pubic skin, perineal skin).
It can be seen from the foregoing arguments that, while 
there is circumstantial evidence for the presence of 5ot-reductase 
in sebaceous glands, hair follicles and fibroblasts, it will be 
necessary to isolate the different tissue types of skin and study 
them individually before direct information about their enzyme 
activities can be obtained,
g . 5p-Reductase (E.C. 1.3J» )
5 p-reduction of testosterone and androstenedione has been 
demonstrated in human and rat liver (Stylianou et al., 1961;
Forchielli et al., 1963)* The conversion of androstenedione 
and testosterone to etiocholanolone by forehead and axillary 
skin suggests that there is a 5|$-reduc tase in human skin. However, 
no conversion (<(0.01%) to 5p~androstane-35 17-dione could be 
detected after chromatography and recrystallization.
Rongone (1966) reported the isolation of etiocholanolone 
after incubating testosterone with mammary skin of a man with 
Klinefel ter1s syndrome. Gomez and Hsia (1968) were however un­
able to detect any conversion of testosterone or androstenedione 
to 56-steroids by normal human abdominal and preputial skin.
Likewise Frost et al. (1969) could demonstrate no 5/3-reduction of 
progesterone in human skin. The results here lend supnort to 
Rongone's earlier studies, but it is obvious that in normal human skin
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-reduction of testosterone and androstenedione is of minor 
importance, compared to 5<X-reduction. From the results of 
'in-vivo' studies of testosterone metabolism in man Mauvais- 
Jarvis et al. (1 969 a, 1 970a) have concluded that 5f5-reduction 
takes place mainly in the liver and possibly intestines. They 
found that the 5o'/5pratio of urinary testosterone metabolites is 
greatest when testosterone is rubbed directly into the skin; 
the ratio is lower for intravenously injected testosterone and 
lowest for orally administered testosterone. In this last case, 
a large part of the testosterone perfuses the liver directly 
before entering the peripheral circulation; so that it would be 
catabolised by the 5^-reductase of liver.
h . 3CL-Hydroxysteroid Dehydrogenase (E. C . 1 . 1 . 1 . 30» )
(abbreviation: Iflt-HSD)
^he conversion of testosterone and androstenedione to 3oL~ 
androstanediol and androsterone shows that there is, in the skin, 
a 3ot-HSD. In liver the 3&-HSD reaction has been shown to be 
freely reversible, and the enzyme will use FAD or FADP as cofactor 
(Tomkins, 1956; Hurlock and Talalay, 1958). It has been suggested 
that because of this dual coenzyme specificity 3&-HSD can act as 
a transhydrogenase effecting the interconversion of oxidized 
and reduced FAD and FADP (Hurlock and Talalay, 1958). Recently, 
it has been shown that FADPH will serve as cofactor for the 
reaction in human skin (Voigt et al. 1970). Histochemical methods 
have been used to demonstrate 3oC~HSD in rat skin; both HAD+ and 
FADP+ have been shown to act as coenzymes for the reaction (Muir, 
1971). However, when the histochemical technique is applied to 
human skin, even to samples known from biochemical studies to 
actively form androsterone, no 3oi-HSD can be detected with either 
FAD+ or NADP+ as cofactors.Soiar no satisfactory explanation for 
this phenomenon has been found.
i . 3£-Hydroxysteroid Dehydrogenase (E.C. 1.1.1. )
(abbreviation: 3J5-HSD)
The conversion of androstenedione and testosterone to 
epiandrosterone and 3p-androstanediol by human skin shows the
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presence of 3p-HSD.
In human prostatic tissues Chamberlain et al. (1966) 
detected jpHSD when testosterone was incubated with NADPH as 
cofactor. In human sebaceous glands, 30-HSD activity can be 
detected histochemically with epiandrosterone as substrate; 
only NAD+ will act as coenzyme (p. 110). It is unknown whether 
the histochemically observed oxidations of epiandrosterone and 
DHA in sebaceous glands are due to two different enzymes or to 
dual substrate specificities of one enzyme, i.e.:
a) Does the histochemical reaction with DHA demonstrate
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activity of A  -3P-HSD while the reaction with 
epiandrosterone demonstrates 3p~HSD?
b) Are both DHA and epiandrosterone being oxidized by 
A 5-3p -HSD?
c) Are both DHA and epiandrosterone being oxidized by 
a 3p-HSD not associated with any isomerase?
This last point is of some importance for interpretation of 
the histochemically observed oxidation of DHA in sebaceous glands, 
for while there is undoubtedly aA'-3p-HSD in skin (conversion of 
DHA to androstenedione) the histochemical reaction in sebaceous 
glands may not be demonstrating its activity so much as that of 
a simple ^p-HSD.
In all the experiments with human skin, the % conversions to 
3p-hydroxysteroids were much less than to 3&-hydroxysteroids 
(3<x/3P )> 10). This was irrespective of body site, sex or age of 
the skin.
Mauvais-Jarvis et al. (1970$ have investigated metabolism 
of 3p-androstanediol "in-vivo" by injecting F^Hj 3f-androstanediol 
into men. They found that more than 80% of the radioactivity 
excreted in the urine was recovered in androsterone and 3oC- 
androstarediol; so there had been extensive conversion of the 
3B-hydroxysteroid to 30t-hydroxysteroids. When L^H "J 30(- 
androstanediol was injected, very little of the urinary radio­
activity was present as 3^-hydroxysteroids, most of it being 
in 3oc-androstanediol and androsterone showing that there was
little conversion of 3oc-hydroxy to 3f-hydroxysteroids.
Interest in 33-androstanediol has been centered around its 
specific stimulation of rat prostatic secretion (Baulieu et al.,
1971) and more recently its effects on sebum secretion and com­
position in rats (Nikkari and Valavaara, 1970). It has been 
suggested that the biological effects of 3p-&ndrostanediol are 
mediated independently of any conversion to dihydrotestosterone 
(Baulieu et al., 1971; Robel 1970). Therefore, the formation of 
this compound in human skin is of great interest, particularly as 
it is a more active stimulator of sebum secretion than is dihydrote- 
sterone when tested on the hypophysectomized female rat (Nikkari 
and Valavaara, 1970). 
j. Hydroxylases.
Human skin apnears to contain an enzyme system which hydroxy-
lates C 1r-steroids. As yet, nothing is known about its properties 
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and even the exact identities of the polar metabolites are unknown. 
Faredin et al. (1967, 1969) have reported the hydroxylation at 
positions 7a, 7p and 160  ^of DHA in human skin. However, as was 
argued earlier it is unlikely that either 7tX-hydroxy or 7-oxo- 
steroids were among the polar metabolites isolated here. Likewise, 
a search for formation of 16$-hydroxy DHA was unsuccessful (p. Gk)•
In all the experiments, the androstenediol fraction isolated from 
the first t.l.c. plate was examined for the presence of 1GCL- 
hydroxy DHA, 1ip-hydroxy androstenedione or any other compounds 
of similar oolarity (see p. 30 Fig. 5)* There was never more than 
about 0 .1% of the total radioactivity associated with such compounds, 
compared to usually more than 10% associated with the more highly 
polar fractions.
The hydroxylation reaction, which decreases the biological activity 
of androgens can be thought of as antagonizing the actions of the 
hydroxysteroid dehydrogenases and 5ot-reductase which may form 
potent androgens from less active precursors in skin, 
k . 1_7_-20 Desmo 1 ase and 1 7o(.-hydroxylase.
Recently in an extensive study of steroid metabolism by rat 
skin (Flamigni et al., 1970) it was shown that both pregnenolone
12L\*
arid progesterone were converted to their 17ot-hydroxy derivatives 
in rat skin. In addition, 17oL-hydroxy progesterone was converted 
to androstenedione and pregnenolone was converted (via 17a .-hydroxy 
pregnenolone) to DHA.
This finding leads to the possibility that pregnenolone and 
progesterone may be converted to potent androgens in the skin. 
However, it should be remembered that Frost et al. (1969) showed 
that more than 85% of progesterone metabolites formed in human 
skin retained either the ^-pregnene or 5<X-pregnane structures, 
and even in Flamigni’s study C^g-steroids were only minor 
metabolites of progesterone. It is now generally accepted that 
in physiological doses progesterone does not stimulate the 
sebaceous glands of human or rat skin (Strauss and Pochi, 1963). 
However it has been shown that topical apnlication of large 
amounts of pregnenolone acetate or progesterone to the aged 
human axilla elicit similar, although much less marked, changes 
to those seen after testosterone administration. The effects 
appeared to be restricted to the axilla under treatment and 
it was suggested that pregnenolone and progesterone were 
transformed locally into "androgenic substance" (Papa and 
Kligman, 1966).
»2'. VARIATIONS OF SKIN STEROID METABOLISM IN RELATION TO AGE,
SEX AND BODY SITE.
The conversion of DHAsulphate and DHA to testosterone, 
dihydrotestosterone and androstanediols by skin from breast, face 
and axilla of male and female has been demonstrated. However, 
there are quantitative differences between skins in the % 
conversions to 17-oxo or 17^-hydroxy metabolites. The metabolic 
differences between axilla skin and forehead or breast skin 
might be interpreted in terms of:-
a) Body site differences related to the presence of 
p ilosebaceous units;
b) Age differences between individuals (female axilla - 
20 years, male forehead-83 years.)
c) Sex differences (male forehead, female axilla and breast);
d) A combination of a, b. c.
Female breast skin and male forehead skin are anatomically 
similar (large sebaceous glands, no terminal hairs) and have a 
similar metabolic pattern dominated by formation of 5a-androstane- 
dione and androsterone ( 17-oxo pathv/ay). Recent experiments 
with Dr. J.B. Hay have shown that forehead skin from a young 
man (20 yrs.) and cheek skin from an old woman (76 yrs.) also 
have a similar metabolic pattern. The total enzyme activity was, 
however, very much reduced in the cheek skin from the old woman 
(sebaceous gland atrophy? (Strauss and Pochi, 1963)). On the other 
hand, skin from the axilla of a 43 yr. old man had a similar 
metabolic pattern to that of the young female axilla (active 
formation of dihydrotestosterone and 3o(-ar drostanediol) • Jenkins 
and Ash (1971) have recently reported in-vitro studies of testo­
sterone metabolism in suprapubic skin of men and women. They 
found a similar metabolic pattern to that which has been found 
in axilla skin and concluded that there were no differences 
between the sexes. While, at first sight, the results of Jenkins 
and Ash show no differences between male and female, if they are 
re-calculated as 1 7/?-hydroxy/1 7-oxo ratios ( dihydrotestosterone/ 
androstenedione + 5<X-androstanedione + androsterone) there are 
differences. The mean value for males is 0.71 0.08 (7) S.E. ;
that for females is 1.04 + 0.10 (7) S.E. ^his difference is 
just statistically significant (0.02 { P <( 0.05. Student's-t • 
test) and shows a greater accumulation of dihydrotestosterone 
relative to 17-oxosteroids in female skin experiments. This was 
mainly due to a greater conversion of testosterone to 17-oxo- 
steroids in male skin experiments than in female skin experiments. 
In view of the fact that old and young male forehead skin formed 
mainly 17-oxosteroid metabolites, it will be interesting to 
study steroid metabolism in facial skin of young women with 
active sebum secretion and compare it v/ith facial skin from 
men of comparable age.
A recent paper by Sansone and Peisner (1971) has reported 
the conversion of testosterone to dihydrotestosterone by facial 
skin from men and women with acne and from "normal" individuals.
They used the incubation system of Wilson and Walker (1969) v/ith 
minced skin incubated in Krebs original Ringer Phosphate - 
Glucose medium for 3 hours.
One finding was that percent conversions to dihydrotestosterone 
were equal to or greater than those to 17-oxosteroids. There was 
very little androsterone formed in those incubations where its 
presence was sought. This is in direct conflict with the results 
of the experiments described here and those recently carried out 
on young male forehead skin. The metabolic pattern was in fact 
similar to that which was observed in axilla skin. It is possible 
that these differences are due to the incubation conditions used 
by both groups of workers. Sansone and Peisner used a testo­
sterone concentration of 0.3yUM, i.e.: 10 times less than that 
used here. In addition, they used an incubation medium with high 
phosphate concentration (22 mK)while a low phosphate medium 
(1.2 mM) was used here. The concentration of phosphate in a tissue 
has been implicated in control of glycolysis and reduction of 
cytoplasmic NAD (Williamson et al., 1967). Any such effects 
on cytoplasmic NAD+/NADH ratios might alter interconversion of 
17^-hydroxy and 17-oxosteroids. Differences in tissue oxygenation 
caused by variation in thickness of slices or minced tissue or 
in the method of gassing the medium might have similar effects 
(Gurpide and Welch, 1969). These problems emphasize the care v/hich 
must be exercised when results of "in-vitro" incubations under 
different conditions are compared and extrapolated to the "in- 
Vivo" situation.
3. STEROID METABOLISM AND ANDROGEN ACTION ON SKIN.
The differences detected between forehead or breast and
axilla skins in accumulation of 17/?>-hydroxy and 17 oxo- 
metabolites emphasise the control which 17^-HSD activity had 
over metabolism. Metabolism via the 17-oxo route could be 
termed "deactivating" as coupled with the high 5tf-neductase 
activity of skin, it leads to accumulation of compounds with 
low biological activity - androsterone, epiandrosterone, 5o(- 
androstanedione. I etabolisra via the 1 7^B-hydroxy route could 
be termed "activating", as it leads to accumulation of highly 
active androgens - dihydrotestosterone and androstanediols (Dorfman 
and Dorfman, 1962, 1963a, t>).
It might be suggested as a hypothesis that target tissues 
have the necessary activating metabolism for converting steroids 
to dihydrotestosterone and androstanediols while non-target 
tissues have a mainly deactivating metabolism. Some support 
for this idea comes from studies of male accessory sex organs, 
which actively convert testosterone to dihydrotestosterone (Gloyna 
and Wilson, 1969) and of non-target tissues which convert testo­
sterone to weakly androgenic substances, eg: human endometrium 
(Collins et al., 1969)» canine urinary bladder (Morfin et al.,
1970) and the submaxillary gland of the dog (Weiner et al.,
1970). In a recent paper, Kelch et al., (1971) compared the 
metabolism of testosterone in various human adult and foetal 
tissues. Results were expressed in terms of conversion to 
dihydrotestosterone relative to conversion to 17-oxosteroids 
(1 7/3-hydroxy/1 7-oxo ratio). It was found that target tissues - 
perineal skin, and vas deferens-had a ratio about 1 while 
presumed non-target tissues - fetal thigh skin, skeletal muscle, 
Mullerian duct, fallopian tubes, all gave ratios less than 0.1.
It would be interesting to know from further studies if 
there are any metabolic differences between androgen target 
organs which develop in both sexes (eg; axillary hair) and those 
which develop only in the male (eg. prostate). While prostatic 
tissue incubated in-vitro converted testosterone mainly to 
dihydrotestosterone there was little conversion of DHA or andro- 
stenedione to testosterone and dihvdrotestosterone (Collins et 
al., 1970).
Hov/ever the results of the experiments described here do 
not entirely conform to the above hypothesis. Both male and 
female chest, facial and axilla skin are sensitive androgen
target areas. Their numerous sebaceous glands are stimulated 
by adrenal and gonadal androgens (DHA, androstenedione, testo­
sterone). The terminal hairs of the axillary region are 
similarly sensitive (Part I sections 1i -lii). In spite of this, 
the in-vitro metabolic patterns of forehead and axillary skin are 
quite different. The conversion of DHAsulphate, DHA, androstene­
dione and testosterone to dihydrotestosterone and androstanediols 
in axillary skin fits well with the fact that the hair follicles 
of this region respond to testicular?ovarian and adrenal stimuli. 
However, in breast and forehead skin, the "deactivating" pattern 
of metabolism is predominant with little accumulation of testost­
erone or dihydrotestosterone. Yet the sebaceous glands of fore­
head are among the most sensitive of androgen target tissues.
How can this paradox be explained?
i) The 'in-vitro' studies do not give the same metabolic 
patterns as 'in-vivo1. It has already been argued that 
the different results obtained v/ith axillary or forehead 
skin 'in-vitro' represent real metabolic differences between 
the skins, which resulted in the different percent conversions 
to 17^-hydroxy and 17-oxo-steroids. It is hov/ever possible 
that such metabolic controls 'in-vivo' would give rise to 
other patterns of steroid metabolism. This is not to say 
that 'in-vivo' the control of 17^-HSD activity is unimportant 
in determining patterns of steroid metabolism but that control 
of 17^-HSD 'in-vivo' could give rise to different metabolic 
patterns to those observed 'in-vitro'. Possibly further 
studies of the effects of incubation conditions on 'in-vitro' 
steroid metabolism or 'in-vivo' perfusion experiments would 
help resolve this problem,
ii) Assuming that the patterns of steroid metabolism 'in-vitro' 
are similar to those 'in-vivo',it may be that, in spite of 
a predominantly deactivating metabolism in forehead and breast 
skin, enough biologically active androgen reaches and is 
retained in the sebaceous glands to maintain sebum secretion 
in male and female.
iii) Androgen metabolism in skin is related to some specific 
catabolic function of sebaceous glands. This idea comes 
from the suggestion that sebaceous glands are involved 
in catabolism and excretion of foreign compounds and 
steroids (Rashleigh et al., 1967; Cook and Lorincz 1963).
In this case, an activating metabolism in a relatively 
few androgen target cells might be masked by deactivating 
metabolism in the differentiated sebaceous cells.
4. STEROID METABOLISM IN RELATION TO ENDOCRINE DISEASES INVOLVING 
SKIN.
i) Testicular Feminization:
Attempts have been made to explain the general target organ 
insensitivity to androgen in this condition by impaired conversion 
of testosterone to dihydrotestosterone in target tissues. Various 
in-vitro studies of skin have not provided any convincing evidence 
for this concept. Northcutt et al. (1969), claimed that supra­
pubic skin from individuals with testicular feminization had a 
deficiency of 5ot-reductase. Jenkins and Ash (1971) could not 
confirm this and in two patients the suprapubic skin had normal 
testosterone metabolism. Wilson and Walkers' (1969) experiments 
on mons pubis skin aggree with those of Jenkins and Ash but they 
did claim a possible deficiency of 5<X-neductase in perineal skin 
from subjects with testicular feminization. By applying fpE 1 
testosterone to the skin and simultaneously injecting E^Cl 
testosterone into subjects with testicular feminization, Mauvais- 
Jarvis et al. (1969a) have provided evidence that there may be a 
deficiency of direct A-rirg reduction of testosterone in the 
extrahepatic tissues. There did not appear to be a similar 
deficiency in progesterone 5iX-reduc tion (Mauvais-Jarvis et al. , 
1969b). However Voigt et al. (1970) showed that in skin it is 
probably the same enzyme which catalyses 50(-reduction of testo­
sterone and progesterone. This is difficult to reconcile with
Mauvais-Jarvis' s findings unless the properties of the 501- 
reductase are altered in testicular feminization. Further 
evidence against a simple 5<X-reductase deficiency being respon­
sible for testicular feminization was provided by Strickland 
and French (1969) who showed that patients with this syndrome 
were unresponsive to dihydrotestosterone.
ii) Idiopathic Hirsutism:
It was suggested in the introduction (p. 5) that this con­
dition might be explained in terms of the prehormone concept.
It appears from the 'in-vitro' experiments that skin, characterized 
by hair follicles which are sensitive to stimulation by female 
androgen levels (axilla), has an "activating" C^Q-steroid met­
abolism. This appears to result from active conversion of 17- 
oxo to 17/S-hydroxysteroids coupled with high 5^-reductase activity 
and leads to formation of dihydrotestosterone and androstanediols. 
Skin characterized by hair follicles which do not normally respond 
to female androgen levels (breast skin) may have a "deactivating" 
metabolism, resulting in 5(X-androstanedione and androsterone 
formation with little dihydrotestosterone. If the metabolism 
observed is characteristic of the hair follicles and if it is a 
property of the follicles before they have been androgen stimulated 
(i.e. a cause rather than an after-effect of the hormone response), 
it might be suggested that in idiopathic hirsutes the follicles of 
areas which are not normally sensitive to female androgen levels, 
become so through developing an"activating" type of metabolism.
This hypothesis could be tested by studying the steroid metabolism 
of skin from the appropriate body sites of men, normal women and 
women with hirsutism. It would also be important to investigate 
steroid metabolism in areas of skin v/hich differ in androgen 
sensitivity before they have been exposed to androgenic stimulus, 
so that it can be determined whether or not metabolic patterns
characteristic of hairy areas or those with well developed seb­
aceous glands exist before these have developed under androgen 
stimulation. This would require studies of steroid metabolism in 
skin from prepubertal children and foetuses. In addition, the 
enzyme activites of the hair follicles must be established by
direct studies on these organs.
iii) Acne Vulgaris:
Increased sebum secretion and hyperplasia of the sebaceous
gland duct in acne might be caused by an abnormal target organ 
response to androgens. Workers in Hungary have recently claimed 
that skin of acne patients contains more DHA (DHA + DHAsulphate) 
than skin of normals (Vadasz and Debreczeni, 1969). Drawing on 
the original hypotheses of Baillie, Milne and co-workers (Baillie 
et al., 1965, 1966) they suggest that increased conversion of
DHA to testosterone in skin is a cause of acne. In a limited 
study, Chakraborty found no differences of A  3^-HSD activity in 
shoulder skin of acne patients compared to normals (Chakraborty 
et al., 1970). Sansone and Reisner (1971) have studied the con­
version of testosterone to dihydrotestosterone in acne patients.
No significant differences between acne and normal were noted for 
face or back skin of men (although 2 normal forehead specimen-s had 
lower conversions to dihydrotestosterone than did acne specimens). 
There was, however, a highly significant increase of dihydrotest­
osterone formation in face and back skin of females with acne 
compared to normals. However, these workers give no indication 
of the ages of their normal and acne groups. An age difference 
of steroid metabolism could be important if total enzyme activ­
ities are at all related to the presence of active sebaceous 
glands. This will be especially so in the female, as sebaceous 
gland activity declines quite sharply with increasing age in 
women (Strauss and Pochi, 1963). Sansone and Reisner do not state 
whether increased conversions to dihydrotestosterone were assoc­
iated with increases or decreases in conversion to other steroid 
metabolites (17-oxo, 3&-hydroxy, 3^-hydroxy). As the experiments 
described here showed that the % conversion of four different 
steroids to dihydrotestosterone were not dependent so much on the 
level of 501-reductase in the skin as on the activity of 17p-HSD, 
it may well be that changes in dihydrotestosterone formation, by 
skin, in acne, are associated v/ith alterations in the 17|§-HSD 
reaction rather than with increases of 5o(-reductase activity.
In view of this, any attempts to study changes of steroid metabol­
ism in skin of "normal" and diseased subjects must take into 
account the overall steroid metabolic patterns. Even so, the
observations of Sansone and Peisner (1971) are of great interest 
and a stimulus to further studies.
One particular problem relating to acne is that of the 
effects of testosterone metabolites on sebaceous glands. The 
work of Nikkari and Valavaara (1970) has shown that dihydrotesto­
sterone stimulates sebum secretion in rats but its activity is 
only 50% of that of 3/3-androstanediol or testosterone. Dihydrote­
stosterone is, however, a very active stimulator of preputial 
gland and prostate gland weight increases in the rat (Ebling 
et al., 1971; Dorfman and Dorfman, 1963a). It will be interesting 
to know whether there is any dissociation of effects between 
testosterone, dihydrotestosterone and 3^-androstanediol on 
sebaceous glands as has been demonstrated in organ cultures of 
rat prostate, where dihydrotestosterone caused a marked increase 
in the number and size of epithelial cells while 3p-androstanediol 
specifically stimulated the secretory activity (Baulieu et al.,
1971). It could be that in sebaceous glands 3/3-androstanediol 
stimulates sebum production while dihydrotestosterone causes 
hyperplasia of the gland epithelium and ducts (Sansone and Peisner,
1971). An effect of dihydrotestosterone independent of any 
increase in sebum secretion would be important in acne and could 
help explain the poor correlation between sebum secretion rates 
and the tendency to develop acne (p. 5)*
However, even if some differences in effects or metabolism 
of androgens can be found between skin of acne and non-acne 
groups, the fact that one sebaceous gland may develop a lesion 
while adjacent ones remain unaffected will have to be explained. 
This is a major problem in acne as lesions may develop on all 
normal individuals around puberty; acne sufferers simply have 
more of them than others. Biopsies taken from acne sufferers, 
for 'in-vitro1 studies, will invariably be of largely uninvolved 
skin from areas afflicted by acne, and 'in-vivo' measurements 
(such as sebum secretion) will usually measure activity of both 
unaffected and affected sebaceous glands. Therefore if any 
gross differences are detected in skin of normal individuals
I pp.
and acne sufferers (sebum secretion, steroid metabolism) it will 
have to be determined whether:-
i) They are characteristics of the whole skin on the body 
area from which the specimen was taken (for 'in-vitro* 
study) or on which the measurement was made. If this is 
the case, a second factor must exist which determines 
whether or not a sebaceous gland will develop an acne 
lesion.
ii) They are due to abnormal characteristics of a few
pilosebaceous units which will develop or have developed 
acne lesions.
Before a full understanding is possible of the pathogenesis 
of acne and of the role of steroid hormones in its development, 
it will be necessary to discover what causes sebaceous glands to 
differ in their tendencies to develop acne lesions. For the 
study of skin steroid metabolism in acne, this means that the 
precise anatomical sites of steroid metabolism in skin v/ill have 
to be defined, so that enzymic changes in sebaceous glands 
themselves can be measured, before further progress can be 
expected.
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APPENDIX 1.
TABLES FOR CALCULATING THE % CONVERSIONS OF STEROID SUBSTRATES TO
VARIOUS METABOLITES.
The following tables list the percentage recoveries of initially 
added carrier steroids in the samples taken for crystallization 
from incubations of human skin with different steroid substrates. 
This enables the % conversions to metabolites to be calculated 
from the specific activities obtained after crystallization.
Equation 4 (p«23) gives:
% conversion to metabolite X = Sf.Mx.100 Y
di y
Now . 100 = % recovery (%R) of initially added carrier in 
Mx the sample for crystallization.
% conversion to X = Sf.Y .10^ (5)
di.%R
Sf = specific activity after crystallization (d.p.m./mg)
Y = mg. carrier added for crystallization
di = d.p.m-,- steroid substrate incubated
Thus % conversions can be calculated from the specific activities 
of the crystals and the % recoveries.
In experiments where characterization by derivative formation 
was followed by crystallization (expts. 1D, 2D: table 7, p«55 
and tables 8a-h, pp.56-60) equation 2 (p.24) can be used to 
calculate the % conversion:
% conversion = Sx.Mx.100 Sf (2)
di st
f £ o100 = percent calculated specific activity ( %T)
St
% conversion = Sx.Mx.3T
di
%T is given in the tables of crystal specific activities 
Sx = specific activity of isolated steroid before carrier was 
added for crystallization.
Mx = mass of initially added carrier 
di = d.p.m. substrate incubated.
%RECOVERY OF CARRIER STEROIDS IN SAMPLES TAKEN FOR CRYSTALLIZATION
FROM INCUBATIONS OF HUMAN FEMALE BREAST SKIN WITH DHA
Carrier Steroid Experiment No.
1 a 1b 2a 2b
dihydrotestosterone 4.7 TO.4 12.5
androsterone 16.0 10.4 14.4 15.7
epiandrosterone 18 .2 13.1 19.6 14.2
The above data are used with the specific activities after 
crystallization (tables 8a-8h,pp.56-60) to calculate % conversions 
(table 9,p.65)*
^RECOVERY OF CARRIER STEROIDS IN SAMPLES TAKEN FOR CRYSTALLIZATION
FROM AN INCUBATION OF HUMAN FEMALE BREAST SKIN WITH DHASULPHATE
Carrier Steroid 
DHA
DHAsulphate
androstenediol
androstenediol sulphate
androsterone
androstenedione
5'X-androstanedione
Experiment No.
1 DS 
36.5 
9.6 
1 8 . 1  
1 1 .3 
15.3 
33.8 
26.0
The above data are used with the specific activities after 
crystallization (table 1 0,p.7 1 ) to calculate % conversions 
(table 11,p.72).
% RECOVERY OF CARRIER STEROIDS IN SAMPLES TAKEN FOR CRYSTALLIZATION
FROM INCUBATIONS OF HUMAN MALE FOREHEAD SKIN WITH FOUR STEROID
SUBSTRATES
Carrier Steroid Experiment No.
3D 3DS 3AE 3T
DHA 39. C- 58.3
androsterone 20.7 17.3 14.1 19.3
epiandrosterone 41 .9 39.4 33.4
epiandrosterone 
sulphate
24.6 27.0
androstenediol 12.3 32.9
zp-androstanediol 14.8 14.0
3<X-ardrostanediol 16.7 22.4
testosterone 30.4 38.4 47.7 34.3
5&-androstanedione 46.1 3 0 .8 49.2 51 .8
an drostenedione 78.1 81 .0 78.3 63.2
dihydrotestosterone 47.2 29.9 39. 7
etiocholanolone 21 .2 19.4
DHAsulphate 2 3 . 2 22.3
The above data are used with the specif c activities after
crystallization ( tables 13a-m , pp. 80-86 ) to calculate
% conversions (table 1 3, p.89).
% RECOVERY OF CARRIER STEROIDS IN SAMPLES TAKEN FOR CRYSTALLIZATION
FROM INCUBATIONS OF HUMAN MALE FOREHEAD SKIN WITH FOUR STEROID
SUBSTRATES
Carrier Steroid Exoeriment No.
AD ADS AAE AT
DHA 60.3 A8.1
androsterone 18.A 1 5.0 13.7 20.8
epiandrosterone A A. 7
epiardrosterore 
sulphate
27.0
androstenediol 3A.0
5fc-androstanediol 12.6
3(X- androstanediol 26.3 10.6
testosterone 68.2 A9.2 5A. 6 51 .8
5a-androstanedione 57.6 A9.2 A6.9 A8. A
androstenedione 77.9 69.0 70,1 71.5
dihydrotestosterone A3.7 3 2 . 2 30.8 AA. 9
etiocholanclone 15.0 20.1
DHAsulphate 2A. 5 25.9
vhe above data are used with the specific activities after
crystallization (tables 1 J>a-m, pp .80-8 6 ) to calculate
% conversions (table 16 , p.90).
% RECOVERY OF CARRIER STEROIDS IF SAMPLES TAKEF FOR CRYSTALLIZATION
FROM INCUBATIONS OF HITMAF FEMALE AXILLARY SKIN WITH FOUR STEROID
SUBSTRATES.
Carrier Steroid Experiment No.
3D 5DS 5AE 5T
DHA 61.4 52.1
DHAsulphate 43-3 55.4
epiandrosterone 27.9 38.5 9.8 19.2
epiandrosterone
sulphate
2 8 . 0 31 . 6 28.4
androstenedione 67.6 3 2 .0 51.7 66.9
5oi-andr ostanedione 37.8 24.6 32.1 33.1
androsterone 28.3 22.6 13.7 2 5 . 8
etiocholanolone 16.5 33.8
androstenediol 4 . 0 37.9
androstenediol
sulphate
13.0 11.9
3o(.-androstanediol 3 .4 8.1 3.5 2.9
3f-androstanediol 5.0 13.3 11.8
testosterone 47.8 36.2 33.1 55.9
dihydrotestosterone 24.4 33.0 4.2 4.5
The above data are used with the specific activities after 
crystallization (tables l8a-n, pp.97-104) to calculate % 
conversions (table 20, p.106).
APPENDIX 2.
SOURCES OF REAGENTS
Solvents and general reagents were of Analar grade. 
Silica Gel Hf 254+366 was bought from E.Merck Darmstadt,
W. Germany. Steroids were bought from Steraloids Ltd., 
Croydon, Surrey. Standard reference steroids were obtained 
from the M.R.C. Steroid reference collection.
Padioactive steroids were bought from the Radiochemical 
Centre, Amersham or from New England Nuclear Corp., Frankfurt 
A.M., W. Germany.
